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Abstract 
 Synthetic and naturally-occurring phosphonates have found widespread use in 
both agriculture and medicine. A program at the Institute for Genomic Biology at the 
University of Illinois at Urbana-Champaign was established to discover novel 
phosphonate natural products. In addition to this effort, the metabolic pathways for the 
biosynthesis of these natural products as well as phosphonate catabolism were examined 
for interesting biochemical reactions. Herein are detailed my contributions toward this 
enterprise. 
 2-Hydroxyethylphosphonate dioxygenase (HEPD) is a non-heme iron enzyme 
that catalyzes the cleavage of the carbon-carbon bond of 2-hydroxyethylphosphonate (2-
HEP) during the biosynthesis of the herbicide phosphinothricin. Mechanistic studies were 
undertaken to elucidate the mechanism of catalysis by HEPD. These studies 
demonstrated that an unusual iron(IV)-oxo intermediate is at the heart of the catalytic 
cycle of HEPD. Also reported in this dissertation are studies on an enzyme with distant 
homology to HEPD, methylphosphonate synthase (MPnS), which likewise breaks the 
carbon-carbon bond of 2-HEP. These results strongly suggested the possibility of a 
consensus mechanism between HEPD and MPnS. This hypothesis was further evaluated 
through a combination of substrate analog incubations, site-directed mutants, and 18O 
KIE studies. Additionally, this thesis presents a study on an alcohol dehydrogenase that 
reduces phosphonoacetaldehyde (PnAA) to 2-HEP; the implications for the biosynthetic 
pathway for fosfomycin are discussed. Finally, observations made while studying an 
aldehyde dehydrogenase that oxidizes PnAA to phosphonoacetate are reported. 
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Sing in me, Muse, and through me tell the story 
of that man skilled in all ways of contending, 
the wanderer, harried for years on end, 
after he plundered the stronghold 
on the proud height of Troy. 
    He saw the townlands 
and learned the minds of many distant men, 
and weathered many bitter nights and days 
in his deep heart at sea, while he fought only 
to save his life, to bring his shipmates home. 
 
-The Odyssey by Homer, translated by Robert Fitzgerald 
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 1 
Chapter 1: Phosphonate Biosynthesis and Enzymologya 
 
1.1: Phosphonate Natural Products 
 Both synthetic and naturally-produced phosphonates/phosphinates have found 
widespread usage in fields ranging from agriculture to medicine.1,2 The defining 
structural motifs in these compounds are their carbon-phosphorus (C-P) bonds; 
phosphonates contain one C-P bond whereas phosphinates contain either two C-P bonds 
or one C-P bond and one P-H bond to the same phosphorus atom. Organisms ranging 
from animals such as freshwater snails3 to bacteria such as actinomycetes4 are able to 
employ phosphonate natural products as polar headgroups for lipids or 
exopolysaccharides.5 Actinomycetes in particular, along with some species of 
Pseudomonads and Bacillus, also have the capability to produce phosphonates and 
phosphinates with potent bioactivities.1 These compounds are able to structurally mimic 
molecules that are ubiquitous in metabolic and signaling pathways, such as phosphate 
esters, carboxylic acids, and tetrahedral intermediates formed during transformations of 
carbonyl groups.6 Thus, phosphonates and phosphinates can serve as small-molecule 
inhibitors of many different processes. 
 Many naturally produced phosphonates and phosphinates are found in short 
peptides. Examples of these peptides include the antibacterial agent dehydrophos as well 
                                                
 a Reprinted in part from Methods in Enzymology, Vol. 516 Spencer C. Peck, Jiangtao 
Gao, and Wilfred A. van der Donk, "Mechanistic Investigations of Enzymes Involved in 
Phosphonate Biosynthesis," 101-123, Copyright (2012), with permission from Elsevier. 
Figure 1 was adapted from Current Opinion in Chemical Biology, Vol. 17, Spencer C. 
Peck and Wilfred A. van der Donk, "Phosphonate biosynthesis and catabolism: a treasure 
trove of unusual enzymology," 580-588, Copyright (2013), with permission from 
Elsevier. 
 2 
as bialaphos, a herbicidal peptide7 produced by Streptomyces viridochromogenes8 and 
Streptomyces hygroscopicus, that contains the nonproteinogenic amino acid 
phosphinothricin (glufosinate) (Figure 1.1).9 The phosphinate moiety of phosphinothricin 
mimics the tetrahedral intermediate of glutamate formed during glutamine biosynthesis, 
resulting in inhibition of glutamine synthase.10,11 This inhibition causes build-up of 
ammonia, ultimately killing the plant; phosphinothricin and its derivatives have therefore 
been widely used as herbicides.7 The self-resistance gene from the biosynthetic cluster, 
the bar gene in S. hygroscopicus12,13 and the pat gene in S. viridochromogenes,14 has 
been used as a selectable marker for genetic engineering of crops and fungi.7,15,16 The 
gene encodes phosphinothricin acetyl-transferase, which N-acetylates phosphinothricin 
using acetyl-CoA. Phosphinothricin itself is not an effective antibiotic because of its 
inability to be readily transported across the cell membrane of bacteria. To improve 
uptake by target organisms, the producer strains incorporate phosphinothricin into short 
peptides, often tripeptides. Once transported into the cell by oligopeptide permeases,17,18 
the peptide undergoes proteolysis by peptidases to release the active form. Because the 
compound is taken up in an inactive form and only unveiled as the active form inside the 
cell, phosphinothricin-containing peptides belong to the class of antibiotics known as 
"Trojan horses."19-21  
 3 
 
Figure 1.1: A panel of bioactive phosphonates and one phosphinate, with the bioactivity 
of and the protein(s) inhibited by each molecule detailed below. MurA, also known as 
UDP-N-acetylglucosamine 1-carboxyvinyltransferase, catalyzes the committed step in 
bacterial cell wall biosynthesis. Molecules are the same color as in Figure 1.2. 
 
 With two exceptions, all known phosphonate biosynthesis proceeds through the 
unfavorable rearrangement of phosphonenolpyruvate (PEP) to phosphonopyruvate 
(PnPy) catalyzed by PEP mutase (Figure 1.2);22,23 due to the conservation of this 
mechanism across various biosynthetic pathways, this enzyme has been used as a genetic 
handle to identify the phosphonate biosynthetic gene clusters responsible for making 
phosphinothricin,24 dehydrophos,25 FR-900098,26 and the rhizocticin peptides.27 In some 
cases, the driving force for PnPy formation after the initial unfavorable isomerization is 
an aldol-like condensation to drive flux, as in the biosynthetic pathways to produce 
fosfomycin from Pseudomonads28 and FR-90009826 (blue and red, respectively, in Figure 
1.2). More commonly, the initial isomerization is coupled to an irreversible 
decarboxylation step to afford phosphonoacetaldehyde (PnAA), as in the biosyntheses of 
phosphinothricin,24,29 the antibacterial tripeptide dehydrophos,25 and the antibiotic 
fosfomycin2 (in Streptomyces species) (green, purple, and blue, respectively, in Figure 
1.2). In the dehydrophos, fosfomycin, and phosphinothricin pathways, PnAA produced 
by the action of the decarboxylase is subsequently reduced by a Group III Fe-dependent 
alcohol dehydrogenase (AD) to afford 2-hydroxyethylphosphonate (2-HEP) in a 
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transformation with stereochemistry that was undefined prior to this work.30,31 The 
stereochemistry associated with this NADH-dependent reduction has certain implications 
for the unresolved fosfomycin pathway in Streptomyces species, and in determining that 
the hydride from NADH was transferred to the Re face of PnAA by the AD, certain 
hypothetical pathways could be excluded (Chapter 6).31 
 
Figure 1.2: A simplified overview of phosphonate biosynthesis. Virtually all known 
pathways begin with an unfavorable isomerization followed by an irreversible second 
step. PnAA and 2-HEP are early intermediates that are common to a number of different 
pathways in secondary metabolism. These molecules also play a role in the formation of 
various phosphonolipids and phosphonoglycans.  The colors correspond to those in 
Figure 1.1. 
  
1.2: Catabolism of Phosphonates 
 Although phosphonates are often resistant to enzymes and harsh chemical 
treatments32 that cleave the P-O bonds in phosphate esters and anhydrides, their C-P 
bonds are readily broken by specialized enzymes, and pathways have evolved that allow 
certain organisms to use phosphonates as a phosphorus source.33-40  In many of these 
pathways for phosphorus mobilization, PnAA is a central intermediate. These pathways 
include the hydrolysis of PnAA by phosphonatase (Figure 1.3, black) to yield phosphate 
 5 
and acetaldehyde,41 the transamination of PnAA to 2-AEP followed by its hydroxylation 
and oxidative cleavage (Figure 1.3, blue) to afford phosphate and glycine,42,43 and the 
NADH-dependent oxidation of PnAA to phosphonoacetate (PnA) with subsequent 
hydrolysis by the metalloenzyme PhnA to yield phosphate and acetate.37,44,45 PhnY, the 
protein that catalyzes the formation of PnA, exhibits structural homology with non-
phosphorylating glyceraldehyde-3-phosphate dehydrogenase and was demonstrated to 
have relaxed substrate specificity in vitro (Chapter 6) (note that Martinez et al. have 
designated the protein that hydroxylates 2-AEP PhnY as well).45,46 Additionally, a kinetic 
assay was developed to characterize site-directed mutants of PhnY important for 
activity.45 This study expanded our understanding of the critical role that PnAA plays in 
phosphorus mobilization.   
  
Figure 1.3: Several catabolic pathways exist in which PnAA is a common intermediate. 
In each pathway, PnAA is processed to ultimately liberate phosphate from the 
phosphonate precursors. 
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1.3: HEPD Is a Non-heme Iron-Dependent Enzyme Involved in Phosphinothricin 
Biosynthesis 
 Though the phosphinothricin pathway remains incompletely elucidated after 
formation of 2-HEP,29 a number of noteworthy transformations occur in the later steps. 
Among these reactions are the methyl-insertion carried out by PhpK, a methylcobalamin 
(MeCbl)- and S-adenosylmethionine (SAM)-dependent enzyme,47 the CMP ligation 
reaction catalyzed by PhpF, and the carbon-carbon bond cleavage of 2-HEP performed 
by PhpD (Figure 1.4).48 In vitro characterization of PhpD demonstrated that it was a non-
heme iron-dependent dioxygenase that produced hydroxymethylphosphonate (HMP) and 
formate. The protein was thus renamed 2-hydroxyethylphosphonate dioxygenase 
(HEPD).48 
 
Figure 1.4: A number of unusual reactions take place in the phosphinothricin 
biosynthetic pathway. 
 
 A crystal structure of HEPD was solved in collaboration with the Nair group at 
the University of Illinois Urbana-Champaign.48,49 NHI enzymes are most commonly 
ligated by a pair of endogenous histidine ligands and a carboxylate (either a glutamate or 
aspartate); these proteins belong to the class known as "facial triad" enzymes. Several 
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facets of catalysis by HEPD are unusual compared to catalysis by other NHI enzymes. 
Dr. Rob Cicchillo, a former post-doctoral associate in the van der Donk group, 
demonstrated that HEPD required only Fe(II) and O2 for catalysis, which is in stark 
contrast with many NHI enzymes that require an additional cofactor or cosubstrate for 
activity. The cosubstrate, such as α-ketoglutarate (α-KG), is capable of donating two 
electrons to assist in the complete cleavage of the oxygen-oxygen double bond, a process 
that requires four electrons (Figure 1.5A). This scission is hypothesized to occur with 
concomitant formation of a reactive intermediate with sufficient oxidizing power to 
cleave a C-H bond. Many NHI α-ketoglutarate-dependent enzymes that catalyze 
reactions including hydroxylation, halogenation, desaturation, and epimerization are 
hypothesized to undergo two single electron reductions of the O2 to the peroxo species by 
the Fe(II) center followed by a further two-electron reduction by α-KG to completely 
cleave the oxygen-oxygen bond and form an Fe(IV)-oxo species. This ferryl species is 
thought to be the active oxidant that cleaves the C-H bond to form a carbon-centered 
radical; the fate of this carbon-centered radical determines the reaction that takes place 
(Figure 1.5A). By contrast, NHI enzymes such as tyrosine hydroxylase require the 
cofactor tetrahydrobiopterin (THB) for activity. This cofactor plays an analogous role to 
α-KG in donating two electrons in concert with the Fe(II) center to generate the reactive 
Fe(IV)-oxo intermediate that then activates substrate for downstream reactivity (Figure 
1.5B).50 Though the timing of the electrons transferred from the cosubstrate to O2 is 
slightly different in THB-dependent enzymes than in α-KG-dependent enzymes, the 
critical role played by the different cosubstrates is the same. 
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Figure 1.5: Activation of O2 by non-heme iron enzymes with the aid of a cosubstrate. 
(A) α-KG-dependent enzymes use two electrons from the Fe center and two electrons 
from the cosubstrate to completely cleave the oxygen-oxygen bond. The resulting Fe(IV)-
oxo species is responsible for substrate activation to form a carbon-centered radical. 
Rebound of an iron-bound halide (in halogenases such as CytC3) yields halogenated 
products (blue, 1).51 Rebound instead of the ferric-hydroxide (brown, 2) yields 
hydroxylated products in taurine dioxygenase and prolyl-4-hydroxylase.52-54 Hydrogen 
atom donation from a donor such as a tyrosine to the opposite face of the carbon radical 
(red, 3) yields epimerized products in CarC.55 An electron transfer to the Fe center 
followed by deprotonation would yield desaturated products (purple, 4). (B) THB-
dependent enzymes such as tyrosine hydroxylase instead use a cofactor to initially reduce 
O2 to the peroxide state. The adjacent Fe(II) center can then cleave the peroxide to yield 
hydroxy-THB and an Fe(IV)-oxo intermediate that can then catalyze downstream 
chemistry.50 
 
 Oxidative scission of carbon-carbon bonds is well-precedented in the biochemical 
literature, but the bond targeted for cleavage is usually activated by a proximal functional 
group such as an alkene,56 vicinal diol,57 or aromatic ring.58 Many of these cleavage 
reactions are catalyzed by non-heme iron enzymes that can activate O2 even in the 
absence of a cofactor or cosubstrate. For example, 4-hydroxyphenylpyruvate (4-HPP) 
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dioxygenase is a NHI enzyme that oxidizes (4-HPP) to homogentisate and CO2 in 
tyrosine catabolism (Figure 1.6A). However, it is thought that the α-ketoacid moiety in 4-
HPP functionally mimics the role of α-KG in other non-heme iron dioxygenases in 
generating the active Fe(IV)-oxo complex.59 Other examples of NHI enzymes activating 
O2 without the need for cosubstrates include the extradiol-cleaving dioxygenases, such as 
homoprotocatechuate dioxygenase (HPCD). HPCD effects the four-electron oxidation of 
homoprotocatechuate to 5-carboxymethyl-2-hydroxymuconic semialdehyde (Figure 
1.6B). In this case, it is thought that the electron-rich nature of the substrate facilitates 
oxygen activation via electron transfer to the reactive oxygen species mediated by the 
iron center.60 By contrast, HEPD breaks a relatively unactivated sp3-sp3 carbon-carbon 
bond without an electron-rich moiety and is able to extract all four electrons for complete 
reduction of O2 from its relatively electron-deficient substrate. A corollary to this aspect 
of catalysis is that the 2-HEP substrate, and the 2-HEP substrate alone, enables formation 
of a carbon-hydrogen cleaving complex. This latter facet of catalysis by HEPD is in stark 
contrast with the fashion in which most non-heme iron enzymes operate. 
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Figure 1.6: NHI enzymes capable of activating O2 without the need for a cosubstrate. (A) 
Similar to α-KG-dependent enzymes, 4-HPP dioxygenase acts on a substrate that has an 
α-ketoacid moiety that binds directly to the Fe center and assists in O2 activation. (B) 
Extradiol-cleaving dioxygenases such as HPCD can use their electron-rich substrates to 
form a substrate radical and initiate O2 activation. 
 
 For these reasons, HEPD has been the subject of a number of mechanistic and 
computational studies.48,61-67 These investigations enabled the formulation of a pair of 
mechanistic hypotheses, each of which made distinct predictions regarding the 
stereochemical outcome of the reaction. In collaboration with Dr. John Whitteck, then a 
graduate student in the van der Donk group, and Petra Malova, a graduate student in the 
Hammerschmidt laboratory at the University of Vienna, I helped determine the 
stereochemistry of the HMP product using 2-HEP stereospecifically deuterated at C1 as 
starting material as described in Chapter 2. Contrary to the expectation of net inversion 
during the reaction catalyzed by HEPD, which would have been consistent with a 
hydroperoxylation mechanism that we favored at the time, the product afforded was 
racemic,62 indicating that neither of the previously postulated mechanisms was correct.63 
I therefore set out to obtain direct spectroscopic evidence for intermediates in the 
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catalytic cycle of HEPD with the help of the Bollinger and Krebs group at the 
Pennsylvania State University (Chapter 3). Despite employing a substrate that could have 
enabled trapping the initial reactive oxygen species, I instead detected an unexpected and 
unusual Fe(IV)-oxo species.  
 
1.4: MPnS Is an Enzyme with Homology to HEPD  
 Chapter 4 describes the characterization of a protein homologous to HEPD68 that 
was discovered while attempting to understand why parts of the aerobic ocean are 
supersaturated with CH4 despite the absence of obligate-anaerobe methanogens, a 
situation known as the "oceanic methane paradox."69 Several years ago, researchers 
postulated that the high levels of oceanic CH4 could be explained by C-P lyase 
catabolism of methylphosphonate (MPn) by bacteria to yield CH4 and liberate 
phosphate.70 However, this proposed solution did not adequately explain how MPn was 
biosynthesized. One possible source of MPn was as a product of a gene cluster from 
Nitrosopumilus maritimus (Figure 1.7), an extraordinarily abundant aquatic archaeon.71,72 
This cluster contained the canonical phosphonate biosynthetic genes required to make 2-
HEP as well as an enzyme with distant homology to HEPD. Dr. Benjamin Griffin, then a 
postdoctoral associate in the Metcalf group at the University of Illinois Urbana-
Champaign, reasoned that the first four genes might afford HMP, and that the sulfatases 
in the cluster might reductively cleave the C-O bond in a novel fashion to afford 
methylphosphonate. 
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Figure 1.7: The cluster in which MPnS was located. The action of the first four genes 
yields MPn, which could then be ligated to polysaccharides by the action of the sulfatases 
or nucleotidyl transferase (nct) in the cluster. Bacteria might liberate the MPn from the 
exopolysaccharides so as to convert it to phosphate under phosphorus-limited conditions. 
 
 The HEPD homolog was cloned, expressed, and purified by Dr. Cicchillo. He 
found that this protein accepted 2-HEP as a substrate in an Fe(II)- and O2-dependent 
manner. However, surprisingly, the enzyme directly produced MPn without the need for 
a sulfatase to convert HMP to MPn, indicating that N. maritimus was at least in part 
responsible for MPn (and therefore indirectly CH4) in the ocean. Based on two-
dimensional nuclear magnetic resonance (NMR) spectroscopic experiments, N. maritimus 
probably decorates its exopolysaccharides with MPn as a novel headgroup (hence the 
sulfatases might act as group transfer enzymes).68 This observation underscores that 
phosphonates, such as MPn, 2-HEP, and 2-aminoethylphosphonate, can fulfill key roles 
not just in secondary metabolism or catabolism but also in structural capacities (Figure 
1.2). Biochemical investigation of this HEPD homolog (termed methylphosphonate 
synthase, MPnS) indicated that despite low overall sequence similarity to HEPD and the 
enzyme that catalyzes epoxide ring formation in fosfomycin biosynthesis (2-
hydroxypropylphosphonate epoxidase, HppE), key residues known to be critical for 
either Fe or substrate binding were retained (Figure 1.8). MPnS also exhibited kinetic 
parameters that were similar to HEPD and likewise abstracted the pro-S C2 hydrogen of 
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2-HEP (Chapter 4). However, whereas the pro-R C2 hydrogen is incorporated into 
formate during HEPD catalysis, the hydrogen atom from this position is transferred into 
the MPn product (Figure 1.9).73  
 
Figure 1.8. An alignment of three related mononuclear non-heme iron enzymes involved 
in phosphonate biosynthesis demonstrates that key residues responsible for binding either 
phosphonate (blue) or Fe(II) (red) are mostly conserved. MPnS does not have an 
aspartate or glutamate at the positions where HEPD and HppE have glutamate residues, 
and therefore it is unclear if MPnS functions with only two histidines ligating its active 
site Fe(II).  
 
Figure 1.9: The related dioxygenases (A) HEPD and (B) MPnS use O2 as the cosubstrate 
to oxidize the same phosphonate to different products. The hydrogen atom originating 
from the pro-R position at C2 of 2-HEP (red, "HR") is transferred to the formate by HEPD 
and incorporated into MPn by MPnS. (C) HppE, by contrast, oxidizes (S)-2-
hydroxypropylphosphonate ((S)-2-HPP) to fosfomycin by using H2O2 as the 
cosubstrate.74 This reactivity makes HppE the first known NHI peroxidase. 
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 This unusual labeling pattern led us to propose a consensus mechanism between 
HEPD and MPnS in which product identity is governed by the partitioning of a late-stage 
intermediate. Additional evidence for a consensus mechanism between HEPD and MPnS 
comes from a bifunctional mutant of HEPD that is able to make both HMP and MPn in a 
manner consistent with isotope sensitive branching (Chapter 5). Moreover 18O2 KIE and 
substrate analog studies support key common early intermediates respectively. Taken 
together, the studies on HEPD and on MPnS described in this thesis led to a mechanistic 
proposal that can explain these unusual transformations. 
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Chapter 2: Stereochemical Outcome of the HEPD Reaction with 2-HEPa 
 
2.1: Introduction 
2.1.1: Divergent Hypothetical Mechanisms with Differing Stereochemical Outcomes 
 Previous work on HEPD included X-ray crystal structures,1,2 stable-isotope 
labeling studies,3 substrate-analog incubations,4 and computational calculations.5-7 The 
results of these investigations led to the formulation of two possible mechanisms that 
could explain all experimental observations associated with the reaction between HEPD 
and its native substrate 2-HEP (Figure 2.1). In either mechanism, 2-HEP would first bind 
to the Fe(II) site and trigger O2 binding. One-electron reduction of O2 by the Fe(II) center 
would yield Fe(III)-superoxo species Ia, which would then abstract the pro-S C2 
hydrogen to form ferric-hydroperoxo IIa. Stereospecific abstraction of the pro-S C2 
hydrogen atom was supported by the HEPD•2-HEP cocrystal structure but had not been 
experimentally validated.1,3  
 After formation of the C2 radical intermediate IIa, either a hydroperoxylation or 
hydroxylation route could be operative. In the first mechanism, the hydroperoxo species 
would directly recombine with the C2 radical (hydroperoxylation mechanism). This 
hydroperoxylated intermediate IIIa would then undergo a Criegee rearrangement to 
cleave the carbon-carbon bond, yielding O-formyl-HMP IVa. Though the C2 ester 
carbon is more electrophilic than the C1 carbon, hydrolysis would have to occur at C1 in 
an SN2 fashion to account for solvent incorporation in the hydroxyl of HMP.1 Compelling 
                                                
a This is an unofficial adaptation of two articles that appeared in ACS publications. ACS 
has not endorsed the content of this adaptation or the context of its use. The articles can 
be found online at http://pubs.acs.org/doi/abs/10.1021%2Fja1113326 and 
http://pubs.acs.org/doi/abs/10.1021%2Fbi200804r.  
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evidence for this route arose from the finding by Dr. Whitteck that incubating HEPD with 
1-hydroxyethylphosphonate (1-HEP) yielded acetyl phosphate (AP) (Figure 2.2A). In 
analogy to the reaction with 2-HEP, the most facile explanation for the formation of AP 
from 1-HEP by HEPD also invoked phosphonate binding followed by formation of a 
ferric superoxo species Ib that would abstract a hydrogen atom from C1 to yield radical 
IIb (Figure 2.2B). Following C-H activation, hydroperoxylation would generate 
intermediate IIIb, a transformation highly reminiscent of IIIa in the catalytic cycle of 2-
HEP. In the case of 1-HEP, an ensuing Criegee rearrangement would directly afford AP 
(IVb). A similar mechanism could thus be operative in the catalytic cycle of 2-HEP. 
 
Figure 2.1: Catalysis with 2-HEP could be explained by one of two possible mechanisms 
that could possibly be distinguished by their stereochemical outcomes. (E = glutamate; H 
= histidine; L = unknown ligand.)  
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Figure 2.2: (A) HEPD oxidizes 1-HEP to acetyl phosphate. (B) The most direct route to 
AP formation is through a hydroperoxylated intermediate that undergoes a subsequent 
Criegee rearrangement. Many of the intermediates in the proposed 2-HEP and 1-HEP 
catalytic cycles are analogous to each other. 
 
 Though previous studies on the carbon-carbon bond cleavage mechanism by 
HEPD made a more compelling case for the hydroperoxylation route, the possibility of 
direct hydroxylation of C2 by the ferric-hydroperoxo with concomitant scission of the 
oxygen-oxygen bond could not be excluded. After hydroxylation, the resulting acetal V 
could collapse in a manner similar to a retro-Claisen reaction, yielding formate with 
attack on the electrophilic iron(IV)-oxo in a concerted manner to form HMP 
(hydroxylation route, Figure 2.1). Alternatively, the retro-Claisen reaction might occur in 
a stepwise fashion in which the methylphosphonate (MPn) carbanion would be a discrete 
intermediate with possible stabilization by delocalization into the phosphonate group 
(endowing possible double-bond character to the P-C bond) as well as proximity to the 
positively charged Fe center. The carbanion would then attack the electrophilic iron(IV)-
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oxo species to generate hydroxymethylphosphonate and reset the active site for another 
round of catalysis. 
 The hydroperoxylation and hydroxylation mechanism each make distinct 
predictions regarding the stereochemical outcome of the reaction with 2-HEP 
stereospecifically labeled with deuterium at C1. Were hydroperoxylation active, the 
Criegee rearrangement would take place with retention due to the orbital overlap 
alignment in intermediate IIIa followed by net inversion during the subsequent SN2 
hydrolysis of IVa, leading to net inversion (Figure 2.1). By contrast, the hydroxylation 
route would likely take place in a stereospecific manner due to the concerted collapse of 
the C-C bond and formation of the C-O bond, but it was not possible to exclude the 
possibility that a stepwise process might result in an alternative stereochemical outcome. 
To differentiate between these mechanistic hypotheses, the stereochemistry of the HMP 
product using 2-HEP stereospecifically deuterated at C1 as starting material was 
therefore determined. 
 
2.1.2: Hydrogen Atom Abstraction by HEPD Is Stereo- and Regiospecific 
 To determine the stereochemical outcome of the reaction with WT HEPD, 2-[2-
2H2]-HEP was synthesized by Dr. Whitteck and incubated with HEPD. The produced 
HMP and formate were characterized as previously described1,4 demonstrating that the 
formate, but not the HMP, contained deuterium, confirming that the putative hydrogen 
atom abstraction is regioselective. To test the stereospecificity of this step, (R)- and (S)-2-
[2-2H1]-HEP (84% and 86% ee, respectively; 99% isotopic purity for both compounds) 
were synthesized8 by Dr. Whitteck and incubated with HEPD. The formate produced 
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from (R)-2-[2-2H1]-HEP contained deuterium whereas that produced with the S 
enantiomer did not. These observations show that the pro-S C2 hydrogen is abstracted, 
which agrees well with the active site geometry and bidentate substrate binding observed 
in the co-crystal structure of Cd(II)-HEPD with 2-HEP.1  
 
2.1.3: Mosher's Ester Analysis of the Stereochemical Outcome at C1   
  (R)- and (S)-2-[1-2H1]-HEP (84% and 86% ee, respectively; 99% isotopic purity 
for both compounds) were prepared as substrates for HEPD by Ms. Malova in the 
laboratory of Friedrich Hammerschmidt at the University of Vienna.8 Moreover, 
authentic (R)- and (S)-[2H1]-HMP of 99% ee were prepared from (R)- and (S)-diisopropyl 
hydroxy-[2H1]-methylphosphonate.9 As standards for comparison, Ms. Malova also 
prepared the Mosher's esters of (S) and (R)-dimethyl hydroxy-[2H1]-methylphosphonates. 
 Dr. Whitteck separately incubated synthetic (R)- and (S)-2-[1-2H1]-HEP with 
HEPD that I had prepared, derivatized the produced [2H1]-HMP to the dimethyl ester 
using trimethylsilyl diazomethane, and purified the resulting material to afford several 
milligrams of dimethyl [2H1]-HMP. The stereochemistry of the [2H1]-HMP was assessed 
by conversion to the corresponding Mosher’s esters by Ms. Malova, who also conducted 
the subsequent 1H NMR analysis (Figure 2.3) Unexpectedly, comparison with the 
Mosher’s esters prepared from authentic (R)- and (S)-[2H1]-HMP showed that HEPD 
converted both (R)- and (S)-2-[1-2H1]-HEP into near racemic [2H1]-HMP (Figure 2.3, 
Figure 2.4A).  
 30 
 
Figure 2.3: 1H NMR spectra of the PCHD groups of the authentic standards of (R)-
Mosher esters prepared from dimethyl (A) (R)- and (B) (S)-[2H1]-HMP. The 
enzymatically derived [2H1]-HMP produced from (C) (R)- or (D) (S)-2-[1-2H1]-HEP was 
derivatized to the (R)-Mosher ester in a similar manner and demonstrated that the 
outcome was racemic. Figure prepared by Ms. Malova. 
 
2.1.4: Analysis of Formate Produced Is Consistent with Racemization   
 Given the unanticipated outcome found by Mosher's ester analysis, Dr. Whitteck 
conducted an additional experiment to ensure that the stereochemical information was not 
lost during conversion of HMP to its dimethyl ester or Mosher’s ester. Previous 
experiments demonstrated that HMP was also a substrate for HEPD and was slowly 
converted to phosphate and formate.4 Dr. Whitteck determined the stereochemistry of this 
reaction. When (R)-[2H1]-HMP was incubated with HEPD, the formate generated 
contained no deuterium, whereas when (S)-[2H1]-HMP was used, the produced formate 
contained one equivalent of deuterium. This result was expected because it was 
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consistent with HMP binding in the HEPD active site in the same bidentate fashion as 2-
HEP.1 Having established that oxidation of HMP was stereospecific, Dr. Whitteck 
incubated (R)- and (S)-2-[1-2H1]-HEP with HEPD until full conversion of both 2-HEP 
and the initial HMP product took place, thus resulting in 2 equivalents of formate. If the 
conversion of 2-HEP to HMP were stereospecific at C1, the formate produced from (R)- 
and (S)-2-[1-2H1]-HEP would either contain 50% deuterium or no deuterium (Figure 2.4B 
and 2.4C). However, experimentally both enantiomers of 2-[1-2H1]-HEP resulted in 25% 
deuterium incorporation in formate (Figure 2.4D),3,10 consistent with racemization at C1 
during the conversion of 2-HEP to HMP. 
 
Figure 2.4: Explanation of the stereochemical outcome for the HEPD reaction using 
stereospecifically monodeuterated substrate. (A) The HMP that was obtained from 
reacting (R)- or (S)-2-[1-2H1]-HEP with HEPD was observed to be racemic by Mosher's 
ester analysis. (B) Reacting (R)-2-[1-2H1]-HEP with HEPD all the way to phosphate 
should produce 0% deuterated formate in the case of retention, (C) 50% deuterated 
formate in the case of inversion, or (D) 25% deuterated formate in the case of 
racemization. Similar logic can be applied in the case of (S)-2-[1-2H1]-HEP. 
 
2.2: Results and Discussion 
2.2.1: Experiments to Corroborate Racemization 
  In the previous experiment carried out in section 2.1.4, the ratio of protiated 
formate to deuterated formate during oxidation of 2-[1-2H1]-HEP to [2H1]-HMP and then 
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[2H1]-HMP to phosphate was an indirect assessment of the stereochemical outcome at 
C1. Therefore, I aimed to quench the reaction after the initial oxidation of 2-[1-2H1]-HEP 
to [2H1]-HMP and to purify the [2H1]-HMP to analyze it directly. Multiple attempts were 
made to remove the initial equivalent of formate produced during HMP formation by 
acidifying the reaction mixture and lyophilizing it to dryness. However, when the residue 
was dissolved and HEPD was added in order to react the HMP to phosphate and formate, 
no reaction took place.   
 I therefore pursued an alternative route to isolate the HMP and characterize it. 
First, I measured the steady-state kinetics of oxidation of (R)- and (S)-[2H1]-HMP in 
comparison with unlabeled HMP using a Clark-type oxygen electrode. As shown in 
Figure 2.5, this reaction exhibited a substantial primary kinetic isotope effect (KIE) on 
kcat of 7.6 ± 0.4 for (R)-[2H1]-HMP and a large secondary KIE on kcat of 1.4 ± 0.1 under 
phosphonate-saturating conditions. This observed isotope effect provided the opportunity 
to confirm racemization at C1 by isolating the [2H1]-HMP and using it as a substrate for a 
kinetic experiment. (R)- and (S)-2-[1-2H1]-HEP were separately incubated with HEPD 
until all 2-HEP was consumed as determined by 31P NMR spectroscopy. HEPD was then 
reacted with the resulting [2H1]-HMP, and the rate of oxidation was measured and 
compared to the rate of oxidation of unlabeled HMP. The HMP produced with (S)-2-[1-
2H1]-HEP resulted in an observed KIE of 2.4 ± 0.2 and the HMP produced with (R)-2-[1-
2H1]-HEP displayed an observed KIE of 2.5 ± 0.3. Importantly, a 1:1 mixture of authentic 
(R)- and (S)-[2H1]-HMP displayed an observed KIE of 2.2 ± 0.2 under the same 
conditions, agreeing well with the expected value of 2.4 for a racemic mixture (see 
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section 2.4.2). Thus, all experiments come to the same conclusion: the stereochemical 
integrity at C1 of 2-HEP is lost during the transformation to HMP. 
 
Figure 2.5: Steady-state oxidation kinetics by HEPD of HMP (black), (S)-[2H1]-HMP, 
(blue), or (R)-[2H1]-HMP (red) under air-saturating conditions. 
 
2.2.2: Racemization Does Not Occur After the Reaction 
 A pair of explanations could still allow either the hydroperoxylation or 
hydroxylation mechanism (Figure 2.1) to be operative even with the loss of 
stereochemistry.2 One model consistent with the outcome from either mechanism is 
shown in Figure 2.6. After HMP formation, the P-C bond in the product could be 
transiently broken, generating phosphite and formaldehyde in the active site of HEPD. If 
the formaldehyde is able to rotate along the C=O bond, then phosphite could attack either 
face of the carbonyl group resulting in loss of stereochemistry; racemization would 
therefore occur after the reaction rather than during it. To test this possibility, (R)-[2H1]-
HMP3,9 was incubated with HEPD under anaerobic conditions. Subsequently, the solution 
was sparged with oxygen to effect the slow but stereospecific conversion of HMP to 
phosphate and formate.3 If the (R)-[2H1]-HMP had (partially) racemized, deuterium would 
be incorporated into formate to the same extent as racemization. However, analysis of the 
formate by LC-MS after derivatization4 did not show any deuterium incorporation and 
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hence the experiment provided no evidence for racemization of (R)-[2H1]-HMP (Figure 
2.7).2 
 
Figure 2.6: After formation of HMP, racemization could potentially occur via 
breakdown of the HMP to formaldehyde and phosphite. If the lifetime of the phosphite 
anion were long enough, formaldehyde could conceivably rotate prior to the P-C bond 
being reformed.  
 
 
Figure 2.7: (R)-[2H1]-HMP was reacted with HEPD (A) after a preincubation period or 
(B) without prior preincubation. The produced formate was then derivatized and analyzed 
by LC-MS. In each panel, the blue trace is the protiated formate adduct and the red trace 
represents the formate corresponding to either the deuterated formate or the 13C isotope 
of the formate nitrophenylhydrazide adduct that was used for detection purposes. 
 
2.2.3: A Methylphosphonate Intermediate Does Not Cause Racemization  
 Another possible mechanism that could account for the production of racemic 
HMP from (R)- or (S)-2-[1-2H1]-HEP as well as the generation of acetylphosphate from 
1-HEP is the hydroperoxylation route in Figure 2.8. In this model, intermediate IIIa, 
generated as in Figure 2.1, would undergo C-C bond cleavage to produce performic acid 
and MPn, an intermediate in which all stereochemical information would be lost. Based 
on literature precedence with model compounds,11 the performic acid could oxidize the 
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iron to the corresponding ferryl species VI, which could abstract a hydrogen atom from 
MPn. Rebound of the ferric hydroxide and the organic radical would generate the HMP 
product and reset the enzyme for another turnover. This mechanism could also explain 
the formation of acetyl phosphate from 1-HEP if the hydroperoxylated intermediate 
(IIIb, Figure 2.2) generated with this substrate analog were to undergo a Criegee 
rearrangement instead of formation of performic acid.   
 
Figure 2.8: Either the hydroperoxylation route or the hydroxylation route could involve a 
methylphosphonate intermediate followed by an iron(IV)-oxo species that abstracts a 
hydrogen atom, ultimately leading to recombination of the methylphosphonate radical 
with the ferric-hydroxide. If the orange proton arising from bulk solvent were instead a 
deuteron, it would likely be retained in the product. 
 
 Prima facie, the mechanism in Figure 2.8 appears inconsistent with the previously 
observed retention of both deuterium atoms in HMP after oxidation of 2-[1-2H2]-HEP by 
HEPD.1 This mechanism would predict incorporation of a proton from solvent in 
methylphosphonate, and at least partial retention of this proton in the final product. 
However, abstractions of hydrogen atoms by ferryl species have been reported to result in 
large deuterium KIEs of 50-60 in TauD12 and prolyl-4-hydroxylase.13 A similarly large 
discrimination against deuterium abstraction from [2H1]-MPn by the ferryl intermediate 
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VI in HEPD would account for retention of both deuterium atoms in HMP because the 
sensitivity of the assay used would not be sufficient to detect <5% monodeuterated HMP. 
If the mechanism in Figure 2.8 were operational with a large KIE, an experiment 
performed with unlabeled 2-HEP in D2O should produce monodeuterated HMP (as the 
ferryl should leave the deuterium untouched). 
 HEPD was therefore incubated with 2-HEP in buffer prepared in D2O (> 99.8% 
2H-labeled), and the HMP generated was analyzed by LC-FTMS by Dr. Bradley Evans, a 
post-doctoral researcher in the Metcalf group at the University of Illinois Urbana-
Champaign. Extracted ion chromatograms were obtained using a linear ion-trap Fourier 
transform hybrid mass spectrometer allowing a 10 ppm mass error with respect to the 
theoretical masses. This method can distinguish between [2H1]-HMP and other analytes 
such as natural abundance 13C-HMP. [2H1]-HMP was not detected (Figure 2.9), indicating 
that the hydroperoxylation mechanism in Figure 2.8 cannot be correct. This result also 
excludes an alternative hydroxylation route in which hydroxylation of the C2 radical with 
concomitant ferryl formation would be followed by collapse of the acetal and generation 
of MPn with ferryl VI. As in the hydroperoxylation mechanism, ferryl VI would then 
abstract a hydrogen atom from the transiently present MPn, ultimately leading to HMP 
formation; the absence of any solvent wash-in to the HMP product likewise precludes 
this alternative possibility. 
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Figure 2.9: Extracted ion chromatograms of reaction mixtures of 2-HEP incubated with 
wt HEPD in D2O. [1H2]-HMP was observed (red, calculated 110.9847 m/z, found 
110.9852 m/z), but [2H1]-HMP (blue) was not detected. 
 
2.3: Conclusions 
 Taken together, the evidence presented herein makes a compelling argument that 
hydroperoxylation is not operative during the catalytic cycle of 2-HEP and raises the 
specter that 1-HEP induces alternative chemistry. However, computational calculations 
have suggested that 1-HEP is oxidized to acetyl phosphate without undergoing a Criegee 
rearrangement.6 In the absence of detailed characterization of any intermediates in the 
catalytic cycle of HEPD with 2-HEP, it is difficult to draw any solid conclusions 
regarding the mechanism; attempts to characterize reactive species in the HEPD reaction 
were therefore carried out and are described in Chapter 3. 
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2.4: Materials and Methods 
2.4.1: General Experimental 
 Substrates were prepared by Dr. John Whitteck (van der Donk lab, University of 
Illinois) or Petra Malova (Hammerschmidt lab, University of Vienna) as previously 
detailed elsewhere.1,3,4 Dr. Whitteck was primarily responsible for the milligram-scale 
preparation of enzymatically produced [2H1]-HMP, and Ms. Malova was responsible for 
the Mosher's ester analysis of those products.3 Dr. Whitteck was also responsible for the 
determination of racemization from the percentage of deuterated formate that was 
produced upon complete oxidation of various 2-HEP substrates to Pi and two equivalents 
of formate.3 
 
2.4.2: Steady-State Oxidation Kinetics by HEPD  
 These experiments were performed on 3/14/10, 4/3/10, 6/3/10, 7/30/10, 8/12/10, 
and 8/16/10. Steady-state oxidation kinetics were carried out on a Hansatech Oxytherm 
Electrode Unit with anaerobically reconstituted HEPD (2 µM final concentration, 1 eq. of 
Fe(II)) in air-saturated buffer (25 mM HEPES pH 7.5) by initiating with substrate (HMP, 
(R)-[2H1]-HMP, or (S)-[2H1]-HMP, varying concentrations) in triplicate.3 For the indirect 
examination of the stereochemical outcome in the HEPD reaction with 2-HEP using a 
kinetic isotope effect, reconstituted HEPD (20 µM) was taken up in buffer (25 mM 
HEPES pH 7.5, 2.0 mL total volume), and substrate (2.0 mM) was added to initiate the 
reaction. The reaction was allowed to proceed for 90 min at 23 ˚C and then protein was 
removed by centrifuge filtration (Millipore Micron YM-10, 10 kDa nominal molecular 
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weight limit). Methylphosphonate (internal standard) and D2O were added to a small 
aliquot of the flow through, and then the 31P NMR spectrum was recorded (Varian 
UI600) to confirm that complete HEP consumption had occurred.  Integration of the 31P 
NMR spectrum and comparison with the methylphosphonate internal standard afforded 
the concentration of HMP. 
 The oxygen electrode was used to determine the rate of O2 consumption. HEPD 
was freshly reconstituted as before. Substrate (1.0 mM for all substrates, except for (R)-2-
[1-2H1]-HEP which was 0.50 mM) was added to air-saturated buffer (25 mM HEPES, pH 
7.5) and the reaction was initiated by the addition of HEPD (20 µM).  Samples were run 
in triplicate and KIEs were determined by comparison to the rate of oxygen consumption 
of HMP at the same concentration as the substrate in question. HMP was obtained from 
enzymatically reacted (R)-[1-2H1]-HEP, and (S)-[1-2H1]-HEP. For comparison, HMP, 
(R)-[2H1]-HMP, (S)-[2H1]-HMP, and a 1:1 mixture of chemically synthesized (R)-[2H1]-
HMP and (S)-[2H1]-HMP were also assayed. 
 For (S)-[2H1]-HMP, kcat is 0.042 s-1, and for (R)-[2H1]-HMP, kcat is 0.0078 s-1.  
Because the Km values for (S)-[2H1]-HMP and (R)-[2H1]-HMP are very similar (240 ± 10 
and 260 ± 20 µM respectively), any racemic mixture would result in the enzyme being 
equally likely to act on (S)- or (R)-[2H1]-HMP, and therefore the kcat for the racemic 
mixture should be the average of the values for the individual enantiomers. Therefore, the 
racemic mixture would be predicted to display an apparent kcat  of 0.5 * 0.042 s-1 + 0.5 * 
0.0078 s-1 = 0.025 s-1. Since the kcat for protiated HMP is 0.059 s-1, the expected apparent 
KIE for a racemic mixture would be 0.059/0.025 = 2.4, which is in good agreement with 
the observed values. 
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2.4.3: Testing the Possibility of HMP Breakdown After the Reaction  
 This work was performed on 5/26/10. The possibility that transient breakdown of 
HMP in the HEPD active site to phosphite and formaldehyde could account for the 
observed racemization was evaluated. Anaerobically reconstituted WT HEPD (10 µM 
final concentration) was anaerobically incubated with (R)-[2H1]-HMP (1 mM final) in 
buffer (25 mM HEPES pH 7.5) and then allowed to react for 1 h or was directly allowed 
to react aerobically without any anaerobic preincubation. The reaction was quenched, 
derivatized, and analyzed as described previously.3 Because the formate was analyzed 
after condensing it with 2-nitrophenylhydrazine and the LC-MS method was insensitive 
to the presence of a +1 peak due to natural abundance of 13C in the formate adduct or 
deuterium in the formate, it was necessary to compare the samples with and without pre-
incubation. Both samples had ratios of the parent peak to the +1 peak (10.9:1) that closely 
matched what would be expected based on the isotopic distribution (11.5:1).  
 
2.4.4: Assaying the Possibility of a Methylphosphonate Intermediate  
 This assay was carried out on 10/7/10. To evaluate whether D2O was incorporated 
into HMP during the reaction of 2-HEP with HEPD, HEPD was exchanged into 
deuterated buffer (25 mM HEPES pD 7.5) using a NAP-5 desalting column and 
anaerobically reconstituted. HEPD (10 µM final concentration) was allowed to react with 
2-HEP (2 mM) in the presence of O2 and 25 mM HEPES pD 7.5. The reaction was 
centrifuge-filtered with an Amicon filter and analyzed by LC-FTMS by Dr. Bradley 
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Evans (Metcalf lab, University of Illinois) with extracted ion chromatograms used to 
evaluate the presence of HMP and [2H1]-HMP.  
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Chapter 3: Characterization of an Unexpected Ferryl Intermediate In HEPD 
Catalysis 
 
3.1: Introduction 
 As described in Chapter 2, the stereochemical outcome of HMP produced by 
HEPD was incompatible with the mechanisms postulated previously. Therefore, an 
endeavor was undertaken to obtain direct experimental evidence for an intermediate 
involved in oxidation of 2-HEP, namely the putative initial ferric-superoxo species 
(intermediate Ia in Figure 2.1).1 Despite its postulated critical role as the initial reactive 
oxygen species in catalysis for many non-heme iron enzymes, this intermediate has been 
characterized as the active C-H bond cleaving intermediate in non-heme iron enzymes 
only twice: in the diiron enzyme myo-inositol oxygenase (MIOX)2 and the mononuclear 
non-heme iron enzyme, 2,3-homoprotocatechuate dioxygenase (2,3-HPCD).3 In each 
instance, accumulation of the ferric-superoxide species in quantities necessary for 
characterization was achieved by utilizing a less activated substrate analog or a 
deuterium-labeled substrate, either of which could prolong the lifetime of an 
intermediate. I reasoned that employing 2-[2-2H2]-HEP might engender a substrate 
kinetic isotope effect (KIE) that would impose a higher energy barrier to decay of Ia, thus 
enabling the characterization of this elusive reactive oxygen species. 
 
3.2: Results 
3.2.1: Kinetics of Steady-State Oxidation of 2-HEP by WT HEPD  
 To evaluate whether the wild-type (WT) HEPD reaction with 2-[2-2H2]-HEP was 
a suitable candidate for spectroscopic studies, I first determined the Michaelis-Menten 
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kinetics of 2-[2-2H2]-HEP oxidation by WT HEPD using a steady-state continuous assay 
with an O2 electrode. WT HEPD oxidizes 2-HEP with catalytic efficiency typical of an 
enzyme involved in secondary metabolism (Table 3.1 and Figure 3.1).4 Oxidation of 2-
[2-2H2]-HEP by WT HEPD displayed a minimal KIE on kcat/Km,2-HEP and kcat, the latter of 
which suggests that any slower chemical step may be kinetically masked by a rate-
limiting physical step such as a conformational change or product release. However, the 
significant KIE on kcat/Km,O2 indicates partial-rate limitation prior to the first irreversible 
step in the catalytic cycle with respect to O2 activation upon employing dideuterated 
substrate.  
 
Figure 3.1: Michaelis-Menten oxidation kinetics by WT HEPD with (A) constant O2 and 
varying concentrations of 2-HEP (red) or 2-[2-2H2]-HEP (blue) or (B) constant 
phosphonate (red: 2-HEP, blue: 2-[2-2H2]-HEP) and varying O2 concentrations. 
 
System  
(in H2O) 
kcat (s-1) 
Km,2-HEP 
(µM) 
kcat/Km,2-HEP 
(M-1 s-1) 
Km,O2 
(µM) 
kcat/Km,O2 
(M-1 s-1) KIE (kcat) 
KIE  
(kcat/Km,2-HEP) 
KIE 
(kcat/Km,O2) 
WT HEPD, 
2-HEP 0.35 ± 0.01 10 ± 1 (3.6 ± 0.3) x 10
4 16 ± 3 (2.2 ± 0.5) x 104 
WT HEPD, 
2-[2-2H2]-HEP 
0.36 ± 0.01 14 ± 2 (2.6 ± 0.3) x 104 62 ± 7 (5.7 ± 0.7) x 103 
0.99 ± 0.04 1.1 ± 0.3 4.4 ± 1.4 
HEPD-E176A, 
2-HEP 0.75 ± 0.02 23 ± 2 (3.3 ± 0.2) x 10
4 7 ± 1 (9.9 ± 2) x 104 
HEPD-E176A, 
2-[2-2H2]-HEP 
0.59 ± 0.02 30 ± 3 (1.9 ± 0.2) x 104 28 ± 3 (2.3 ± 0.3) x 104 
1.3 ± 0.1 1.4 ± 0.3 4.3 ± 1.0 
Table 3.1: Michaelis-Menten parameters for WT HEPD and HEPD-E176A in H2O to 
determine if a system was suitable for spectroscopic characterization.  
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3.2.2: Construction and Characterization of an Active-Site Mutant of HEPD 
 Though the lack of a KIE on kcat with WT HEPD oxidation of 2-HEP under 
steady-state conditions does not preclude trapping a reactive intermediate under pre-
steady state conditions, I wondered if a mutant of HEPD might be identified that would 
exhibit a KIE on kcat (i.e. even under steady-state conditions). One candidate for 
mutagenesis was the active site glutamate residue (E176) that ligates the Fe(II). I thought 
that HEPD-E176A might retain activity with two histidines, as the non-heme iron 
halogenases SyrB2 and CytC3 are capable of catalysis despite possessing only two 
endogenous histidine ligands.5,6 Additionally, as E176 is cis to the putative O2 binding 
site in the HEPD crystal structure,7 I hypothesized that its removal might disrupt the 
hydrogen-bonding network responsible for binding H2O to the metal at the putative O2-
binding site in the absence of substrate. A less tightly anchored H2O molecule might in 
turn lead to an active site that was more reactive towards O2.8 Additionally, the steady-
state WT HEPD oxidation kinetics suggested a physical step such as substrate binding 
was rate-limiting, and therefore faster dissociation of the H2O could conceivably unmask 
a substrate KIE on kcat even under steady-state conditions.  
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Figure 3.2: (A) HEPD-E176A produces HMP (17.1 ppm) from 2-HEP (19.6 ppm) as 
observed by 31P NMR spectroscopy (B) as well as formate as determined by single ion 
monitoring (181 m/z) during LC-MS analysis of samples (black = WT HEPD; blue = 
HEPD-E176A; red = unreacted HEPD-E176A control) that had been derivatized as 
previously described.9 
 
 The HEPD-E176A variant was constructed, overexpressed, and purified similar to 
WT HEPD.7 As with WT HEPD, HMP and formate were the only products detected after 
anaerobic reconstitution with Fe(II) and subsequent incubation with 2-HEP and O2 
(Figure 3.2). However, in contrast to WT HEPD, which gained full activity upon 
reconstitution with 1 equivalent of Fe(II), HEPD-E176A required more than 1 equivalent 
of Fe(II) to reach maximal activity (Figure 3.3). With saturating concentrations of Fe(II), 
the Michaelis-Menten kinetics of oxidation of 2-HEP or 2-[2-2H2]-HEP by HEPD-E176A 
were determined as before (Figure 3.4). The kcat/Km,2-HEP of HEPD-E176A was very 
similar to WT HEPD (Table 3.1), though both the Km,2-HEP and kcat were roughly twofold 
higher. Consistent with the hypothesis that removal of the glutamate could enhance the 
reactivity with O2, the kcat/Km,O2 of HEPD-E176A for either 2-HEP or 2-[2-2H2]-HEP was 
approximately fivefold higher compared to WT HEPD. A small but reproducible KIE on 
kcat was observed suggesting that chemistry was partially rate-limiting; as with WT 
HEPD, the KIE on kcat/Km,2-HEP was relatively small and the KIE on kcat/Km,O2 was much 
larger.  The steady-state kinetics suggested that both WT HEPD and HEPD-E176A 
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would be suitable candidates for attempting to trap a reactive intermediate under pre-
steady-state conditions.  
 
Figure 3.3: WT HEPD (blue) or HEPD-E176A (red) were reconstituted with varying 
equivalents of Fe(II) followed by assaying the activity of each protein (2 µM final 
concentration in the reaction) towards 2-HEP using an O2 electrode. Under these 
conditions, WT HEPD does not require more than 1 equivalent of Fe(II) to achieve 
maximal activity, whereas HEPD-E176A does. 
 
 
Figure 3.4: Steady-state oxidation kinetics of HEPD-E176A with (A) constant O2 and 
varying concentrations of 2-HEP (red) or 2-[2-2H2]-HEP (blue) or (B) constant 
phosphonate (red: 2-HEP, blue: 2-[2-2H2]-HEP) and varying O2 concentrations. 
 
3.2.3: Pre-Steady State Kinetics Assessed by Stopped-Flow UV-Visible Spectroscopy 
 To assess whether the ferric-superoxide intermediate accumulated under pre-
steady state conditions, a collaboration was established with the Bollinger and Krebs 
group at the Pennsylvania State University. With the help of Laura Dassama, then a 
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graduate student in that group, I reconstituted WT HEPD anaerobically with Fe(II) and 
added an anaerobic solution of 2-HEP or 2-[2-2H2]-HEP. The reaction was initiated by 
rapidly mixing the anaerobic protein-phosphonate solution with an O2-saturated buffer in 
a stopped flow UV-Visible experiment. No intermediates that absorbed from 300-700 nm 
were detected. By contrast, when reconstituted HEPD-E176A was mixed with 2-[2-2H2]-
HEP and then reacted with O2-saturated buffer under identical conditions, a species that 
absorbed maximally at 320 nm was accumulated (Figure 3.5A), suggestive of a possible 
Fe(IV)=O intermediate10-12 rather than the expected ferric-superoxo species.2 As 
described previously (Chapter 1), HEPD does not require an exogenous source of 
electrons, and therefore I had anticipated that Fe(III)-superoxo I would be responsible for 
substrate activation. 
 Because the detection of a putative Fe(IV) species was surprising, this 
intermediate was further characterized to determine how it was involved in substrate 
activation. In two separate experiments, Chen Wang, a graduate student in the Bollinger 
and Krebs group, reacted HEPD-E176A with (R)-2-[2-2H1]-HEP, and I reacted HEPD-
E176A with the (S) enantiomer. The reaction resulted in a similar growth and decay of 
the intermediate as with 2-[2-2H2]-HEP for the (S) enantiomer but not the (R) enantiomer, 
indicating that the intermediate decayed by abstracting the hydrogen atom that originates 
from the pro-S C2 position. To determine the most favorable conditions for intermediate 
accumulation, Ms. Wang reconstituted HEPD-E176A with Fe(II) but did not add 2-[2-
2H2]-HEP. The anaerobic protein solution was then reacted with buffer containing both 2-
[2-2H2]-HEP and O2. The formation of the species absorbing at 320 nm was substantially 
diminished in quantity and delayed compared to preloading HEPD-E176A with 2-[2-
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2H2]-HEP (Figure 3.5), demonstrating that pre-forming the phosphonate-enzyme complex 
leads to greater amounts of intermediate accumulation.   
 
Figure 3.5: Stopped-flow experiments with HEPD-E176A under various conditions. (A)  
HEPD-E176A was reconstituted, preloaded with either 2-HEP (red), 2-[2-2H2]-HEP 
(blue) or (S)-2-[2-2H1]-HEP (black), and reacted with O2-saturated buffer. The reaction 
with (R)-2-[2-2H1]-HEP is not shown for clarity. (B) HEPD-E176A was reconstituted and 
preloaded with 2-HEP and reacted with O2 (black), preloaded with 2-[2-2H2]-HEP and 
reacted with O2 (blue), or reacted with 2-[2-2H2]-HEP in oxygenated buffer (red, no 
preloading). Note the significantly delayed maximum in the case of no pre-incubation of 
enzyme with phosphonate substrate. Panel B was prepared by Ms. Wang. 
 
3.2.4: Characterization of the Intermediate by Rapid-Freeze Quench Mössbauer 
Spectroscopy  
 To further characterize the species detected in the stopped-flow experiment, Dr. 
Dassama and I reconstituted HEPD-E176A anaerobically with 57Fe and then added an 
anaerobic solution of 2-[2-2H2]-HEP. This mixture was rapidly mixed with O2-saturated 
buffer before quenching in liquid N2/isopentane at various reaction times. Mössbauer 
spectra obtained by Professor Carsten Krebs and Dr. Dassama in the presence of a weak 
external magnetic field (53 mT) revealed the growth and then decay of a peak (Figure 
3.6) roughly in accord with the time course of the intermediate observed in the stopped 
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flow experiment. The quadrupole doublet associated with unreacted Fe(II) was 
determined by analyzing an unreacted anaerobic control; by subtracting out this Fe(II) 
signal, the parameters associated with the quadrupole doublet of the new species could be 
determined. The parameters (δ = 0.22 mm/s, |∆EQ| = 0.69 mm/s) are reminiscent of those 
associated with high spin Fe(IV)-oxo species observed in other enzymes, such as taurine 
dioxygenase (TauD), prolyl-4-hydroxylase (P4H), and tyrosine hydroxylase.11,13,14 
Additionally, the Mössbauer spectrum enabled the quantification of the amount of ferryl 
isolated, enabling the determination that ε320 = 1,300 M-1 cm-1 in conjunction with the 
stopped-flow experiment, in good agreement with iron(IV)-oxo species trapped 
previously.11,15 When Dr. Dassama and I reacted HEPD-E176A with 2-HEP or reacted 
WT HEPD with 2-[2-2H2]-HEP in oxygenated buffer, no signal other than a quadrupole 
doublet characteristic of high spin Fe(II) was detected. However, when WT HEPD was 
reacted with 2-[2-2H2]-HEP and chlorite dismutase/chlorite was used to generate O2 
levels in excess of what can be achieved by employing O2-saturated buffer,16 a peak 
consistent with the ferryl detected in the HEPD-E176A reaction was observed (Figure 
3.7). Based on the similarity of the spectroscopic parameters with the parameters from 
other iron-oxo species, this intermediate was assigned as an iron(IV)-oxo species. After 
the decay of the putative iron(IV)-oxo species, a second species accumulated with 
parameters consistent with an Fe(II) species. This species is likely an Fe(II)-product 
complex similar to those previously observed in TauD and P4H.11,15 
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Figure 3.6: Mössbauer spectra of 57Fe-reconstituted HEPD-E176A mixed with 2-[2-2H2]-
HEP and reacted with O2-saturated buffer with reaction times indicated (dashed black 
line). The theoretical spectrum of the ferryl (parameters provided in text) is shown in the 
solid red line. The spectra were recorded by Professor Krebs and Dr. Dassama. Dr. 
Dassama assembled the figure. 
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Figure 3.7: (Top) A time course of Mössbauer spectra of WT HEPD reacted with 2-[2-
2H2]-HEP using chlorite dismutase and chlorite to generate a bolus of O2 followed by 
quenching at various time points; the solid red line has the parameters that were extracted 
from the HEPD-E176A Mössbauer experiment and indicate that there is likely a ferryl 
species in the WT HEPD reaction as well. However, this peak only exists when WT 
HEPD is reacted with O2 levels in excess of what is obtainable under O2-saturating 
conditions (bottom). The reactions were performed by me and Dr. Dassama, who also 
prepared the figure. Spectra were recorded by Dr. Dassama and Professor Krebs. Dr. 
Dassama made the figure. 
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3.2.5: Kinetic Fitting of the Spectroscopic Data 
 I separately fit the stopped-flow UV-Visible data and the Mössbauer time course 
to an equation describing an intermediate formed from a single reactant and decaying to a 
single product (A B  C; A to B is governed by kform and B to C is governed by kdecay). 
The rate constants extracted from fitting the stopped-flow data yielded 2Hkform as 130 s-1 
and 2Hkdecay as 7.7 s-1. These were in good agreement with the rate constants derived from 
fitting the Mössbauer time course (2Hkform = 140 s-1 and 2Hkdecay = 8.7 s-1) (Figure 3.8). 
With protiated substrate, the ferryl species decayed too fast to obtain an accurate rate, and 
therefore only a lower bound of 100 s-1 can be placed on 1Hkdecay. The observation of a 
KIE ≥ 11 for this step is consistent with the large KIEs associated with the decay of ferryl 
species observed in TauD and P4H.11,13 Such a large KIE suggests that the ferryl decays 
by abstracting the hydrogen/deuterium atom that originates from the pro-S position at C2 
of 2-HEP. 
 
Figure 3.8: Simulated kinetics of the trapped intermediate. (A) Overlay of the quantity of 
Fe(IV) as determined by Mössbauer spectroscopy (red dots, left axis) over the stopped-
flow trace from reacting HEPD-E176A with [2-2H2]-HEP (blue trace, right axis). The 
simulation of the stopped-flow data (shown in black) and Mössbauer data gave similar 
results.  
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3.2.6: Chemical Quench Experiments Demonstrate Competence of the Intermediate 
 To ascertain whether the intermediate observed spectroscopically was 
catalytically relevant, product formation as a function of time was determined by Ms. 
Wang under similar conditions as in the previous experiments. HEPD-E176A was 
reconstituted anaerobically and then 2-[2-2H2]-HEP was added anaerobically. The 
reaction was initiated by mixing the anaerobic protein-phosphonate solution with O2-
saturated buffer and was quenched at various times. The amount of HMP present at each 
time point was quantified by LC-MS using synthetic [2H2]-HMP as an internal standard 
(Figure 3.9). Fitting the data to an exponential curve yielded a rate of product formation 
(9.5-10 s-1 from two separate experiments) that closely mirrored the rate at which the 
ferryl disappeared in both the freeze-quench Mössbauer (8.7 s-1) and stopped-flow UV-
Vis experiments (7.7 s-1), consistent with a model in which the Fe(IV) species decays 
concomitant with product formation. This observation strongly suggested that this species 
was on-pathway and not an artifact of the assays used to generate it. 
 
Figure 3.9: Rapid chemical quench experiments by Ms. Wang of HEPD-E176A with 2-
[2-2H2]-HEP demonstrate time-dependent HMP formation. Each time point was run in 
triplicate, and the entire time course was run twice. A representative curve assembled by 
Ms. Wang is shown. 
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3.2.7: Reacting HEPD-E176A with 2-[2-2H2]-HEP in Deuterated Buffer Yields 
Greater Amounts of the Ferryl Species  
 To fully characterize the reaction of HEPD-E176A with 2-[2-2H2]-HEP, Ms. 
Wang anaerobically reconstituted the protein with Fe(II) and loaded it with 2-[2-2H2]-
HEP in buffer that had been made up in H2O or D2O. The anaerobic protein-phosphonate 
solution was then mixed against O2-saturated buffer in either H2O or D2O in a stopped-
flow UV-Vis experiment, resulting in greater accumulation of a species that absorbed 
maximally at 320 nm (Figure 3.10A). To confirm that the species observed by stopped-
flow was the same ferryl species detected previously, Ms. Wang also reconstituted 
HEPD-E176A with 57Fe(II) and loaded it with 2-[2-2H2]-HEP in buffer in either H2O or 
D2O. Each solution was mixed with O2-saturated buffer in H2O or D2O, respectively, and 
then quenched by freezing the mixture in liquid N2-isopentane after identical reaction 
times. Mössbauer spectra obtained by Professor Krebs demonstrated that a species with 
the same parameters as the ferryl from earlier accumulated to greater extent in the 
reaction run in D2O (Figure 3.10B). 
 
Figure 3.10: Reactions with HEPD-E176A resulted in increased accumulation of the 
ferryl intermediate in deuterated buffer compared to protiated buffer. (A) Stopped-flow 
reactions of with 2-[2-2H2]-HEP and O2 in protiated buffer (black line) or deuterated 
buffer (red line) demonstrated that the ferryl formed and decayed at the same rate but has 
a higher amplitude in deuterated buffer. (B) Mössbauer spectra of HEPD-E176A 
incubated with 2-[2-2H2]-HEP and O2 in protiated buffer (left) or deuterated buffer 
(right). Each reaction was quenched after the same period of time. The solid red line 
indicates the signal attributed to the ferryl species. Figure compiled by Ms. Wang. 
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3.2.8: Solvent Wash-in Decreases with Increasing Ferryl Accumulation 
 In non-heme iron enzymes or catalysts that hydroxylate their substrates, the 
observation of solvent-derived hydroxyl groups in the product has been rationalized by 
invoking solvent exchange through an oxo-hydroxo tautomerism at a high-valent iron 
intermediate (Figure 3.11A) prior to C-H bond cleavage rather than during the short-lived 
ferric hydroxide substrate radical stage after substrate activation.17-19 I confirmed that 
when HEPD-E176A was incubated with 18O2 and 2-HEP, the HMP product displayed 
retention of roughly 60% 18O, in line with what had previously been observed with WT 
HEPD under similar conditions.7 Next, I incubated HEPD-E176A with 18O2 and 2-[2-
2H2]-HEP. Though greater ferryl accumulation could enable more solvent exchange to 
occur, instead 60% 18O retention in the HMP product was again observed.  
 
Figure 3.11: (A) The paradigm for solvent exchange in non-heme iron enzymes invokes 
an oxo-hydroxo tautomerism, in which two positions are equilibrated by a proton transfer 
step. (B) The data at hand suggests that solvent exchange does not take place during the 
ferryl intermediate, but rather likely occurs at the ferric hydroxide stage.  
 
 Finally, I reasoned that by performing the reaction with HEPD-E176A and 18O2 
with 2-[2-2H2]-HEP in D2O, thus accumulating the maximal amount of ferryl possible, a 
greater amount of solvent exchange might take place. In this case, the 18O content in the 
HMP product increased to roughly 80%, consistent with a decrease in solvent exchange. 
To further investigate this unexpected observation, the deuterium content of the reaction 
buffer of the WT HEPD or HEPD-E176A reaction with 2-[2-2H2]-HEP was 
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systematically varied, with the 18O label originating from 18O2 or from a combination of 
H218O/D218O. After correcting for the fraction of isotopic enrichment, the conclusion 
reached was the same: solvent wash-in is significantly diminished in the presence of 
deuterated buffer (Figure 3.12), leading to the proposal that solvent exchange occurs not 
during the ferryl intermediate, but instead at the ferric-hydroxide intermediate (Figure 
3.11B and see Discussion). The observed solvent isotope effect on solvent exchange/O2 
retention in the product could originate from rebound occurring preferentially with the 
hydroxide (originally derived from O2) over the water ligand; proton transfer (more 
energetically challenging in deuterated buffer) would be required to equilibrate these two 
positions and effect solvent wash-in. 
 
Figure 3.12: The percent of label retention from the gas source increases as the 
deuterium content of the reaction increases. The results from using the label in the gas 
(18O2, blue) agree well with using labeled water (red, H218O and/or D218O as appropriate). 
 
3.2.9: Kinetics of Steady-State Oxidation of 2-HEP by WT HEPD and HEPD-E176A 
in Deuterated Buffer 
 Given these changes in the pre-steady state reactivity and the solvent exchange in 
reactions run in D2O, I decided to examine whether there was a solvent kinetic isotope 
effect under steady-state conditions. With either WT HEPD or HEPD-E176A, steady-
state kinetics in deuterated buffer completely abolished the small substrate KIE on kcat 
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while introducing a large solvent KIE on kcat (Figure 3.13 and Table 3.2). Proton 
inventories of WT HEPD or HEPD-E176A with either 2-HEP or 2-[2-2H2]-HEP appeared 
linear in all cases (Figure 3.14), consistent with a single solvent-exchangeable proton 
moving in the isotopically-sensitive rate-determining step. The kinetic data is consistent 
with proton transfer during product release as the slow step under steady-state conditions. 
 
Figure 3.13: Michaelis-Menten kinetics in D2O with WT HEPD (A) with varying 2-HEP 
and constant O2 and (B) with varying O2 and constant 2-HEP. Michaelis-Menten kinetics 
of HEPD-E176A were similarly determined in D2O (C) with varying 2-HEP and constant 
O2 and (D) with varying O2 and constant 2-HEP. In each graph, the protiated 2-HEP 
curve is in red, and the 2-[2-2H2]-HEP curve is in blue. 
 
System  
(in D2O) 
kcat (s-1) 
Km,2-HEP 
(µM) 
kcat/Km,2-HEP 
(M-1 s-1) 
Km,O2 
(µM) 
kcat/Km,O2 
(M-1 s-1) 
Solvent KIE 
(kcat) 
Substrate KIE 
(kcat) 
WT HEPD, 
2-HEP 0.11 ± 0.004 8.3 ± 1.0 (1.3 ± 0.2) x 10
4 8.2 ± 0.9 (1.3 ± 0.2) x 104 3.3 ± 0.4 
WT HEPD, 
2-[2-2H2]-HEP 
0.10 ± 0.01 9.3 ± 1.4 (1.1 ± 0.2) x 104 22 ± 2 (5.0 ± 0.5) x 103 3.0 ± 0.2 
1.0 ± 0.1 
E176A HEPD, 
2-HEP 0.30 ± 0.02 62 ± 5 (4.9 ± 0.5) x 10
3 6.1 ± 1.1 (5.2 ± 0.9) x 104 2.5 ± 0.3 
E176A HEPD, 
2-[2-2H2]-HEP 
0.30 ± 0.01 34 ± 3 (8.7 ± 0.7) x 103 21 ± 3 (1.5 ± 0.2) x 104 2.2 ± 0.1 
1.0 ± 0.1 
Table 3.2: Steady-state kinetic parameters of 2-HEP or 2-[2-2H2]-HEP oxidation by WT 
or HEPD-E176A in D2O. 
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Figure 3.14: Proton inventories of (A) WT HEPD with 2-HEP (red) or 2-[2-2H2]-HEP 
(blue) demonstrate linear relationships, consistent with a single proton moving in the 
isotopically sensitive step. The same phenomenon is observed with (B) HEPD-E176A 
with 2-HEP (red) or 2-[2-2H2]-HEP (blue). Crossing at (or near) n = 1.0 indicates that the 
kcat for either substrate in D2O is roughly the same, consistent with the Michaelis-Menten 
kinetics observed in Figure 3.11. 
 
3.3: Discussion 
 A combination of isotope labeling studies, use of substrate analogs, and DFT 
calculations were previously used to formulate a pair of mechanistic hypotheses for 
HEPD catalysis (Figure 2.1). Each of these mechanisms postulated that a Fe(III)-
superoxo species (Ia in Figure 2.1) cleaves the C-H bond of 2-HEP. Attempts to trap this 
species in this study instead resulted in identification of an intermediate with UV-Vis and 
Mössbauer spectral characteristics strongly resembling Fe(IV)-oxo species  trapped in 
other enzymes such as TauD, P4H, and tyrosine hydroxylase.11,14,15 Each of these 
enzymes requires two electrons from the Fe(II) center and two electrons from a 
cosubstrate (either α-ketoglutarate for TauD and P4H or tetrahydropterin for tyrosine 
hydroxylase) to completely cleave the O2 and to form the Fe(IV)=O species. By contrast, 
HEPD requires no cosubstrate other than O2 for catalysis, and therefore formation of the 
iron-oxo intermediate can only occur after two electrons have been extracted from the 
substrate rather than prior to substrate activation. Conceivably two tyrosines in the active 
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site could each donate a single electron to cleave O2 prior to substrate activation, but 
mutation of these residues to phenylalanine residues yields constructs that remain active. 
A second compelling reason that the Fe(IV)=O reported herein cannot be responsible for 
the initial C-H cleavage is that reacting HEPD-E176A with 2-[2-2H2]-HEP in deuterated 
buffer increases the amount of ferryl detected by stopped-flow UV-Vis and freeze-
quench Mössbauer spectroscopy (Figure 3.10). Neither of the C2 protons is solvent-
exchangeable prior to substrate activation, and thus the observation of a solvent kinetic 
isotope effect indicates that the ferryl probably decays by abstracting a hydrogen atom 
from a rapidly exchangeable position that is likely a heteroatom. 
 Given these results, a reformulated mechanism is proposed in Figure 3.15. For the 
reasons discussed above, a ferric-superoxo species I (rather than the characterized ferryl) 
likely cleaves the C-H bond to activate the substrate. From ferric-hydroperoxo II, at least 
two possible pathways could explain the formation of the trapped Fe(IV). Based on DFT 
calculations on HEPD20 as well as studies with substrate analogs with 
hydroxypropylphosphonate epoxidase, which demonstrated rapid electron transfer from a 
ketyl radical to the Fe center,21,22 one scenario involves electron transfer from the ketyl 
radical to the metal, reducing the Fe(III) to Fe(II) ("electron transfer" route). The ferrous-
hydroperoxo III could then undergo heterolytic scission with nucleophilic attack on the 
nearby aldehyde to form the ferryl species. In an alternative route, homolytic bond 
cleavage of the peroxo species would directly yield the acetal and iron(IV) oxo species 
IV ("hydroxylation" route). 
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Figure 3.15: A mechanistic hypothesis for catalysis by HEPD. 
 
 In either of these routes, several intermediates can undergo exchange of the 
original pro-S hydrogen at C2 of 2-HEP (blue in Figure 3.15) for a deuterium derived 
from bulk solvent. Such exchange could explain all of the observations with labeled 
substrates or solvent. First, the observation that the ferryl did not accumulate with 2-HEP 
but was observed with 2-[2-2H2]-HEP in protiated buffer is consistent with incomplete 
wash-out of the deuterium from the substrate on the time-scale of the intermediates 
leading to the ferryl. Indeed, as predicted, when the reaction was performed in buffered 
D2O, a significantly greater amount of ferryl was observed, consistent with the 
abstraction of a solvent-exchangeable hydrogen atom. The model can also explain several 
other observations. First, the reaction in D2O resulted in increased build-up of the ferryl 
with 2-[2-2H2]-HEP but use of D2O did not lead to observation of the intermediate with 
unlabeled HEP. The inability to observe any intermediate in the reaction with unlabeled 
HEP in H2O suggests that the conversion of intermediate IV to gem-diol V is fast. If so, it 
may be too fast for solvent exchange, explaining why conducting the experiment with 
unlabeled HEP in D2O did not result in observation of the ferryl species. On the other 
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hand, when the substrate was deuterium labeled, the hydroxyl group in IV (blue in Figure 
3.15) would be deuterated. Apparently the KIE on the conversion of IV to V is 
sufficiently large to allow detection of IV. This prolonged lifetime may in turn allow 
solvent exchange, resulting in more build-up of the intermediate when the reaction was 
conducted with 2-[2-2H2]-HEP in D2O than in H2O because in D2O intermediate IV 
would be fully deuterium labeled, whereas in H2O, some of the deuterium originating 
from 2-[2-2H2]-HEP would exchange with protium from solvent. The inability to detect 
the iron(IV)-oxo intermediate in the reaction of unlabeled HEP in D2O demands that the 
exchange must take place at intermediate IV and not earlier (e.g. intermediates II  or III).   
The identical rates of formation of the ferryl when the experiment was conducted 
with 2-[2-2H2]-HEP in H2O and D2O are readily explained since all steps up to the 
formation of the ferryl do not involve a chemical step cleaving/forming a bond to a 
hydrogen/deuterium that is in an exchangeable position. The identical rates of decay in 
H2O and D2O are at first glance more puzzling. Once again, it is important to note that 
the intermediate is not observed with unlabeled 2-HEP suggesting IV decays too fast to 
be detected by stopped-flow UV-Vis if the hydroxyl group of the acetal carries a protium. 
Therefore, all of the species observed in the stopped-flow experiments presumably 
contain a deuterium on the hydroxyl group, and the decay rate of this species will be 
identical in H2O and D2O.  
One facet of this mechanism that needs discussion is that the bond dissociation 
energy for an O-H bond is at least 7-10 kcal/mol higher than the C-H bonds typically 
targeted for cleavage by iron(IV)-oxo species. Though high spin Fe(IV)=O intermediates 
typically require the targeted H atom to align collinearly with the Fe-O bond, recent work 
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has shown that these intermediates can activate their substrates even when collinear 
arrangements are impossible by using intermediates with π character.27-29 Due to the 
constraints of the active site, the latter route is likely operative in the case of HEPD; 
indeed, two separate theoretical studies postulated that such a π attack by a ferryl in 
HEPD could cleave the O-H bond depicted in Figure 6.10,12 Hirao and Morokuma 
concluded that ferryl IV was not smoothly connected to the intermediates that came 
before it and that it would have to traverse energy barriers higher than their preferred 
alternative mechanism.10 By contrast, Du et al. argued that in the preferred pathway, a 
ferryl IV performs water-assisted abstraction of the hydrogen in the O-H bond of the 
acetal to cause β-scission in a concerted fashion.12 The detection of a chemically and 
kinetically competent ferryl intermediate provides experimental support for its 
intermediacy during HEPD catalysis, and the observed substrate and solvent kinetic 
isotope effects provides support for its abstraction of a hydrogen atom from an H-O bond.  
 After hydrogen abstraction by the ferryl IV, the proposed catalytic mechanism is 
unchanged from previous proposals. Cleavage of the O-H bond of IV yields a gem-diol 
radical V that could undergo beta scission to generate a methylphosphonate radical and 
ferric hydroxide VI. The P-C bond in the methylphosphonate radical has been calculated 
to have a low energy barrier to rotation.11 Rotation before recombination would explain 
the racemization in the HMP product when 2-HEP stereospecifically deuterated at C1 
was employed as substrate.7 Subsequent product release is likely the rate-determining 
step under steady-state conditions, as evidenced by the small substrate KIEs on kcat under 
steady-state conditions with wt HEPD under steady-state conditions9 and the 
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accumulation of an Fe(II)-product complex in the Mössbauer experiment even in the 
presence of excess substrate.  
 The combination of pre-steady-state kinetics and steady-state kinetics has enabled 
the placement of this ferryl intermediate in the context of the catalytic cycle for HEPD. It 
is unclear why it is possible to trap the Fe(IV) species in HEPD-E176A but not WT 
HEPD. One possibility is that HEPD-E176A exhibits enhanced reactivity with O2 
compared to WT HEPD. This hypothesis is consistent with the greater kcat/Km,O2 for 
HEPD-E176A compared to WT HEPD as well as the detection of the Fe(IV) species in 
WT HEPD when it was reacted with higher O2 concentrations accessible only by using 
chlorite dismutase/chlorite to generate a bolus of O2.16 Yet another possibility is that 
deletion of the glutamate residue compromises reactivity of reactive intermediates up to 
and including the ferryl, and (through means not fully understood) delays the formation 
and decay of the ferryl to a time regime that is compatible with the spectroscopic 
techniques employed herein. It is tempting to speculate that this mechanistic hypothesis 
for HEPD could also explain the catalytic cycle for a related non-heme iron dioxygenase, 
methylphosphonate synthase, 35 as discussed in Chapters 4 and 5.  
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3.4: Materials and Methods. 
3.4.1: Fe(II) Titrations for WT HEPD and HEPD-E176A  
 These assays were performed on 2/1/10 and 12/8/11. Steady-state oxidation 
kinetics for WT HEPD and HEPD-E176A were determined using a Clark-type Oxytherm 
Electrode Unit (Hansatech, Inc). First, the affinity for Fe(II) was established. WT HEPD 
(40 µM final concentration) or HEPD-E176A (70 µM final concentration) was 
anaerobically reconstituted in 25 mM HEPES pH 7.5 by adding varying equivalents of 
Fe(II) (0-3 eqs. for WT HEPD, 0-5 eqs. for HEPD-E176A), and the protein solution was 
allowed to incubate on ice for 10 min. Activity was then assayed by monitoring O2 
consumption in air-saturated buffer (25 mM HEPES pH 7.5, 280 µM O2) at 20 ˚C in the 
presence of WT HEPD or HEPD-E176A (2 µM) after addition of 2-HEP (250 µM for 
WT HEPD or 400 µM for HEPD-E176A). Activity at each concentration of Fe(II) was 
normalized to the maximum observed; assays were run in triplicate.  
 
3.4.2: Steady-State Kinetic Assays with WT HEPD and HEPD-E176A  
 These experiments were carried out on 10/29/13, 3/20/14, 3/21/14, 3/23/14, 
3/26/14, 3/28/14, 4/4/14, 4/7/14, 4/8/14, and 4/10/14. WT HEPD or HEPD-E176A were 
purified as previously specified with an additional size exclusion purification step as 
detailed elsewhere to isolate the active dimer fraction.4,7 In a typical reconstitution, WT 
HEPD or HEPD-E176A was first anaerobically reconstituted on ice with Fe(II) (1 eq. for 
WT HEPD, 3 eq. for HEPD-E176A) to a final concentration of 40 µM in 50 mM HEPES 
pH 7.5. After at least 10 min of incubation, the protein was removed from the anaerobic 
chamber. For Michaelis-Menten kinetics with varying phosphonate and a constant O2 
 66 
concentration, 1 µM of protein was diluted into air-saturated 50 mM HEPES pH 7.5 
(~280 µM O2 at 20 ˚C); then the phosphonate substrate (5-100 µM for WT HEPD, 10-
250 µM for HEPD-E176A) was added and the rate of O2 consumption was monitored. 
For varying the concentration of O2, the buffer (50 mM HEPES pH 7.5) was sparged with 
N2 from a house source for various amounts of time to generate solutions with different 
concentrations of O2 (10-250 µM). The protein (1 µM final concentration) and then 
phosphonate were added (250 µM for either WT HEPD or HEPD-E176A), and the rate of 
O2 consumption was monitored in triplicate. For the Michaelis-Menten kinetics 
determined in D2O, the assays were run as above, except the buffer of the protein solution 
was first exchanged to buffer made in D2O (50 mM HEPES pD 7.5) by washing the 
protein in a 0.5 mL Amicon centrifuge filter five times such that the theoretical residual 
amount of protiated buffer was <1%. Additionally, substrate stocks were diluted into D2O 
such that in any given reaction, the deuterium content was >98%. For the proton 
inventory assay, WT HEPD or HEPD-E176A were reconstituted as before; either protein 
(1 µM final concentration) was then assayed for activity at a saturating concentration of 
phosphonate (250 µM for either enzyme with 2-HEP or 2-[2-2H2]-HEP) in buffer with 
varying D2O content (adjusted by varying the concentration of 50 mM HEPES pH 7.5 
and 50 mM HEPES pD 7.5). 
 
3.4.3: Confirming the Products of HEPD-E176A Catalysis  
 These experiments were done on 4/1/10 and 5/26/10. The products of incubating 
2-HEP with HEPD-E176A were confirmed to be HMP by 31P NMR spectroscopy and 
formate by an LC-MS analysis following derivatization. To confirm HMP formation, 
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HEPD-E176A was reconstituted as before and then incubated (10 µM final 
concentration) with O2-saturated buffer (25 mM HEPES pH 7.5) in the presence of 2-
HEP (2 mM). After 2 h incubation, EDTA (25 mM final concentration), dithionite (10 
mM final concentration), and D2O (20% final v/v) were added, and the 31P NMR 
spectrum was recorded.36 Signals were confirmed by spiking with the authentic samples. 
To confirm formate production, reconstituted HEPD-E176A (2 µM final concentration) 
was incubated with 2-[2-13C]-HEP (2 mM, to circumvent spurious formate 
contamination) in O2-saturated buffer (25 mM HEPES pH 7.5). After 5 min of reaction, 
the solution was quenched, derivatized, and analyzed as previously described in detail.9 A 
positive control run with WT HEPD under identical conditions confirmed that HEPD-
E176A produced formate under these conditions. 
 
3.4.4: Stopped-Flow UV-Visible Experiments 
 This experiment was carried ou on 9/5/11. I assayed WT HEPD and HEPD-
E176A by stopped-flow for a possible intermediate under nearly-identical conditions. 
Either construct was reconstituted (4.0 mM stock, 1.0 mM final concentration) 
anaerobically with Fe(II) (1 eq. for WT, 3 eqs. for HEPD-E176A) in 50 mM HEPES pH 
7.5 at 4 ˚C for >10 min. An anaerobic solution of 2-HEP, 2-[2-2H2]-HEP, or (S)-2-[2-
2H1]-HEP was added (2.0 mM final concentration), and the protein-substrate solution was 
allowed to incubate at 4 ˚C for a further >10 min. This solution was mixed (1:1 v/v) with 
buffer (50 mM HEPES pH 7.5) that had been O2-saturated at 0 ˚C by repeated pump-
refill cycles, and the UV-Vis spectrum was monitored as a function of time at ~4 ˚C. 
Additional experiments without preloading the protein with the phosphonate substrate, 
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reacting HEPD-E176A with (R)-2-[2-2H1]-HEP, and comparing the accumulation of the 
ferryl intermediate in a reaction run in H2O vs. D2O were performed by Ms. Wang. 
 
3.4.5: Mössbauer Time Course of HEPD-E176A and 2-[2-2H2]-HEP  
 This assay was carried out on 9/6/11. Aided by Dr. Dassama, I constructed a 
Mössbauer time course of HEPD-E176A reacting with 2-[2-2H2]-HEP by first 
reconstituting HEPD-E176A (4.0 mM stock, 3.4 mM final concentration) with 1 eq. 57Fe 
in 50 mM HEPES pH 7.5 at 4 ˚C for 10 min. An anaerobic solution of 2-[2-2H2]-HEP 
was added (6.8 mM final concentration) at 4 ˚C, and the solution was allowed to incubate 
for 10 min. An aliquot of the protein-phosphonate solution was removed as an unreacted 
anaerobic control to serve as a baseline for comparison; the remainder was transferred 
into a 1 mL glass-barrel syringe. Buffer (50 mM HEPES pH 7.5) that had been O2-
saturated at 0 ˚C by repeated pump-refill cycles was loaded from a tonometer into a 2 mL 
glass-barrel syringe. The solutions were mixed together (1:2 v/VI mix of protein-
phosphonate:O2-saturated buffer) at 4 ˚C followed by quenching the reaction by rapidly 
freezing it in a solution of liquid N2/isopentane maintained at -155 ˚C  (final reaction 
concentrations: 1.1 mM 57Fe-HEPD-E176A, 2.3 mM 2-[2-2H2]-HEP, 1.3 mM O2 in 50 
mM HEPES pH 7.5) after varying reaction times (10-500 ms). Samples were packed into 
Mössbauer cups and analyzed by Mössbauer spectroscopy in the presence of a weak 
external magnetic field (53 mT) by Professor Krebs and Dr. Dassama. 
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3.4.6: Generating the Ferryl Intermediate in WT HEPD  
 These assays were performed on 7/29/11 and 7/31/11. Dr. Dassama also helped 
me in an attempt to generate the same ferryl by reacting WT HEPD with 2-[2-2H2]-HEP. 
To do this, WT HEPD (3.4 mM final concentration prior to mixing) was reconstituted 
with 57Fe (1 eq.) in 50 mM HEPES pH 7.5, and then 2-[2-2H2]-HEP was added 
anaerobically (2 eqs., 6.8 mM pre-mix concentration). An aliquot was removed as an 
unreacted control sample, and the remainder of the anaerobic protein-phosphonate 
solution was transferred to a 2 mL glass-barrel syringe. Chlorite (96 mM premix) and 
chlorite dismutase (125 µM premix) were separately prepared in 50 mM HEPES pH 7.5 
and loaded into two 0.5 mL glass-barrel syringes. The reaction was initiated at 4 ˚C by 
mixing the protein-phosphonate solution with the chlorite dismutase and then rapidly 
mixing the resulting solution with the chlorite solution (final reaction conditions: 2.3 mM 
57Fe-WT HEPD, 4.6 mM 2-[2-2H2]-HEP, 20 µM chlorite dismutase, 16 mM chlorite in 
50 mM HEPES pH 7.5) followed by rapid quenching after 70-80 ms in a liquid 
N2/isopentane cold bath. Samples were also generated at 10 and 25 ms using identical 
conditions but with lower concentrations of WT HEPD (900 µM) and 2-[2-2H2]-HEP (1.8 
mM). Samples were packed into Mössbauer cups and analyzed by Mössbauer 
spectroscopy in the presence of a weak external magnetic field (53 mT) by Professor 
Krebs and Dr. Dassama. 
 
3.4.7: Quantifying Solvent-Exchange in HEPD-E176A 
 These reactions were performed on 10/31/13, 1/28/14, 2/3/14, and 4/4/14. To 
quantify solvent wash-in or retention of oxygen from O2 in the HMP product, 18O2 (97% 
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18O) was obtained from Sigma Aldrich while H218O (97% 18O) and D218O (97.6% D, 97% 
18O) were obtained from Cambridge Isotope Labs. In a typical assay using labeled 18O2, a 
stock solution of HEPD-E176A was made anaerobic by using a NAP-5 column 
equilibrated with anaerobic buffer (50 mM HEPES pH 7.5, degassed on a Schlenk line by 
repeated pump-refill cycles). The degassed HEPD-E176A solution (40 µM final 
concentration) was anaerobically reconstituted with Fe(II) (3 eqs.) in 50 mM HEPES pH 
7.5 and 2-[2-2H2]-HEP was added (1 mM final concentration). For the reaction in D2O, 
the same conditions were used as in the protiated case except the HEPD-E176A bulk 
solution was exchanged into buffer made in D2O (50 mM HEPES pD 7.5) using a 0.5 mL 
30 kDa MWCO Amicon centrifuge filter. This process ultimately allowed a deuterium 
content of ~99% to be reached in the final reaction. For the ~50% deuterated buffer 
conditions, equal parts of the anaerobic protein-phosphonate solution in H2O and in D2O 
were mixed. Each reaction (500 µL total) was transferred to a 15 mL round-bottom flask 
equipped with a stir-bar and sealed tightly with a septum and Parafilm. A canister of 18O2 
was fitted with the appropriate regulator and septum, and the regulator headspace was 
purged with 18O2 several times. A 10 mL sample lock syringe was used to remove 18O2 
from the canister and to charge each of the three reaction flasks (~10 mL of 18O2, 
pressure unknown). The reactions were allowed to stir in an anaerobic chamber at room 
temperature for 2 h. The reactions were quenched by removing the protein in each with a 
0.5 mL 30 kDa centrifuge filter that had been rinsed with degassed water to remove any 
traces of contaminating 16O2.  
 The filtrates (1 µL) were separated by liquid chromatography coupled to multi-
reaction mode, which monitors the transition of a given m/z value fragmenting to another 
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m/z. The components of the filtrate were separated by using LC (Thermo Scientific 
Hypercarb 100 x 4.6 mm, 5 µm mesh) with a gradient of 25 mM ammonium acetate in 
H2O (buffer A) and acetonitrile (buffer B). The column was equilibrated with a 98:2 
mixture of buffer A:buffer B. Following injection, this ratio was maintained for 2 min, 
after which the mobile phase was gradually changed to 50:50 mixture of buffer A:buffer 
B over the course of 8 min. The mobile phase was returned to a 98:2 mixture of A:B over 
1 min and held at that concentration for a further 6 min to reequilibrate the column. At all 
stages, the flow rate was maintained at 0.3 mL/min. After chromatographic separation, 
the samples were analyzed by in-line detection with a 5500 QTrap (AB Sciex)  by 
monitoring the 113->62.9 m/z (18O-HMP) and 111->62.9 m/z (16O-HMP) transitions in 
negative mode (curtain gas: 32 psi; voltage: 4,500 V; temperature: 450 ˚C; N2 gas one: 50 
psi; N2 gas two: 65 psi). Percent retention of the label was corrected for based on the 
isotopic composition of the reaction. 
 For the labeling reactions using H218O and/or D218O, WT or HEPD-E176A (final 
concentration of 40 µM) was reconstituted with Fe(II) (1 eq. for WT HEPD, 3 eq. for 
HEPD-E176A) directly in H2O, or first exchanged into buffer made in D2O and then 
reconstituted depending on the desired final D2O content of the reaction. The buffer used 
in all cases was 25 mM HEPES pH/D 7.5. The protein solution (5 µM final concentration 
in the reaction) was removed from the anaerobic chamber and additional H218O, H2O, 
D2O, and/or D218O were added as needed to adjust the total deuterium content of the 
solution to the desired concentration (0-98%) while maintaining the 18O content of the 
reaction at 48.5%. Substrate (2-HEP or 2-[2-2H2]-HEP) was added (1 mM final 
concentration), and the solution (150 µL) was allowed to react under atmospheric 
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conditions for 2 h at room temperature. The reaction was quenched by filtering with a 0.5 
mL 30 kDa MWCO centrifuge filter and analyzed by LC-MRM as before. 
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Chapter 4: Stereochemical Outcome of the MPnS Reactiona 
 
4.1: Introduction 
 As outlined in Chapter 1, methylphosphonate synthase (MPnS) is a non-heme iron 
enzyme with low sequence similarity to 2-hydroxyethylphosphonate dioxygenase 
(HEPD) and 2-hydroxypropylphosphonate epoxidase (HppE). Despite low sequence 
similarity, many of the residues known to be important either for binding the phosphonate 
substrate or Fe(II) in HEPD or HppE are conserved in the MPnS sequence (Figure 1.8). 
MPnS was shown to accept 2-HEP in an O2-dependent manner to produce MPn1 and, as 
with HEPD, the enzyme does not require external electrons for catalysis. However, 
HEPD transfers the oxygen atoms from O2 to both C1 and C2 of 2-HEP whereas MPnS 
completely oxidizes C2 to CO2 or bicarbonate while reducing C1. This unprecedented 
reaction between MPnS and 2-HEP requires the removal of both hydrogen atoms at C2. 
Understanding the chemistry associated with MPnS catalysis not only is important for 
understanding phosphonate metabolism but also has environmental implications as the 
enzyme may represent a key step in methane production in the oceans.1 
 To investigate the mechanism of catalysis by MPnS with 2-HEP, a post-doctoral 
researcher in the van der Donk group, Dr. Heather Cooke, first determined the ratio of O2 
consumed to MPn produced during the reaction. An assay mixture containing 1 µM 
MPnS, which was anaerobically reconstituted with one equivalent of Fe(II), was allowed 
                                                
a This is an unofficial adaptation of an article that appeared in an ACS publication. ACS 
has not endorsed the content of this adaptation or the context of its use. The article can be 
found online at http://pubs.acs.org/doi/abs/10.1021%2Fja306777w.  
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to equilibrate in the chamber of a Clark-type oxygen electrode. Catalysis was initiated by 
the addition of 2-HEP, and the consumption of O2 was monitored. An aliquot of the assay 
mixture was removed when about 25 µM O2 had been consumed. The sample was 
quenched, and the mixture was analyzed by LC-MS to determine the amount of MPn 
produced using a standard curve. The ratio of MPn produced to O2 consumed was 1.05 ± 
0.07 based on three independent experiments.2 Consistent with this unity stoichiometry of 
O2 consumed to product oxidized (both transformations are four-electron processes), I 
was unable to detect H2O2 formation (a two-electron reduction of O2) during 2-HEP 
turnover by MPnS.2 
 
4.2: Results 
4.2.1: Steady-State Oxidation Kinetics of 2-HEP Isotopologues 
 With the stoichiometry of O2 consumption established, the kinetic parameters of 
the oxidation of 2-HEP by MPnS were determined by both Dr. Cooke and me. The 
dependence of the rate of O2 consumption on the concentration of O2 was established by 
a steady-state continuous assay using the oxygen electrode, establishing a Km,O2 < 5 µM. 
The dependence of O2 consumption on the concentration of 2-HEP, determined by initial 
rate measurements, also exhibited Michaelis-Menten kinetics with a Km of 4.5 µM for 2-
HEP and a kcat of 0.18 ± 0.01 s-1 at an oxygen concentration of 280 µM (Table 4.1, Figure 
4.1).2 To provide information on the timing of the removal of the two hydrogen atoms at 
C2 and to investigate whether either hydrogen transfer occurred in a (partially) rate-
limiting step, the kinetics of three previously synthesized isotopologues,3,4 (R)- and (S)-2-
[2-2H1]-HEP, and 2-[2-2H2]-HEP were determined (Figure 4.1). At saturating 2-HEP 
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concentrations, the isotopologues displayed rates that were not significantly different 
from that of unlabeled 2-HEP at close to identical O2 concentrations (280 µM), indicating 
that hydrogen transfers do not contribute substantially to the overall rate equation for kcat 
under these conditions. Although the errors on Km are relatively large, making strong 
conclusions difficult to draw, the values of kcat/Km suggest that a small kinetic isotope 
effect (KIE) on the bimolecular rate constant for both enantiomers of 2-[2-2H1]-HEP may 
exist (Table 4.1). One possible explanation for these observations is that the rate of kcat 
may be limited by a physical step such as substrate binding or product release whereas 
the steps involved in removal of each of the hydrogen atoms at C2 contribute to kcat/Km. 
 
Figure 4.1: Steady-state oxidation kinetics by MPnS of (A) 2-HEP, (B) (R)-2-[2-2H1]-
HEP, (C) (S)-2-[2-2H1]-HEP, or (D) 2-[2-2H2]-HEP under air-saturating conditions. 
 
Substrate kcat Km (µM) kcat/Km (M-1 s-1) 
2-HEP 0.18 ± 0.01 4.5 ± 1.4 (4.0 ± 1.3) x 104 
(R)-2-[2-2H1]-HEP 0.17 ± 0.01 7.1 ± 2.3 (2.4 ± 0.8) x 104 
(S)-2-[2-2H1]-HEP 0.17 ± 0.01 6.6 ± 2.0 (2.5 ± 0.7) x 104 
2-[2-2H2]-HEP 0.17 ± 0.01 7.2 ± 1.2 (2.4 ± 0.4) x 104 
Table 4.1: Kinetic parameters of phosphonate oxidation by MPnS. 
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4.2.2: Stereochemistry of Initial Hydrogen Atom Abstraction from 2-HEP 
 Based on previous observations when the enantiomers of 2-
hydroxypropylphosphonate ((2R)- and (2S)-HPP) were reacted with HEPD,5 only the 
(2R)-HPP substrate was expected to bind in the MPnS active site in a conformation that 
would present a hydrogen atom for abstraction. Reactivity with one substrate but not the 
other would therefore indicate which hydrogen atom of 2-HEP is removed by MPnS in 
the initial activation of the substrate. Dr. Cooke observed negligible oxygen consumption 
with (2S)-HPP, suggesting that this enantiomer is not a substrate for MPnS. In contrast, 
when Dr. Cooke reacted (2R)-HPP with MPnS, oxygen consumption was observed but 
the activity ceased well before complete consumption of the substrate. Furthermore, the 
recovered enzyme was inactive towards 2-HEP. These findings suggest a time-dependent 
inactivation of MPnS by (2R)-HPP. Next, Dr. Cooke and I separately carried out an assay 
containing 1.5 mM (2R)-HPP and 0.5 mM MPnS and analyzed the reaction by 31P NMR 
spectroscopy, revealing three new resonances (Figure 4.2). Nearly all of the substrate was 
converted to 2-oxopropylphosphonate (OPP; 10.8 ppm), with small amounts of MPn 
(23.1 ppm) and inorganic phosphate (Pi, 3 ppm) also formed. Very little substrate 
remained (20.3 ppm). The identity of all products was confirmed by spiking with 
authentic synthetic materials.3,5 Oxidation of an alcohol group to a ketone in a substrate 
analog was also observed with HEPD5 and HppE.6,7 That only the R enantiomer of 2-HPP 
was a substrate for MPnS suggested that the pro-S hydrogen on C2 of 2-HEP was 
removed initially, consistent with a similar first step of HEPD with 2-HEP. Furthermore, 
the stereochemical removal of the pro-S hydrogen of 2-HEP is also congruent with the X-
ray structure of HEPD3 and the sequence homology of HEPD with MPnS (Figure 1.8). 
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(2S)-HPP is likely not a substrate because the C2 hydrogen is not positioned correctly in 
the active site for abstraction. 
 
Figure 4.2: 31P NMR spectrum demonstrating that MPnS abstracts the pro-S hydrogen 
atom from (2R)-HPP and subsequently converts it to a variety of products. Figure 
assembled by Dr. Cooke. 
 
 The inactivation of MPnS by (2R)-HPP must be a complex process because 
several phosphorus-containing products are observed: methylphosphonate, phosphate, 
and 2-oxopropylphosphonate. The mechanism in Figure 4.3 tentatively explains the 
formation of the detected products as well as the observed enzyme inactivation. 
Assuming that the initial steps for MPnS catalysis with (2R)-HPP are the same as those 
for 2-HEP (vide infra), superoxo intermediate Ia would abstract the C2 hydrogen atom to 
form hydroperoxo species IIa. Following reduction of the Fe center to the ferrous state, 
intermediate IIIa could partition to generate either 2-oxopropylphosphonate and release 
hydrogen peroxide (which can oxidize the enzyme to an inactive ferric state) or, by 
analogy to the HEPD catalytic cycle with 2-HEP, hydrogen atom abstraction by species 
IVa would yield a gem diol radical that would then induce β-scission and form a MPn 
radical (Figure 4.3, red arrow). In the absence of formate (see below), this MPn radical 
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may abstract a hydrogen atom from the methyl group of acetate bound to the metal. 
Alternatively, hydrolysis of intermediate IIIa would yield phosphate and an enolate 
anion; protonation of this species would form acetone.  
 
Figure 4.3: A possible mechanism by which both 2-OPP and MPn could be produced 
from incubating MPnS with (2R)-HPP. The rate of hydroxylation of ketone IIIa would 
govern how much 2-OPP is made compared to how much MPn is formed. Phosphate 
could be formed if the 2-OPP substrate were attacked in a manner reminiscent of how 
many phosphonate hydrolases operate. 
 
 Formation of MPn via the mechanism outlined in Figure 4.3 would also yield an 
equivalent of glycolate if recombination with the hydroxide took place. I therefore further 
examined the byproducts of the reaction between MPnS and (2R)-HPP. Indeed, glycolate 
was observed after derivatization of the organic acids5 and subsequent analysis by LC-
MS (Figure 4.4). Control reactions in which MPnS was not reconstituted but the reaction 
mixture was derivatized5 did not display any derivatized glycolate. Similarly, a control in 
which the MPnS reaction was run normally but 2-nitrophenol hydrazine (2-NPH) was 
omitted during the derivatization procedure displayed no derivatized glycolate. Hence, 
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the glycolate appears to be enzyme-generated. Our proposed mechanism was further 
supported indirectly by showing, via O2 consumption with 2-HEP as substrate, that MPnS 
was reactivated upon addition of fresh Fe(II) (100 µM) or ascorbic acid (1 mM) signaling 
that inactivation appears to be a consequence of oxidation of the iron, possibly as a 
consequence of H2O2 release. 
 
Figure 4.4: Extracted ion chromatograms (210 m/z, negative mode, corresponding to 
derivatized glycolate) of various experiments after derivatization. The glycolate standard 
(black) eluted with the same retention time as an unknown organic acid found in the 
reaction between MPnS and (2R)-HPP (red). No glycolate was detected in the 
unreconstituted MPnS control reaction (blue) or when 2-NPH was omitted from the 
derivatization reaction (green). 
 
4.2.3: Origin of the Incipient Hydrogen in MPn 
 The conversion of 2-HEP to MPn requires the acquisition of a proton or hydrogen 
atom at C1 during or following C-C bond cleavage. This hydrogen can come from either 
bulk solvent (or enzyme) or from the substrate itself. Dr. Cooke and I independently 
examined both possibilities by assaying MPnS in 99.9% D2O with 2-HEP, and in H2O 
with (S)- or (R)-2-[2-2H1]-HEP. The resulting MPn products were analyzed by LC-FTMS 
by Dr. Bradley Evans to determine whether [2H1]-MPn (m/zcalc = 95.99663) or unlabeled 
MPn m/zcalc = 94.99036) was produced (Figure 4.5). The assays containing D2O and (S)-
2-[2-2H1]-HEP produced unlabeled MPn, signifying that the new hydrogen on the carbon 
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of MPn does not originate from solvent (or solvent exchangeable residues on the enzyme) 
or from the pro-S hydrogen on C2 of 2-HEP (Figure 4.5A and 4.5B). In the assay 
containing (R)-2-[2-2H1]-HEP, however, only deuterium labeled MPn was observed by 
FT-MS (Figure 4.5C), indicating that the pro-R hydrogen of 2-HEP is transferred to MPn 
during catalysis. A 1H-coupled 31P NMR spectrum enabled observation of the coupling of 
the protons to the 31P nucleus, and confirmed the transfer of the pro-R hydrogen on C2 of 
2-HEP to the methyl group of the MPn product (Figure 4.6). 
 
Figure 4.5: MPnS labeling results by MS. FT-MS analysis (negative mode) after 
incubation of MPnS with (A) 2-HEP in D2O, (B) (S)-2-[2-2H1]-HEP in H2O or (C) (R)-2-
[2-2H1]-HEP in H2O to determine the origin of the third hydrogen on MPn. The ion at 
m/z 95.02508 in panel C is not unlabeled MPn but an unknown impurity outside the 10 
ppm error range calculated for MPn. The MS data was corroborated by 31P NMR 
analyses of the products (Figure 4.6). Figure made by Dr. Evans. 
 
Figure 4.6: Confirming incorporation of the pro-R hydrogen in the MPn product. 1H-
coupled 31P NMR analysis of with (A) 2-HEP in D2O, (B) (S)-2-[2-2H1]-HEP in H2O or 
(C) (R)-2-[2-2H1]-HEP in H2O demonstrated the presence of a -CH3 group in the MPn 
product in the first two cases and a CH2D moiety (hence the triplet) in the last case. 
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4.3: Discussion 
 Taken together, the data presented herein suggest that the initial abstraction step 
in MPnS catalysis mirrors that in HEPD catalysis and that the final intermediate is also a 
MPn radical (Figure 4.7).2,4 Therefore, as in HEPD catalysis, after abstraction of the 
pro-S hydrogen atom from C2 of 2-HEP by the ferric superoxo species Ib, the ketyl 
radical IIb might transfer an electron to the Fe(III), generating phosphonoacetaldehyde 
ligated to the iron (Figure 4.7).8 These two steps could also occur in a concerted process 
with electron transfer commencing during hydrogen atom abstraction from C2. As with 
HEPD, attack of ferrous-hydroperoxo IIIb with cleavage of the O-O bond could be one 
possible route to generate ferryl IVb (Figure 4.7); direct hydroxylation would also afford 
intermediate IVb. A second hydrogen atom abstraction event by the ferryl would 
generate a gem-diol radical,8 ultimately resulting in C-C bond cleavage, forming a MPn 
radical and formate bound to the ferric-iron center (Vb). In MPnS, however, the MPn 
radical is proposed to abstract the hydrogen atom on formate, resulting in MPn and a CO2 
radical anion. The latter is a very strong reductant9 that can reduce the metal center back 
to its ferrous state, preparing the enzyme for another round of catalysis following release 
of CO2 and MPn. Alternatively, hydrogen atom abstraction from formate and electron 
transfer to the Fe(III) could occur simultaneously.  
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Figure 4.7: A possible mechanism to explain the incorporation in MPn of the hydrogen 
atom originating from the pro-R position at C2 (shown in orange) of 2-HEP. 
 
 In HEPD catalysis, MPn radical Vb likely has a low barrier to rotation along the 
P-C bond axis, resulting in scrambling of the stereochemistry at C1 and racemic HMP.4 
The MPnS active site likely traps formate in the active site and positions it to facilitate 
abstraction of the hydrogen atom (originally derived from the pro-R position at C2). 
Though there is no direct evidence for equivalent intermediates in HEPD and MPnS 
catalysis (i.e. a consensus mechanism), the likelihood that the active site architectures are 
similar (Figure 4.8) coupled with the hypothesis that the first and last intermediates are 
similar constrains the energetic landscape and mechanistic trajectory. As described in 
Chapter 5, the characterization of a mutant of HEPD that produces both MPn and HMP 
with isotope-sensitive branching is consistent with a late-stage intermediate that 
determines product identity. 
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Figure 4.8: Overlay of the active site of MPnS (light blue sticks) from a homology model 
generated by Phyre10 with the HEPD•Cd(II)•2-HEP cocrystal structure (green sticks).3  
 
 In summary, this study provides the first mechanistic insights into catalysis by 
MPnS. The data suggest that following removal of the pro-S hydrogen, the pro-R 
hydrogen is transferred from C2 of 2-HEP to the methyl group of MPn. Neither step is 
rate-limiting under saturating substrate concentrations. Further elucidation of the details 
of the early steps requires spectroscopic characterization of the intermediates11 or 
possibly a combination of 2H and 18O-kinetic isotope effects.12,13 Preliminary studies 
using the latter are described in Chapter 5. MPnS is another addition to the impressive 
array of transformations catalyzed by non-heme iron dependent enzymes.14,15 
 
4.4: Materials and Methods 
4.4.1: Kinetic Assays  
 These experiments were performed on 9/2/12, 9/6/12, and 3/25/14. MPnS was 
purified and reconstituted as previously reported.1,2 For steady-state kinetic assays of 
MPnS, MPnS was anaerobically reconstituted with 1 eq. of Fe(II) in 50 mM HEPES pH 
 89 
7.5. Kinetic assays were performed by holding one substrate (O2 or phosphonate) at a 
saturating concentration and varying the concentration of the other substrate with MPnS 
(1 µM final concentration) in 50 mM HEPES pH 7.5 at 20˚ C. Dr. Heather Cooke (van 
der Donk group, University of Illinois) independently assayed MPnS steady-state kinetics 
and obtained very similar numbers. 
 
4.4.2: Stereochemistry of Hydrogen Atom Abstraction  
 These experiments were performed on 8/19/12, 8/23/12, and 9/6/12. Dr. Cooke 
also established the activity of MPnS towards (2R)-HPP and not (2S)-HPP. I confirmed 
that glycolic acid was formed during the incubation of MPnS (first anaerobically 
reconstituted with 1 eq. Fe(II), 500 µM final concentration) with 2R-HPP (1.5 mM) in 25 
mM HEPES pH 7.5 by subsequently derivatizing the reaction with 2-nitrophenyl 
hydrazine and the coupling reagent EDC as specified elsewhere.4 I also confirmed that 
after incubation with (2R)-HPP (1.5 mM), MPnS (10 µM) activity towards 2-HEP was 
partially rescued by adding ascorbic acid (1 mM) or Fe(II) (100 µM). 
 
4.4.3: Determining the Origin of the Incipient Hydrogen Atom in MPn  
 This assay was performed on 9/2/12. Samples to determine the origin of the 
incipient proton in MPn were generated by both Dr. Cooke and myself; LC-FTMS 
analysis was carried out by Dr. Bradley Evans (Metcalf group, University of Illinois), and 
31P NMR analysis was carried out by me. Briefly, anaerobically reconstituted WT MPnS 
in deuterated buffer (25 mM HEPES pD 7.5, total 2H content > 98%) or in protiated 
buffer (25 mM HEPES pH 7.5) was added (20 µM final protein concentration) to 
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substrate (2-HEP in D2O, (S)-2-[2-2H1]-HEP in H2O or (R)-2-[2-2H1]-HEP in H2O, 1 mM 
final concentration) and the reaction mixture was allowed to incubate at room 
temperature. After 2 h, the reaction mixtures were filtered through an Amicon centrifuge 
filter (30 kDa MWCO); 20% (v/v) D2O was added to all reaction samples, and the 31P 
NMR spectrum was recorded with the 1H decoupler turned off. An aliquot was also 
reserved for LC-FTMS analysis. 
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Chapter 5: Evidence of a Consensus Mechanism for HEPD and MPnS 
 
5.1: Introduction 
 The sequence homology between HEPD and MPnS combined with the 
observation that MPnS transfers the pro-R hydrogen atom from C2 of 2-HEP to the 
methyl group in MPn led to the hypothesis that these proteins operate by a similar 
mechanism in the early stages of catalysis but then diverge at a late intermediate. Based 
on the accumulated evidence for HEPD (Chapters 2 and 3) and MPnS (Chapter 4), this 
intermediate is likely a carbon-centered radical that can either recombine with the ferric 
hydroxide to afford HMP or abstract a hydrogen atom from formate to generate MPn 
(Figure 5.1). That neither enzyme requires an exogenous source of electrons implies that 
putative ferric-superoxo species I is responsible for the initial substrate activation in each 
enzyme. In each case, cleaving the pro-S hydrogen atom at C2 of 2-HEP would yield 
ketyl radical II (Figure 5.1).  As discussed in Chapter 3, this intermediate is then 
hypothesized to convert to a ferryl that was observed for HEPD, but these early steps of 
catalysis in each protein remained uncharacterized experimentally.  
 
Figure 5.1: Hypothesized early and late intermediates in the catalytic cycle of HEPD and 
MPnS. Studies on active site mutants of HEPD and the HEPD/MPnS homologs described 
in this chapter were designed to find a system that could facilitate accumulation of 
intermediate I. The substrate analogs were designed to report on the existence of ketyl 
radical II. 18O KIE studies could in theory report on any intermediate as long as it occurs 
before the first irreversible step (here shown as the hydrogen atom abstraction step). 
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 Several different approaches were pursued to characterize these hypothesized 
early intermediates in catalysis. Given the success at trapping an intermediate with the 
HEPD-E176A construct (Chapter 3), I hypothesized that it might be possible to trap 
ferric-superoxo I by perturbing the active site. To do so, the iron-binding glutamate 
residue in WT HEPD was mutated to a histidine to endow the active-site Fe(II) in HEPD 
with a 3-His coordination sphere and perturb the kinetics or stability of the ferric-
superoxo species, possibly enabling its accumulation. In a second approach to identify the 
early pathway intermediates, I characterized a series of HEPD and MPnS homologs 
identified in bacterial genomes with the hope that different active site architectures in one 
of these proteins might sufficiently stabilize the ferric-superoxo species such that it could 
be trapped. Cleavage of the C-H bond would generate ketyl radical II, which could be 
indirectly detected by using a moiety that reports on the presence of an α radical such as 
a cyclopropane group, which can undergo ring-opening in the presence of a nearby 
radical or cation,1-3 or halogenated substrate analogs, which can undergo halide ion 
elimination in the presence of a nearby radical.4,5 Because it was unknown which of these 
substrate analogs would be accepted for turnover by HEPD and MPnS, a series of 
analogs were synthesized and tested. Finally, competitive 18O KIE studies were 
performed with WT HEPD and WT MPnS and 2-HEP and 2-[2-2H2]-HEP as substrates in 
collaboration with the Klinman laboratory at U.C. Berkeley. This measurement reflects 
the reactive intermediates up to and including those in the first irreversible step in the 
catalytic cycle6 and therefore could report on putative intermediates in the mechanism 
including ferric-superoxo I and ferric-hydroperoxo II.  
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5.2 Results and Discussion 
5.2.1: A Bifunctional Mutant of HEPD 
 HEPD-E176H was constructed via site-directed mutagenesis, overexpressed, and 
purified using the same procedure as has been detailed elsewhere for WT HEPD.7 The 
protein was reconstituted anaerobically with varying equivalents of Fe(II), and the 
activity of the mutant was determined with a continuous, steady-state assay using a Clark 
O2 electrode as reported previously.8 In contrast to WT HEPD, which required only 1 
equivalent of Fe(II) to reconstitute full activity, HEPD-E176H needed more than 1 
equivalent of Fe(II) to attain maximal activity, similar to the observations with the E176A 
construct (Chapter 3). Use of the O2 electrode also enabled determination of Michaelis-
Menten parameters for both 2-HEP and 2-[2-2H2]-HEP as well as those of O2 (Table 5.1, 
Figure 5.3). HEPD-E176H appeared to have a minimal kcat enhancement compared to that 
observed when the glutamate was mutated to alanine and overall exhibited similar kinetic 
parameters to WT HEPD and HEPD-E176A (Table 3.1). The high affinity for O2 
however precluded any determination if there was a KIE on kcat/Km,O2. 
 
Figure 5.2:  Dependence of the activity of HEPD-E176H on the equivalents of Fe(II) 
demonstrating that more than 1 equivalent of Fe(II) was required to saturate the active 
site. In the assay used as a proxy for Fe(II) binding, the HEPD-E176H concentration was 
2 µM, and maximal activity was achieved with roughly 6 µM Fe(II) in the reaction.  
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Figure 5.3: Steady-state kinetics with HEPD-E176H were determined with 2-HEP (red) 
or 2-[2-2H2]-HEP (blue). 
 
Substrate kcat (s-1) Km,2-HEP (µM) Km,O2 (µM) KIE, kcat 
2-HEP 0.38 ± 0.01 23 ± 3 < 5  
2-[2-2H2]-HEP 0.26 ± 0.01 25 ± 2 < 5 
1.50 ± 0.05 
Table 5.1: Steady-state Michaelis-Menten kinetic parameters with HEPD-E176H. 
 
 To confirm HMP formation, the products generated by incubation of HEPD-
E176H and 2-HEP were analyzed by 31P NMR spectroscopy, which showed complete 
consumption of starting material and the appearance of three species (Figure 5.4A). The 
signals at 17 and 3 ppm were identified as HMP and Pi, respectively, as determined by 
spiking with the authentic compounds; Pi is likely the result of HEPD-like oxidation of 
HMP. However, the additional resonance at 23 ppm remained unidentified. Because of 
the homology between MPnS and HEPD, the additional resonance was likely MPn. This 
hypothesis was confirmed by spiking the sample with authentic MPn, indicating that the 
E176H mutation had endowed this protein with the ability to bifurcate activity between 
native HEPD activity and novel MPnS functionality. 
 As discussed in Chapter 4, the incipient hydrogen atom in MPn generated by 
reacting 2-HEP with MPnS is derived from the pro-R hydrogen at C2 rather than from 
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bulk solvent or solvent-exchangeable protons from the protein itself.9 This result enabled 
the formulation of a mechanism that could explain this observation (Figure 4.7). To 
investigate whether an identical labeling pattern occurred in MPn produced by HEPD-
E176H, 2-HEP was incubated with enzyme in buffer made up in D2O, and (R)-2-[2-2H1]-
HEP or (S)-2-[2-2H1]-HEP were separately incubated with the enzyme in buffer made up 
in H2O. After Chelex treatment to remove Fe(II), removal of enzyme, and addition of 
D2O, the 1H-decoupled 31P NMR spectra were recorded (Figure 5.4). While the 
experiment with 2-HEP in D2O and the reaction of (S)-2-[2-2H1]-HEP in H2O had similar 
MPn to HMP and Pi ratios, the reaction with (R)-2-[2-2H1]-HEP displayed a greatly 
reduced amount of MPn compared to HMP and Pi. In addition, the 1H-coupled 31P NMR 
spectra demonstrated that the additional proton in MPn did not derive from either bulk 
solvent (Figure 5.4A inset) or the pro-S C2 hydrogen (Figure 5.4B inset) as observed by a 
quartet splitting pattern for the phosphorus in MPn in each case. In the case of (R)-2-[2-
2H1]-HEP, the MPn signal appeared to be a triplet (Figure 5.4C inset). However, a triplet 
would be consistent with transfer of the pro-R hydrogen at C2 into the methyl group of 
MPn, which is the labeling pattern observed in MPn produced by MPnS.9 The 
approximately 1:1 ratio of HMP and phosphate to MPn when 2-HEP was the substrate 
indicated that the energy barriers for hydroxyl radical recombination (Figure 5.5, blue 
arrow, "HEPD") or hydrogen atom abstraction from formate (green arrow, "MPnS") were 
roughly equal in height. The dramatic shift in product distribution to 11:1 in favor of 
HEPD activity with a deuterium atom installed at the C2 pro-R position implied a large 
kinetic isotope of approximately 10 in the step that determined whether MPn or HMP 
was formed. 
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Figure 5.4: 1H-decoupled 31P NMR spectra of the reaction of HEPD-E176H with (A) 2-
HEP in buffered D2O, (B) (S)-2-[2-2H1]-HEP in buffered H2O or (C) (R)-2-[2-2H1]-HEP 
in buffered H2O. Inset: the MPn signal from the 1H-coupled 31P NMR spectrum of each 
reaction; the MPn derived from 2-HEP in D2O or (S)-2-[2-2H1]-HEP in H2O split into 
quartets whereas that from (R)-2-[2-2H1]-HEP in H2O split into a triplet. 
 
 
Figure 5.5: Energy landscape of the partitioning of HEPD-E176H. His176 could form a 
hydrogen bond to the formate and orient it for attack by the MPn radical. 
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 Because of the limited quantity of (R)-2-[2-2H1]-HEP available and the small 
amount of MPn produced from this substrate, I sought to corroborate transfer of the pro-R 
C2 hydrogen by using 2-[2-2H2]-HEP as a substrate in a relatively large-scale reaction 
with HEPD-E176H. After treating the reaction with Chelex to remove Fe(II), removing 
the enzyme, and lyophilizing the reaction mixture, the residue was redissolved in D2O. 
Separately, protiated and monodeuterated MPn were generated enzymatically as 
standards by reacting MPnS with either 2-HEP or 2-[2-2H2]-HEP. A 1H-decoupled 31P 
NMR spectrum of the HEPD-E176H reaction with 2-[2-2H2]-HEP displayed two resolved 
peaks at ~23 ppm (Figure 5.6). The identities of the two peaks were confirmed as 
protiated and monodeuterated isotopologues of MPn by spiking with the authentic 
standards. The upfield peak corresponded to protiated MPn, whereas the downfield peak 
corresponded to monodeuterated MPn. The observation of protiated MPn is a 
consequence of consequence of incomplete deuterium-labeling in the substrate. Though 
the lack of baseline resolution between the isotopologues of MPn in the 31P NMR 
spectrum precludes unambiguous quantitation, the product distribution agrees relatively 
well with the outcome observed in the reactions of HEPD-E176H with the 
monodeuterated enantiomers (Figure 5.4). 
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Figure 5.6: To corroborate the transfer of the pro-R hydrogen at C2 into MPn, (A) a large 
scale reaction (5 mL) was carried out between HEPD-E176H and 2-[2-2H2]-HEP 
resulting in the formation of two signals corresponding to different MPn isotopologues. 
(B) The upfield peak was confirmed to be protiated MPn by spiking with enzymatically 
generated MPn, and (C) the downfield peak was determined to be monodeuterated MPn 
by spiking with enzymatically generated [2H1]-MPn using MPnS and 2-[2-2H2]-HEP. The 
integration numbers are such that the total product (including HMP and Pi, not shown) is 
100.  
 
5.2.2: Pre-Steady-State Reactivity of the HEPD-E176H Mutant 
 As mentioned previously, I hypothesized that a 3-His coordination sphere might 
perturb the kinetics and/or stability of the reactive intermediates leading to the ferryl 
intermediate that was trapped in HEPD-E176A (Chapter 3) and permit the accumulation 
of the still-elusive Fe(III)-superoxo complex. Therefore, HEPD-E176H was anaerobically 
reconstituted and either 2-HEP or 2-[2-2H2]-HEP was added. The anaerobic protein-
phosphonate solution was rapidly mixed with O2-saturated buffer, and the reaction was 
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monitored in a stopped-flow UV-Visible spectroscopic experiment (Figure 5.7). Whereas 
no intermediates absorbing from 300-700 nm accumulated when the reaction was carried 
out with 2-HEP, an intermediate with maximal absorbance at 320 nm formed with 2-[2-
2H2]-HEP and decayed at faster rates (2Hkform = 170 ± 10 s-1 and 2Hkdecay = 19 ± 1 s-1)  than 
the ferryl observed in the case of HEPD-E176A (2Hkform = 140 s-1 and 2Hkdecay = 8.7 s-1) 
(Chapter 3). The origin of the rate enhancement for formation and decay of the ferryl 
species in HEPD-E176H is unclear, but the observation of the ferryl suggested that it is 
operative in catalysis by both HEPD-E176H and HEPD-E176A. Unfortunately, this result 
also indicated that HEPD-E176H and 2-[2-2H2]-HEP would not enable trapping the 
putative Fe(III)-superoxo species. 
 
Figure 5.7: Stopped-flow experiments with HEPD-E176H under various conditions. 
HEPD-E176H was reconstituted, premixed with either 2-HEP (red) or 2-[2-2H2]-HEP 
(blue) and reacted with O2-saturated buffer. 
 
5.2.3: Tuning the Product Distribution of the HEPD-E176H Mutant 
 To determine if the active site architecture of HEPD-E176H might provide an 
explanation for its unanticipated bifunctional activity, HEPD-E176H was cocrystallized 
with Cd(II) by Jon Chekan, a graduate student in the Nair group at the University of 
Illinois Urbana-Champaign. Rather surprisingly, the Cd(II) structure exhibited ill-defined 
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electron density for His176 (Figure 5.8), in contrast to the well-defined electron densities 
for the native histidines, which were conformationally fixed by virtue of binding to the 
active site Cd(II). The multiple conformers observed for His176 suggested that it did not 
bind the active site metal, and that E176H exists as a 2-His-ligated enzyme rather than a 
3-His enzyme. The flexibility also explained why more than one equivalent of Fe(II) was 
necessary to reconstitute full activity of the construct. Moreover, compared to the 
Cd(II)•WT HEPD crystal structure, the Cd(II) was displaced farther from the residue at 
position 176 (Figure 5.8); this cavity might enable the His176 residue to form a hydrogen 
bond with formate in the active site of HEPD-E176H and anchor it so as to facilitate 
abstraction of the hydrogen atom from formate to generate MPn rather than HMP. 
 
Figure 5.8: Crystal structure of Cd(II)•HEPD-E176H (green sticks) superimposed on the 
Cd(II)•WT HEPD•2-HEP cocrystal structure (blue sticks). (B) A rotated view of panel A. 
The Cd(II) was displaced and might have caused a cavity to form that formate could 
occupy. Note the multiple conformations adopted by His176, indicated by the arrow. 
   
 To explore the hypothesis that formate lingering in the active site of HEPD-
E176H enabled formation of MPn (Figure 5.5), HEPD-E176H was reacted with 2-HEP 
with or without exogenous formate and the product distribution was determined by 31P 
NMR spectroscopy. If the HEPD-E176H active site were solvent-exposed during 
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catalysis, formate could dissociate from the protein; additional formate in the reaction 
buffer might then saturate the active site and skew the product ratio towards MPn and 
away from HMP. However, the reaction supplemented with formate had a nearly 
identical ratio of MPn to HMP as the reaction without formate (Figure 5.9). 
 
Figure 5.9: 31P NMR spectra of the reaction of (A) HEPD-E176H (5 µM) with 2-HEP (1 
mM) or with (B) additional formate (1 mM) added prior to the start of the reaction. The 
ratio of MPn (21.5 ppm) to HMP (16.5 ppm) was approximately the same in either case. 
The signal at 18.7 ppm corresponded to residual 2-HEP. 
 
 In the crystal structures of WT HEPD and HEPD-E176H, the hydroxyl group of 
Ser196 was observed to be 4.1 Å from the Cd(II). Mutating Ser196 to a larger residue 
that projects farther into the active site and has the capacity to donate a hydrogen bond to 
the formate might lock the formate into a conformation better suited for attack by the 
methylphosphonate radical and skew product distribution towards MPn. Therefore, the 
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HEPD-E176H/S196D and E176H/S196N double mutants were constructed by site-
directed mutagenesis, expressed, and purified. After anaerobic reconstitution with Fe(II), 
the constructs were incubated with 2-HEP and the reaction mixtures were analyzed by 31P 
NMR spectroscopy. HMP was the only product observed in the samples (Figure 5.10). 
The increased size of the Asp and Asn residues might have caused a steric clash that 
precluded retention of the formate in the active site, or they may have reoriented the 
formate such that hydrogen atom abstraction by the MPn radical was no longer possible.  
 
Figure 5.10: 31P NMR spectrum of the reaction of 2-HEP (20.5 ppm) with (A) HEPD-
E176H/S196D or (B) HEPD-E176H/S196N indicated that HMP (17.6 ppm) was the sole 
product of catalysis. MPn (~23 ppm) was not detected. 
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5.2.4: Enzymes with Homology to HEPD and MPnS 
 In an effort to discover novel phosphonate biosynthetic gene clusters and possible 
bioactive compounds, Dr. Kou-San Ju, a post-doctoral scholar in the Metcalf group at the 
University of Illinois Urbana-Champaign, led a team in screening several thousand 
strains from the Agricultural Research Service/Northern Regional Research Laboratory 
(NRRL) for phosphonate biosynthetic gene clusters. To do so, the team screened the 
genomic DNA of these species with degenerate primers for the gene encoding 
phosphoenolpyruvate mutase (PepM), which catalyzes the initial step in most known 
phosphonate biosynthetic pathways. From this initial screen, several hundred strains 
encoding PepM were identified; the genomes of these strains were subsequently 
sequenced to obtain information about their phosphonate biosynthetic gene clusters, 
many of which were found to harbor HEPD/MPnS analogs. With the help of Dr. James 
Doroghazi, a post-doctoral associate in the Metcalf group at the University of Illinois, I 
constructed a phylogenetic tree based on the amino acid alignment of the various 
homologs revealed that putative HEPD and MPnS proteins separated into two distinct 
clades (Figure 5.11). Notably, the gene cluster responsible for argolaphos biosynthesis in 
Streptomyces monomycini contained an HEPD/MPnS-like protein that clustered with 
MPnS even though HEPD-like activity would enable a more direct route to the isolated 
phosphonotripeptide product (Figure 5.12). Therefore, I sought to clarify this discrepancy 
between the hypothesized reactivity and the phylogeny of these enzymes. Additionally, it 
was hoped that homologous enzymes might be more amenable either to crystallization 
conditions (to which MPnS has proved recalcitrant) or to spectroscopic techniques to trap 
the putative ferric-superoxo species I. 
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Figure 5.11: A phylogenetic tree based on an amino acid alignment of the proteins with 
homology to MPnS or HEPD. The originally characterized HEPD from S. 
viridochoromogenes is indicated in red; MPnS from N. maritimus is in blue. 2-
Hydroxypropylphosphonate epoxidase from S. wedmorensis was used as an outgroup. 
Figure assembled with help from Dr. Doroghazi. 
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Figure 5.12: (A) The phosphonate gene cluster from S. monomycini contains a number of 
proteins widely found in other phosphonate gene clusters. (B) A retrosynthetic analysis of 
the phosphonotripeptide natural product isolated from S. monomycini. After the 
successive action of PepM, phosphonopyruvate decarboxylase (Ppd) and a group III 
alcohol dehydrogenase (AD) to furnish 2-HEP, a number of other proteins in the cluster 
could lead to the final product. The implicated ligases are outside the depicted window of 
the gene cluster. The cluster lacks an appropriate hydroxylase, further supporting the 
notion that the HEPD/MPnS homolog is functionally an HEPD. 
 
 The homolog from S. monomycini was cloned as an N-terminal His6-fusion, 
overexpressed, and purified. The protein was anaerobically reconstituted with one 
equivalent of Fe(II) and incubated with 2-HEP. The O2 concentration during the reaction 
was monitored using an O2 electrode (Figure 5.13A), which demonstrated that O2 
consumption occurred in an enzyme-dependent fashion. 31P NMR spectroscopy 
confirmed that HMP was the sole product of 2-HEP oxidation by the S. monomycini 
HEPD homolog (Figure 5.13B). Interestingly, this protein retains many residues observed 
in the HEPD7 or HppE10 crystal structures that are important for substrate or metal 
binding (Figure 5.14) but the S. monomycini protein lacks a metal-binding residue at the 
positions where HEPD and HppE harbor carboxylic acids. The absence of a conserved 
carboxylic acid ligand is more reminiscent of MPnS from Nitrosopumilis maritimus 
rather than HEPD from Streptomyces viridochromogenes. 
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Figure 5.13: Activity of the homolog from S. monomycini towards 2-HEP. (A) The 
protein was observed to consume O2 in the presence of 2-HEP; additional aliquots of 
enzyme were added at 100 s and 200 s to confirm that this consumption of O2 was 
enzyme-dependent. (B) The sole product that was observed by 31P NMR spectroscopy 
was HMP. 
 
 
Figure 5.14: A Clustal alignment of the characterized HEPD/MPnS homologs. Residues 
thought to be important for substrate binding are highlighted in red; those responsible for 
binding Fe(II) are highlighted in blue. As with MPnS, the four homologs that cluster with 
MPnS but are functional HEPDs lack a carboxylic acid at either position where HEPD or 
HppE have a glutamate residue (indicated by a blue arrow). 
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 Curious about how many other functional HEPD homologs might be clustered 
based on sequence with MPnS in the phylogenetic analysis, the HEPD/MPnS homologs 
from Streptomyces albus, Streptomyces griseus, and Streptomyces griseofuscus were 
cloned as N-terminal His6-fusions, overexpressed, and purified to homogeneity. Though 
all these homologs are clustered in the same clade as the S. monomycini protein, these 
three additional proteins were picked because Dr. Kou-san Ju in the Metcalf group had 
already isolated genomic DNA from those three organisms. After anaerobic 
reconstitution with Fe(II), each protein was found to consume O2 in the presence of 2-
HEP and oxidized 2-HEP to HMP as determined by 31P NMR spectroscopy (Figure 
5.15). To understand the structural features that induce MPnS activity over HEPD 
activity, an attempt was made to obtain crystal structures in collaboration with a post-
doctoral researcher in the Drennan group at the Massachusetts Institute of Technology, 
Dr. Jennifer Rabb. Unfortunately, this effort has not yet yielded tractable crystals, nor 
have the proteins been evaluated for their potential to trap the putative ferric-superoxo 
species.  
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Figure 5.15: 31P NMR spectroscopy analyzing the reactions of 2-HEP with the 
HEPD/MPnS homologs from (A) S. albus, (B) S. griseus, or (C) S. griseofuscus. In each 
case, HMP was the sole product detected. 
 
5.2.5: Incubation of HEPD and MPnS with Cyclopropyl Substrate Analogs 
 Because HEPD-E176H did not enable trapping of intermediates early in the 
catalytic cycle, indirect methods that might allow their characterization were pursued. 
Abstraction of the C2 pro-S hydrogen of 2-HEP by the ferric-superoxo species I would 
result in ketyl radical II (Figure 5.1). Indirect evidence for its intermediacy could 
conceivably be obtained by incubating either HEPD or MPnS with a series of substrate 
analogs with intramolecular traps that could undergo ring-opening of the adjacent 
strained cyclopropane ring (Figure 5.16, compounds 5.4 and 5.6). I reasoned that these 
substrate analogs could provide us with insight about the lifetime of the ketyl radical II 
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and perhaps allow us to distinguish between a divergent electron transfer route and direct 
hydroxylation route (Figure 3.15 and Figure 4.7) by possibly undergoing ring-opening 
(Figure 5.16C). Additionally, substrate analogs with cyclopropane rings have been used 
to establish the presence and lifetime of the C2 ketyl radical in the case of 2-
hydroxypropylphosphonate epoxidase (HppE),11,12 an enzyme with distant homology to 
HEPD and MPnS. 
 
Figure 5.16: The synthetic scheme to accessing (A) 2-cyc-2-HEP and (B) 1-cyc-1-HEP. 
(C) A general scheme for protein inactivation via cyclopropane ring-opening upon 
incubation with compound 5.4 (incubation with 5.6 would be expected to provide similar 
results). Damage to the protein active site by the primary radical or by interruption of the 
catalytic cycle (possibly leaving the Fe in a ferric state) would result in protein 
inactivation. 
 
 Compound 5.4 was synthesized following a previously published literature 
procedure (Figure 5.16A).11 Bromination of cyclopropyl methyl ketone followed by an 
Arbuzov reaction between the brominated derivative 5.1 and triethyl phosphite afforded 
phosphonate 5.2. Reduction of the ketone moiety with NaBH4 in MeOH yielded alcohol 
5.3; deprotection of the phosphonate ethyl ester groups with trimethylsilyl bromide 
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(TMSBr) produced the desired substrate analog 2-cyc-2-HEP (5.4). Although 5.4 was 
synthesized as a racemic mixture, it was anticipated based on the Cd(II)•WT HEPD•2-
HEP cocrystal structure that the (R) enantiomer would present a hydrogen atom for 
abstraction and that binding of the (S) enantiomer would occur in a fashion that rendered 
hydrogen atom abstraction impossible. 
 WT HEPD and WT MPnS (400 µM of each) were anaerobically reconstituted and 
then separately incubated with 2 molar equivalents of 5.4 (800 µM, only 1 equivalent 
with respect to the (R) enantiomer). The reactions were treated with Chelex, filtered 
through a centrifuge filter to remove protein, added to D2O, and analyzed by 31P NMR 
spectroscopy (Figure 5.17). Only a single peak corresponding to starting material was 
observed, suggesting that either no reaction had taken place or that the (R) enantiomer 
had been partially converted in a one-turnover inactivation process to products with 
concentrations too low to observe by 31P NMR spectroscopy. To distinguish between 
these possibilities, WT HEPD and WT MPnS were incubated with 5.4, and the O2 
concentration of each reaction was monitored using a Clark-type O2 electrode. No O2 
consumption was detected in the reaction with this substrate analog, but robust O2 
consumption was observed when 2-HEP was added to either reaction (Figure 5.18), 
indicating that the enzymes did not accept 5.4 as a substrate analog. 
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Figure 5.17: 31P NMR spectroscopy of (A) 2-cyc-2-HEP in buffer or (B) reacted with 
WT MPnS or (C) reacted with WT HEPD. Only starting material was detected in the 
samples. 
 
Figure 5.18: WT HEPD (blue) and WT MPnS (red) were incubated with 2-cyc-2-HEP, 
but no O2 consumption was observed. After ~100 s, 2-HEP was added, resulting in rapid 
O2 consumption and demonstrating that the lack of activity towards 2-cyc-2-HEP was not 
due to inactive enzyme. 
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 Examination of the active site of WT HEPD suggested that the steric bulk of 
Y184 might preclude binding of (R)-5.4 by clashing with the cyclopropane moiety 
(Figure 5.19); the phenyl ring of Y184 was only 3.8 Å from C2 of 2-HEP in the WT 
HEPD•2-HEP cocrystal structure. To potentially relieve this interference, the HEPD-
Y184A and -Y184L mutants were constructed, expressed, and purified. The HEPD-
Y184A variant did not express well, so only the HEPD-Y184L mutant was tested for 
activity. HEPD-Y184L only weakly consumed O2 in the presence of 2-HEP (Figure 
5.20); no activity towards compound 5.4 was observed by O2 electrode or 31P NMR 
spectroscopy with this construct. Enlarging the active site of HEPD may perturb it in an 
unforeseen fashion that prevents binding of 5.4 and disrupts binding of phosphonates in 
general. 
 
Figure 5.19: The phenyl ring of Y184 is directly in-line of the projected cyclopropane 
position of (R)-5.4, likely causing a steric clash. 
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Figure 5.20: HEPD-Y184L weakly consumed O2 in the presence of 2-HEP (red) but not 
in the presence of 2-cyc-2-HEP. In each case, substrate was added after roughly 10 s.  
 
 I therefore turned our attention to a different cyclopropane analog, 1-cyc-1-HEP 
(5.6). With the help of an undergraduate summer rotation student, Victor Garcia-Lopez, I 
condensed dimethyl phosphite with cyclopropanecarbaldehyde to afford phosphonate 
alcohol 5.5 (Figure 5.16B); deprotection of the phosphonate methyl groups with TMSBr 
yielded the substrate analog 5.6. As with compound 5.4, no attempt was made to initially 
synthesize this analog 5.6 in a stereospecific fashion; were activity observed, then a 
stereospecific synthesis might be pursued. WT HEPD and WT MPnS were reconstituted 
and incubated with multiple equivalents of compound 5.6 while the O2 concentration was 
monitored. However, no O2 consumption was detected with either protein during the 
incubation with this substrate analog (Figure 5.21). When 2-HEP was added to the 
reactions as a positive control, the rate of O2 consumption was roughly equal to the rate 
of O2 consumption in the absence of compound 5.6. As with compound 5.4, this 
observation suggests that substrate 5.6 was too bulky to bind in the active site of WT 
HEPD or WT MPnS, but no single residue in the active site stood out as the reason for 
the failure of 5.6 to bind in the active site. 
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Figure 5.21: WT HEPD (blue) and WT MPnS (red) were incubated with substrate analog 
5.6 while the O2 was monitored. After not observing any decrease in the O2 levels for ~60 
s, 2-HEP was added, and O2 was rapidly consumed, demonstrating that the proteins were 
still active.  
 
5.2.6: Halogenated Substrate Analog Studies with WT HEPD 
 The steric bulk of the cyclopropane moiety at either the C1 or C2 position did not 
appear to be well tolerated by HEPD or MPnS, and therefore a smaller functionality that 
might report on the presence of a C2 radical was sought. One possibility was to employ 
halogenated substrate analogs in a manner that has been useful for elucidating the 
mechanism of ribonucleotide reductase.4,13-15 When the halogen is alpha to a carbon-
centered radical, it has been observed to undergo elimination as the halide anion or 
halogen atom and often results in the inactivation of the enzyme.16 This expulsion is 
responsible for one mode of action of the potent drug gemcitabine.17 By reducing the 
commercially available phosphonates 5.7 and 5.8 with BH3-THF to yield alcohols 5.9 
and 5.10 (Figure 5.22A) followed by removal of the phosphonate ethyl ester groups in 
refluxing HCl, I was able to access the racemic phosphonic acids 5.12 and 5.13. 
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Figure 5.22: (A) Synthetic scheme for various halogenated 2-HEP analogs. (B) Possible 
explanations for the enzymatic inactivation of HEPD and MPnS that account for the 
formation of phosphate. Either an elimination of the halogen (blue arrow) followed by 
hydrolysis or direct hydrolysis (red arrow) could account for the formation of phosphate 
in a manner reminiscent of the hydrolysis of PnAA by phosphonatase. Halogen atom 
elimination is unlikely in the case of the reaction of 1-F-2-HEP, as fluoride radical 
formation would be unfavorable. (C) A possible scheme for the nonenzymatic release of 
halide anions from halohydroxymethylphosphonate. The resulting phosphono-
formaldehyde could be hydrolyzed or inactivate HEPD or MPnS. (D) Synthetic scheme 
for the synthesis of chloromethylphosphonate. 
 
 WT HEPD was incubated with 1-Cl-2-HEP under multiple turnover conditions, 
and O2 consumption was continuously monitored via a Clark-type oxygen electrode. 
Rapid inactivation of WT HEPD occurred, though the partial restoration of activity after 
addition of reductant (ascorbic acid) or Fe(II) suggested that inactivation was not 
damaging the overall scaffold of the protein (Figure 5.23). When 1-F-2-HEP was 
incubated with WT HEPD under identical conditions, a very similar result was observed: 
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inactivation of WT HEPD after approximately 1 equivalent of O2 was consumed, with 
activity mostly restored via addition of either reductant or fresh Fe(II) (Figure 5.24). 
When either 1-Cl-2-HEP or 1-F-2-HEP was incubated with HEPD under single turnover 
conditions, approximately 1 equivalent of O2 was consumed (Figure 5.23C and 5.24D). 
This result indicated that even though 1-F-2-HEP and 1-Cl-2-HEP were racemic 
mixtures, either enantiomer was accepted for turnover by WT HEPD. Additionally, when 
WT HEPD (100 µM) was incubated with 1-F-2-HEP (1 mM) and the fluoride 
concentration was monitored with a fluoride electrode, fluoride was released over time 
(Figure 5.25). A control experiment with a solution of (NH4)2Fe(II)(SO4)2 (100 µM) 
showed no corresponding increase. Because of the high response time of the fluoride 
electrode at low concentrations of fluoride and the non-linear response below ~10 µM 
fluoride, the data in Figure 5.25 should be treated as qualitative rather than quantitative. 
After 24 h, the reaction of WT HEPD with 1-F-2-HEP had resulted in release of 150 µM 
free fluoride, suggesting that 1-F-2-HEP does not quantitatively inactivate WT HEPD. 
 In the single turnover reactions between WT HEPD and compound 5.12 (Figure 
5.23C) or compound 5.13 (Figure 5.24D), O2 consumption occurred with biphasic 
kinetics, consistent with a model in which one enantiomer was consumed preferentially 
over the other. However, in each case, the amplitude associated with the fast phase was 
roughly four-fold larger than the amplitude associated with the slow phase; if each rate 
corresponded to consumption of a separate enantiomer, the amplitudes of each would be 
equal. The reason for this kinetic complexity is unclear at this time, and further 
investigations will be required to elucidate whether one enantiomer is preferentially 
turned over with WT HEPD. 
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Figure 5.23: Reaction of WT HEPD with 1-Cl-2-HEP. (A) WT HEPD underwent 
inactivation when incubated with 1-Cl-2-HEP as demonstrated by the lack of significant 
O2 consumption when incubated with 2-HEP. However, activity could partially be 
restored by addition of ascorbic acid or (B) a fresh aliquot of Fe(II). (C) Approximately 1 
equivalent of O2 was consumed when WT HEPD (200 µM) was incubated with 1-Cl-2-
HEP (200 µM), suggesting that both enantiomers were accepted for turnover. 
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Figure 5.24: Reactions of WT HEPD with 1-F-2-HEP. (A) WT HEPD (10 µM) was 
mostly inactivated under multiple turnover conditions (1 mM substrate) after turning over 
slightly more than 1 equivalent of 1-F-2-HEP (dashed line indicates 1 equivalent of O2). 
(B) Activity could be partially restored by the addition of ascorbic acid or (C) a fresh 
aliquot of Fe(II). (D) In a single turnover experiment in which WT HEPD (200 µM) was 
incubated with 1-F-2-HEP (200 µM), roughly 1 equivalent of O2 was consumed 
(indicated by the dashed line), consistent with either enantiomer being accepted for 
catalysis. 
 
 
Figure 5.25: Fluoride release occurred in a time-dependent manner when 1-F-2-HEP (1 
mM) was incubated with WT HEPD (100 µM, blue) or WT MPnS (100 µM, red) but not 
when it was incubated with Fe(II)-only (100 µM, black). After 24 h, 1.5 and 0.3 
equivalents of fluoride were released with in the WT HEPD and WT MPnS reactions 
respectively; the Fe(II)-only reaction had free fluoride concentrations < 1 µM. 
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 An attempt was made to determine what products resulted from 1-X-2-HEP 
turnover with WT HEPD and whether these could help corroborate the existence of 
radical II. I therefore incubated WT HEPD with either 1-Cl-2-HEP or 1-F-2-HEP and 
then analyzed the reaction mixture by 31P NMR spectroscopy (Figures 5.26 and 5.27). In 
each case, residual starting material and phosphate were identified by spiking 
experiments, suggesting that inactivation might proceed through one of two pathways 
depicted in Figure 5.22B. In the elimination pathway (blue), the halogen would be 
eliminated as the halogen atom. Protonation of C1 could be followed by hydrolysis of the 
halo-phosphonoacetaldehyde (PnAA) molecule in a manner reminiscent of the hydrolysis 
of phosphonates by various phosphonate hydrolases.18,19 However, an alternative 
possibility is that halide anions were released nonenzymatically from 
halohydroxymethylphosphonate (the product of normal turnover of 1-X-2-HEP without 
inactivation), and that HEPD was instead inhibited by the resulting 
phosphonoformaldehyde (Figure 5.22C). Given that fluorine atom release is highly 
unlikely, the mechanism shown in Figure 5.22C is the most likely explanation of the 
data.. In an attempt to determine the carbon-containing products and distinguish between 
these possibilities, the reaction mixture and the headspace were analyzed by GC-MS. 
Despite repeated attempts to identify what should presumably be volatile one- or two-
carbon products, no products were detected, possibly due to their low concentrations.  
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Figure 5.26: (A) 31P NMR spectrum of the reaction of WT HEPD (100 µM) with 1-Cl-2-
HEP (2 mM) in the presence of ascorbic acid (2 mM). (B) The peak at 2 ppm spiked with 
authentic phosphate. (C) The singlet at 12 ppm was confirmed to be starting material by 
spiking the reaction with 1-Cl-2-HEP. 
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Figure 5.27: (A) 31P NMR spectrum of the reaction of WT HEPD (750 µM) with 1-F-2-
HEP (1 mM). (B) The doublet at 9 ppm was confirmed to be starting material by spiking 
the reaction with 1-F-2-HEP, resulting in an increase in intensity relative to the peak at 2 
ppm. Because of the low signal-to-noise ratio of the spectrum, discerning whether the 
signal at 8 ppm is real was challenging. The peak at 2 ppm is likely to be phosphate, in 
analogy to the WT HEPD reaction with 1-Cl-2-HEP.  
 
5.2.7: Halogenated Substrate Analog Studies with WT MPnS 
 In contrast to WT HEPD, if WT MPnS were to undergo normal turnover with 1-
X-2-HEP without expulsion of the halogen atom during the catalytic cycle, the presumed 
product would be halomethylphosphonate. This product would be unable to undergo 
spontaneous non-enzymatic elimination of the halogen, and therefore WT MPnS might 
be less readily inactivated by incubation with these substrate analogs. Indeed, WT MPnS 
consumed multiple equivalents of O2 prior to inactivation by 1-Cl-2-HEP (Figure 5.28A). 
As with WT HEPD, addition of fresh Fe(II) or ascorbic acid could partially restore 
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oxygen consumption, and both enantiomers of 1-Cl-2-HEP were accepted for turnover 
(Figure 5.28C). As with WT HEPD, the consumption of O2 by WT MPnS in the presence 
of 1-Cl-2-HEP occurred with biphasic kinetics, consistent with a model in which one 
enantiomer is preferentially accepted by WT MPnS. However, also as before, the 
amplitude of the fast phase was roughly 2.4 times larger than the amplitude of the slow 
phase. The reason for this discrepancy is at present unclear. 
 Upon incubating WT MPnS (100 µM) with 1-F-2-HEP (1 mM), fluoride release 
was detected by using a fluoride electrode assay, though the release was much slower 
than in the case of WT HEPD (Figure 5.25). Analysis of the reaction after 24 h indicated 
that approximately 27 µM fluoride had been released, whereas a control experiment with 
a solution of (NH4)2Fe(II)(SO4)2 resulted in fluoride concentrations below the detection 
limit. Moreover, inactivation of MPnS by 1-F-2-HEP was much slower than inactivation 
by 1-Cl-2-HEP, and was sufficiently slow that steady-state Michaelis-Menten parameters 
of 1-F-2-HEP oxidation by MPnS could be obtained with an oxygen electrode (Figure 
5.29). The Km,1-F-2-HEP (23 ± 3 µM) was higher than that of the native substrate 2-HEP (~5 
µM),9 but quite surprisingly, kcat  was also several-fold larger than that of the native 
substrate (0.99 ± 0.04 s-1 vs ~0.2 s-1). This observation suggests that the rate-limiting step 
in MPnS catalysis with 2-HEP could be deprotonation of the hydroxyl at C2 to spur 
subsequent H2O dissociation and subsequent O2 activation. Similar to how the fluorine in 
2-fluoroethanol depresses the hydroxyl group pKa (by 1.8 units) compared to ethanol,20 
the C1 fluorine of 1-F-2-HEP may be able to inductively stabilize the incipient negative 
charge on the deprotonated hydroxyl at C2. Deprotonation has been posited to be 
necessary for subsequent C-H cleavage.21 To test this hypothesis, dideuterated substrate 
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(1-F-2-[2-2H2]-HEP, 5.14) was synthesized in an analogous manner and assayed. No 
significant change in Km (20 ± 3 µM) was observed, but a significant decrease in kcat 
(0.37 ± 0.01) was noted, resulting in a moderate KIE on kcat (2.7 ± 0.1). This KIE 
suggests that it might be possible to use 1-F-2-[2-2H2]-HEP and MPnS to trap the initial 
putative ferric-superoxo species, although the KIE is lower than that observed with 
MIOX or other reactions involving ferric-superoxo species.22,23 
 
Figure 5.28: Incubations of WT MPnS (10 µM) with 1-Cl-2-HEP (1 mM). (A) After 
inactivation with 1-Cl-2-HEP, WT MPnS activity could be partially restored by addition 
of ascorbic acid (1 mM) or (B) a fresh aliquot of Fe(II) (100 µM). (C) A single-turnover 
experiment between WT MPnS and 1-Cl-2-HEP (200 µM each) demonstrated that 
approximately 200 µM O2 was consumed, suggesting that both enantiomers of 1-Cl-2-
HEP are accepted for turnover.   
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Figure 5.29: (A) WT MPnS (10 µM) catalyzes multiple turnovers with 1-F-2-HEP (1 
mM) (the dashed line is where 1 turnover would have been). (B) Inactivation was 
sufficiently slow that steady-state Michaelis-Menten kinetics with WT MPnS and 1-F-2-
HEP (red) or 1-F-2-[2-2H2]-HEP (blue) could be determined. 
 
 To identify the products formed upon incubation of MPnS with 1-F-2-HEP and 1-
Cl-2-HEP, I analyzed the reaction mixtures by 31P NMR spectroscopy. In the reaction 
with 1-Cl-2-HEP, three signals were observed. The signals at 12 ppm and 2 ppm were 
identified by spiking with starting material and phosphate, respectively, leaving the 
singlet at 13 ppm unidentified (Figure 5.30).  In the case of 1-F-2-HEP, both phosphate at 
0 ppm and an unidentified doublet at 12.7 ppm were observed (Figure 5.31). Based on 
NMR spectroscopic evidence, it was hypothesized that the unidentified peak in each 
spectrum was likely the corresponding halomethylphosphonate, i.e. the products of 
normal catalysis. To confirm this supposition, chloromethylphosphonate was 
synthesized24,25 (Figure 5.22D) and spiked into the assay of WT MPnS and 1-Cl-2-HEP, 
confirming the production of this compound. By analogy, the product of the reaction of 
WT MPnS with 1-F-2-HEP likely was fluoromethylphosphonate, consistent with the 
spectral data obtained from a variety of NMR techniques (Figure 5.31). The observation 
of halomethylphosphonates as products strongly suggests that partitioning occurs 
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between release of the halide during catalysis, and catalysis proceeding as normal without 
release of the halide. However, either pathway depicted in Figure 5.22B could lead to 
formation of phosphate, so the observation of phosphate does not allow any conclusions 
to be drawn about the inactivation pathway. 
 
 
Figure 5.30: MPnS reaction with 1-Cl-2-HEP analyzed by 31P NMR spectroscopy. (A) 
The MPnS reaction with 1-Cl-2-HEP. (B) Spiking with 1-Cl-2-HEP confirmed that the 
resonance at 12 ppm is residual starting material and (C) spiking with synthetically 
prepared chloromethylphosphonate confirmed that the resonance at 13 ppm is 
chloromethylphosphonate. Separately, the broad resonance at 2 ppm was confirmed to be 
phosphate by spiking. 
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Figure 5.31: (A) 1H-decoupled 31P NMR spectrum of the reaction of WT MPnS with 1-
F-2-HEP. Inset: The 1H-coupled 31P NMR signal of the doublet at 12.7 ppm, which splits 
into a doublet of triplets due to a pair of α protons. (B) Spiking the sample with 1-F-2-
HEP creates a new doublet. (C) The peak at 0 ppm was determined to be phosphate by 
spiking with a standard of phosphate. (D) A two dimensional [1H-31P] HMBC spectrum 
demonstrated that the doublet at 12.7 ppm in the 31P dimension (vertical axis) was 
coupled to a doublet of doublets at 4.47 ppm in the 1H dimension (horizontal axis). The 
spectral characteristics of this peak are consistent with fluoromethylphosphonate. 
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5.2.8: 18O KIE Studies 
 As described in the preceding sections, neither the attempts to obtain direct 
spectroscopic evidence nor the use of substrate analogs has been productive in 
characterizing the putative initial ferric-superoxo species. I therefore pursued 18O KIE 
studies in collaboration with the Klinman group at U.C. Berkeley to examine the early 
intermediates in the catalytic cycle of WT HEPD and WT MPnS. Due to the very small 
nature of heavy atom oxygen KIEs (< 4%), these experiments are run with natural 
abundance 16O2 and 18O-16O to improve the precision of the measurement. As a 
consequence of the competition between these isotopologues, the KIE reflects the early 
steps of catalysis up to and including the first irreversible step in the mechanism (i.e. the 
KIE is measured on kcat/Km rather than kcat).6 This technique has been useful to glean 
insight into the intermediates in the catalytic cycles of non-heme iron enzymes such as 1-
aminocyclopropane-1-carboxylic acid oxidase (ACCO)26 and taurine dioxygenase27 that 
would otherwise have been difficult to characterize.  
 Although the actual magnitude of the KIE is of somewhat limited value, the 
relative values with protiated and deuterated substrate can give an indication as to the 
timing of the abstraction of the hydrogen atom with respect to steps involving O2 
activation. If the 18O KIE were to increase with deuterated substrate compared to 
protiated substrate, abstraction of the hydrogen atom must be at least partially reversible 
because events that occur after the first irreversible step are not measured by this 
technique. If, by contrast, the hydrogen atom abstraction occurs after the first irreversible 
step with respect to O2 (thought to be oxygen-oxygen bond cleavage), the 18O KIE would 
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be insensitive to whether a deuterium or protium were abstracted from substrate, and 
therefore the 18O KIEs would be identical for both substrates. In other words, if the 
hydrogen abstraction is performed by a ferric superoxide (i.e. before the first irreversible 
step with respect to oxygen), a difference may be observed between the 18O KIE with 
protiated and deuterated substrates, whereas if the hydrogen abstraction from substrate is 
performed by the ferryl (i.e. after the first irreversible step), the 18O KIE should be 
unaffected by labeling of 2-HEP. Therefore, 18O KIE measurements could provide 
support for or against our favored mechanism.  
 I therefore prepared both protein (WT HEPD and WT MPnS) and substrates (2-
HEP and 2-[2-2H2]-HEP) in quantities necessary for applying this technique. Two post-
doctoral researchers in the Klinman group at U.C. Berkeley, Dr. Florence Bonnot and 
later Dr. Hui Zhu, then reacted WT HEPD and WT MPnS with 2-HEP or 2-[2-2H2]-HEP 
to varying stages of completion. The reactions were quenched by acidifying the mixture, 
and the residual 16O2/18O-16O atmosphere was combusted in the presence of excess 
graphite to CO2. Isotope ratio mass spectrometry was then used to evaluate the 18O 
content of the CO2. The 18O KIEs that were extracted for WT HEPD were 1.015 ± 0.001 
with 2-HEP and 1.020 ± 0.001 with 2-[2-2H2]-HEP; with WT MPnS the KIEs were 
measured as 1.016 ± 0.001 with 2-HEP and 1.022 ± 0.003 with 2-[2-2H2]-HEP. The 
observation of an altered 18O KIE upon deuterium-labeling of the substrate indicates that 
the hydrogen atom abstraction step must occur before the first irreversible step with 
respect to oxygen chemistry. This observation then necessitates that hydrogen atom 
abstraction occurs prior to ferryl formation, consistent with the mechanisms previously 
discussed in Chapters 3 (Figure 3.15) and 4 (Figure 4.7). 
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5.3: Conclusions 
 The experiments herein detail the attempts to detect and characterize early 
intermediates in the catalytic cycle of HEPD and MPnS. I hoped that in doing so, 
evidence that the early intermediates in the catalytic cycle of HEPD and MPnS were 
identical would be acquired.  18O KIE studies in collaboration with the Klinman lab at 
U.C. Berkeley strongly suggest that each protein uses a ferric-superoxo species I to effect 
the initial hydrogen atom abstraction and yield ketyl radical II (Figure 5.1). Efforts to 
indirectly detect this carbon-centered radical with cyclopropane substrate analogs failed, 
and attempts with halogenated substrate analogs yielded mixed results. WT HEPD was 
potently inactivated by either 1-Cl-2-HEP or 1-F-2-HEP and seemingly formed 
phosphate as the sole product detectable by 31P NMR spectroscopy. However, it was 
unclear if inhibition was due to halogen atom expulsion during or after catalysis. Any 
halohydroxymethylphosphonate products formed by normal turnover could eliminate 
halide anions to yield phosphonoformaldehyde. Although this product was not observed 
by 31P NMR spectroscopy, its formation could account for enzyme inactivation. By 
contrast, MPnS catalysis with these halogenated substrate analogs yielded 
halomethylphosphonates, which would be unable to non-enzymatically eliminate the 
halide anion. Inactivation of WT MPnS with these substrates might then reflect the 
existence of ketyl radical II. Indeed, MPnS was only inactivated very slowly and 
catalyzed multiple turnovers. Hence, whereas the substrate analogs were designed to 
promote non-native chemistry, the enzymes appeared to mostly convert the substrate 
analogs using the same chemistry as with their native substrates. 
 132 
  Though the investigation into active site mutants of HEPD and homologs of 
HEPD/MPnS began as an attempt to find a system that would be amenable to trapping of 
the putative ferric-superoxo intermediate I, these experiments ultimately yielded 
compelling evidence that a consensus mechanism is operative in HEPD and MPnS. The 
isotope-sensitive branching in HEPD-E176H is particularly compelling evidence that the 
early intermediates are identical in HEPD and MPnS catalysis. Thus far, conditions that 
transform HEPD completely into MPnS have not been found. However, the existence of 
several homologs that cluster with the authentic MPnS but carry out HEPD activity 
suggests that the shared mechanism between these proteins may extend to their 
evolutionary history as well. 
 
5.4: Materials and Methods 
5.4.1: HEPD-E176H Construction and Kinetic Characterization  
 These experiments were performed on 4/28/11 and 5/5/11. HEPD-E176H was 
constructed by using the QuikChange kit. Primers were as follows with the mutated 
codon in red and bolded: 
Forward primer: 
gcgactcctacgtgcatccctcgtactgc 
Reverse complement primer: 
gcagtacgagggatgcacgtaggagtcgc 
 
 Following sequencing to confirm the mutation of the desired codon, the protein 
was expressed and purified by immobilized metal affinity chromatography followed by 
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size exclusion chromatography as previously described for WT HEPD.28 HEPD-E176H 
was anaerobically reconstituted with about 0.50 to 5.0 equivalents of (NH4)2Fe(II)(SO4)2 
(actual numbers were 0.51 to 5.1 equivalents, once corrected for small variation in 
protein concentration as determined by the UV-Vis absorbance at 280 nm) in 25 mM 
HEPES pH 7.5 and the protein solution was allowed to incubate on ice for at least 10 
min. The activity was assayed by monitoring the rate of O2 consumption in air-saturated 
buffer (280 µM O2, 25 mM HEPES pH 7.5) at 20 ˚C in the presence of HEPD-E176H (2 
µM) and 2-HEP (500 µM). 
 Following the determination that approximately three equivalents of Fe(II) were 
required to reach maximal activity with HEPD-E176H, the steady-state Michaelis-
Menten parameters of 2-HEP oxidation were determined by incubating HEPD-E176H (2 
µM) with 2-HEP or 2-[2-2H2]-HEP (10-250 µM) at a constant O2 concentration (280 µM) 
in buffer (25 mM HEPES pH 7.5) at 20 ˚C. The Km for O2 was determined by incubating 
HEPD-E176H (2 µM) with saturating concentrations of each phosphonate substrate (2-
HEP and 2-[2-2H2]-HEP, 250 µM) and varying O2 concentration (adjusted by sparging 
the reaction buffer with N2 from a house source) in buffer (25 mM HEPES pH 7.5). 
 
5.4.2: Identification of the Products Formed by HEPD-E176H  
 These assays were carried out on 11/4/11, 9/15/12, 9/17/12, 9/25/12, 3/28/14, 
3/30/14, and 4/6/14. HEPD-E176H was anaerobically reconstituted with one equivalent 
of Fe(II) in either buffer made up in H2O (25 mM HEPES pH 7.5) or in buffer made up in 
D2O (25 mM HEPES pD 7.5). The HEPD-E176H (20 µM final concentration) was then 
incubated with substrate ((R)-, (S)-2-[2-2H1]-HEP or 2-HEP, 1 mM) in either buffer made 
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up in H2O for the monodeuterated enantiomers (25 mM HEPES pH 7.5) or buffer made 
up in D2O in the case of 2-HEP (25 mM HEPES pD 7.5). The reaction volume was 500 
µL. After incubation for 2 h, the enzyme was removed with a centrifuge filter (30 kDa 
MWCO), treated with Chelex, and then D2O was added (20% final v/v). The samples 
were analyzed by 31P NMR spectroscopy with the proton decoupler on and off.  
 To corroborate the incorporation of the hydrogen atom originating from the pro-R 
face at C2 of 2-HEP into MPn produced by HEPD-E176H, reconstituted HEPD-E176H 
(80 µM) was incubated with 2-[2-2H2]-HEP (1 mM) in 50 mM HEPES pH 7.5 on a larger 
scale (5 mL). The reaction was allowed to react for 8 h, frozen in liquid N2, and 
lyophilized to afford a white residue. The residue was redissolved in D2O, treated with 
Chelex, and filtered by centrifugation (30 kDa MWCO). The sample was analyzed by 1H-
coupled 31P NMR spectroscopy as well as 31P NMR spectroscopy with the 1H decoupler 
enabled. To confirm the identity of the two singlets observed in the 31P NMR spectrum, 
the sample was spiked with enzymatically-generated MPn and [2H1]-MPn, which had 
been obtained by reacting reconstituted WT MPnS (10 µM) with either 2-HEP or 2-[2-
2H2]-HEP (2 mM) in 50 mM HEPES pH 7.5. 
 
5.4.3: Analysis of HEPD-E176H by Stopped-Flow UV-Vis Experiments  
 This assay was performed on 8/4/11. Similar to the protocol detailed for the 
stopped-flow experiment with HEPD-E176A (Section 3.4.4), HEPD-E176H (0.6 mM) 
was anaerobically reconstituted with Fe(II) (3 equivalents, 1.8 mM) in 50 mM HEPES 
pH 7.5 at 4 ˚C for 10 min. The protein was mixed with either 2-HEP or 2-[2-2H2]-HEP (2 
equivalents, 1.2 mM) and allowed to incubate for a further 10 min at 4 ˚C. This solution 
 135 
was mixed (1:1 v/v) with buffer (50 mM HEPES pH 7.5) that had been O2-saturated at 0 
˚C by repeated pump-refill cycles, and the UV-Vis spectrum was monitored as a function 
of time at ~4 ˚C. 
 
5.4.4: HEPD-E176H/S196D and -E176H/S196N Double Mutant Construction and 
Characterization  
 These experiments were carried out on 1/30/14, 2/4/14, and 2/13/14. The double 
mutant constructs were generated by using the QuikChange site-directed mutagenesis kit 
(Agilent) using HEPD-E176H as the template. Primers were as follows, with the mutated 
codon in bold and red: 
HEPD-E176H/S196D forward:  
cccgcccggatcgtcgactacaccgcccagtcgaac 
 
HEPD-E176H/S196D reverse complement:  
gtcgacgatccgggcgggcgcgtcgccggcgagcgag 
 
 
HEPD-E176H/S196N forward:  
cccgcccggatcgtcaactacaccgcccagtcgaac 
 
HEPD-E176H/S196N reverse complement:  
gttgacgatccgggcgggcgcgtcgccggcgagcgag 
 
 
 The double mutants were purified as previously described by immobilized metal 
affinity chromatography.28 The mutants (80 µM) were anaerobically reconstituted with 
one equivalent of Fe(II) in 50 mM HEPES pH 7.5 on ice for 10 min. The double mutants 
(10 µM final concentration) were reacted with 2-HEP (1 mM) in buffer (50 mM HEPES 
pH 7.5, 500 µL total reaction volume) for 4 h at room temperature, treated with Chelex, 
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and filtered with an Amicon centrifuge filter (30 kDa MWCO). D2O was added (20% 
final v/v), and the reaction mixtures were analyzed by 31P NMR spectroscopy. 
 
5.4.5: Attempting to Skew the HEPD-E176H Product Distribution by Addition of  
Exogenous Formate  
 This reaction was carried out on 1/21/14. HEPD-E176H (40 µM) was 
anaerobically reconstituted with Fe(II) (120 µM) in buffer (50 mM HEPES pH 7.5) on 
ice for 10 min. The protein (5 µM) was incubated with 2-HEP (1 mM) in the absence or 
presence of formate (1 mM) in buffer (50 mM HEPES pH 7.5, 500 µL total reaction 
volume) for 2 h at room temperature. The reaction mixture was treated with Chelex and 
filtered with an Amicon centrifuge filter (30 kDa MWCO). D2O was added (20% final 
v/v) and the reaction mixtures were analyzed by 31P NMR spectroscopy. 
 
5.4.6: Cloning and Characterization of HEPD/MPnS Homologs  
 These experiments were carried out on 7/13/13, 7/16/13, 7/18/13, 7/19/13, 
7/23/13, 7/29/13, 8/5/13, 8/6/13, 12/13/13, and 1/3/14. Genomic DNA from S. 
monomycini, S. albus, S. griseus, and S. griseofuscus were obtained from Dr. Kou-san Ju. 
The S. monomycini genome was not closed in the N-terminal region of the homolog, and 
therefore this gap was first amplified and sequenced, revealing that the missing coding 
sequence was: ATGTCCGTACCGGACCCTGCCTTCGACCGGCGG. With help from a 
post-doctoral scholar in the van der Donk group, Dr. Despina Bougioukou, the homolog 
from S. monomycini was amplified in Failsafe Buffer I (Epicentre) using the instructions 
with the kit with primers designed for ligation into pET15b using Gibson assembly; the 
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other homologs were similarly amplified except Failsafe Buffer G was used (all primers 
are listed below). The amplicon was purified by using a QIAQuick PCR Purification kit 
(Qiagen) or Promega Wizard SVI Gel and PCR Clean-Up kit (Promega) per the 
instruction manual. Amplification was checked with a 1% agarose gel made and run in 
0.5X TAE buffer (20 mM tris(hydroxymethyl)aminomethane, 10 mM acetic acid, 0.5 
mM EDTA). After initial amplification, the amplicon was ligated into a pET15b vector 
using a Gibson Assembly kit (New England Biolabs) and E. coli electrocompetent cells  
were transformed with the plasmid (either homemade DH5α or NEB 5α competent from 
New England Biolabs). Following recovery, selection was achieved by plating on a 1.5% 
agar LB plate supplemented with 100 µg/mL of ampicillin (LB-Amp100) and growing at 
37 ˚C overnight. Individual colonies were picked and grown in 5 mL of LB-Amp100, and 
then the plasmids were isolated using a QIAprep Spin Miniprep kit (Qiagen). Sequencing 
(ACGT, Inc) was used to confirm that the correct sequence had been amplified. Proteins 
were expressed by transforming the plasmid into Rosetta 2 and expressing and purifying 
as has been described elsewhere for HEPD and MPnS.7  
 Primers used for amplification are shown below. In each case, the underlined 
portion has homology to the pET15b vector that was used for expression, and the 
capitalized portion is for the homolog of interest. The forward primers were designed 
with an NdeI restriction site; the reverse primers contain an XhoI restriction site. 
 
S. monomycini forward primer: 
gcagcggcctggtgccgcgcggcagccatatgATGTCCGTACCGGACCCTGCCTTCGACCG 
 
S. monomycini reverse complement primer: 
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cctttcgggctttgttagcagccggatcctcgagTCAGTTGCCTTCCTTGCTGTACCAGAGC 
S. albus forward primer: 
gcagcggcctggtgccgcgcggcagccatatgAGCACGCCGGACGCGTTGGGTTCCGATGC 
S. albus reverse complement primer: 
cctttcgggctttgttagcagccggatcctcgagTCAGTACCAGAGCCGGTCCTCGGCGATGTAAC
GGC 
 
S. griseus forward primer: 
gcagcggcctggtgccgcgcggcagccatatgGTGCGGCCAGAGGACGATTTCACCCGGCGTG
C 
S. griseus reverse complement primer: 
cctttcgggctttgttagcagccggatcctcgagTCAGCTGTACCACAGCCGGTCCTCGGCC 
S. griseofuscus forward primer: 
gcagcggcctggtgccgcgcggcagccatatgCGACACCACGAACACGACGTGGACTTCG 
S. griseofuscus reverse complement primer: 
cctttcgggctttgttagcagccggatcctcgagCTACCGGGAGGTGTTGTTGTCACTGTTCTCTCT
TCCC 
 
 In a typical reconstitution, each homolog (40 µM) was anaerobically reconstituted 
with one equivalent of Fe(II) in buffer (25 mM HEPES pH 7.5). The protein (2 µM) was 
incubated with 2-HEP (500 µM) in buffer (25 mM HEPES pH 7.5) while the O2 
concentration was monitored using a Clark-type O2 electrode. The reaction mixture was 
supplemented with additional aliquots of protein to confirm that the observed O2 
consumption occurred in an enzyme-dependent fashion. For characterization of the 
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reaction product by NMR spectroscopy, a similar assay was carried out, except higher 
concentrations of protein (10 µM) and 2-HEP (1 mM) were used. Following incubation 
overnight at room temperature, the reactions were treated with Chelex and filtered 
through a centrifuge filter (30 kDa MWCO). D2O (20% final v/v) was added, and the 31P 
NMR spectrum was recorded. 
  
5.4.7: Syntheses of Cyclopropyl Substrate Analogs  
 These experiments were performed on 7/1/10, 7/4/10, 7/5/10, 7/6/10, 7/7/10, 
5/23/13, 5/24/13, 5/26/13, 5/27/13, 6/4/13, 6/5/13, 6/12/13, 6/13/13, and 6/17/13. 
Compound 5.1 (bromomethylcyclopropane ketone) was synthesized following a known 
literature procedure.29 The spectral data matched the reported literature values. 
Compounds 5.2, 5.3, and 5.4 were synthesized as described elsewhere in greater detail.11 
The spectral data for the isolated compounds matched the reported literature values. 
 
Synthesis of Compound 5.5 (Dimethyl 1-cyclopropane-1-hydroxymethyl-
phosphonate). To a scintillation vial on ice was added CH2Cl2 (1 mL), dimethyl 
phosphite (260 µL, 2.8 mmol) and cyclopropane carboxaldehyde (160 µL, 2.8 mmol) 
followed by KF/Al2O3 (1:1 wt/wt, 130 mg total). The white suspension was stirred and 
allowed to warm to room temperature. After 4 h, the slurry was filtered, and the cake was 
washed with CH2Cl2. The filtrates were concentrated under a stream of N2. Compound 
5.5 was purified by column chromatography on silica gel (gradient of 0% to 5% MeOH/ 
CH2Cl2 v/v). The fractions containing the product were combined and concentrated under 
reduced pressure to afford a colorless oil. Yield: 228 mg, 44%. 1H NMR (500 MHz, 
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CDCl3): δ 3.14 (dd, 1H, J = 8.9, 6.3 Hz), 1.07 (m, 1H), 0.50 (m, 2H), 0.33 (m, 2H) ppm. 
1H-coupled 13C NMR (126 MHz, CDCl3): δ 71.6 (dd, J = 164, 6.5 Hz), 53.4 (m), 12.3 (d, 
J = 6.7 Hz), 3.6 (d, J = 13 Hz), 3.0 (s) ppm.  
 
Synthesis of compound 5.6 (1-cyclopropane-1-hydroxymethylphosphonate). To a 
solution of starting material (228 mg, 1.26 mmol) dissolved in dry CH2Cl2 (3 mL) under 
a N2 atmosphere was added trimethylbromosilane (TMSBr, 0.5 mL, 3 equivalents). The 
mixture was refluxed under N2 for 3 h. The reaction was allowed to cool to room 
temperature, and the solvent was removed under reduced pressure. EtOH/H2O (3 mL, 1:1 
v/v) was added, and the mixture was stirred for 5 min. 31P NMR spectroscopy indicated 
that the reaction had not proceeded to completion, so the material was concentrated under 
reduced pressure and an additional 3 equivalents of TMSBr were added in dry CH2Cl2 (3 
mL), and the mixture was refluxed for an additional 3 h. Solvent was removed, H2O (3 
mL) was added, and the cloudy suspension was stirred for 10 min. Solvent was removed 
on the high vacuum line to afford an orange oil. Yield: 192 mg, 92%. 1H NMR (500 
MHz, D2O): δ 2.47 (dd, 1H, J = 9.5, 7.5 Hz), 0.41 (br, 1H), -0.020 (m, 2H), -0.027 (m, 
2H) ppm. 31P NMR (202 MHz, CDCl3): δ 24.2 (s) ppm. HRMS (ESI)+: calculated 
153.0317, found 153.0321. 
 
5.4.8: Enzymatic Assays with the Cyclopropyl Substrate Analogs  
 These assays were performed on 6/19/13, 6/20/13, 9/19/13, 9/24/13, 10/8/13, 
10/9/13, and 7/26/14. WT HEPD and WT MPnS (700 µM of each) were anaerobically 
reconstituted with one equivalent of Fe(II) in 25 mM HEPES pH 7.5. Each protein (400 
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µM final concentration) was removed from the anaerobic chamber and incubated with 
potential substrate analog 5.4 (2-cyc-2-HEP, 800 µM) in buffer (25 mM HEPES pH 7.5) 
for 30 min at room temperature. The samples were treated with Chelex and filtered 
through a centrifuge filter (30 kDa MWCO) to remove the enzyme. D2O (20% v/v) was 
added, and the 31P NMR spectrum was recorded. To assay activity with 5.4 using an O2 
electrode, WT HEPD and WT MPnS were reconstituted as before but to a final 
concentration of 200 µM. The enzyme (50 µM) was incubated with 5.4 (1 mM) in air-
saturated buffer (25 mM HEPES pH 7.5) at 20 ˚C while O2 consumption was monitored. 
After ~100 s of no O2 being consumed, 2-HEP (250 µM) was added to the reaction 
mixture as a positive control to ensure that the proteins were still active. 
 HEPD-Y184A and HEPD-Y184L were constructed using the standard site-
directed mutagenesis protocol for the QuikChange kit (Agilent) with pET15b-WT HEPD 
as a template. Primers are provided below, with the mutated codon in bold and red. 
Proteins were expressed and purified as previously described,7,28 but HEPD-Y184A 
expressed poorly (~1 mg/L) and may have been poorly folded. Therefore, only HEPD-
Y184L was further characterized. The mutant (100 µM final concentration) was 
anaerobically reconstituted with 1 equivalent of Fe(II) in buffer (25 mM HEPES pH 7.5). 
A positive control with HEPD-Y184L (2 µM) and 2-HEP (250 µM) in buffer (25 mM 
HEPES pH 7.5) indicated that the protein was active with the native substrate. HEPD-
Y184L (40 µM) was incubated with compound 5.4 (1 mM) in buffer (25 mM HEPES pH 
7.5) while the O2 concentration was monitored, but no O2 consumption was detected.  
 
HEPD-Y184A forward: 
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tactgcccccacagcgcctcgctcgccggcgac 
HEPD-Y184A reverse complement: 
ggcgctgtgggggcagtacgagggctccacgtagga 
HEPD-Y184L forward: 
tactgcccccacagcctctcgctcgccggcgac 
HEPD-Y184L reverse complement: 
gaggctgtgggggcagtacgagggctccacgtagga 
 
 Assays to evaluate the activity of WT HEPD and WT MPnS towards compound 
5.6 (1-cyc-1-HEP) were conducted by anaerobically reconstituting the protein (100 µM) 
with one equivalent of Fe(II) in buffer (50 mM HEPES pH 7.5). The protein was then 
incubated with 5.6 (1 mM) while the O2 consumption was monitored with an O2 
electrode. After approximately one minute, no O2 consumption was observed, so 2-HEP 
(250 µM) was spiked into the reaction mixtures to confirm that the enzymes had not been 
inactivated. 
 
5.4.9: Syntheses of Halogenated Substrate Analogs  
 These experiments were carried out on 12/12/11, 1/19/12, 1/25/12, 1/29/12, 
7/12/12, 7/13/12, 7/18/12, 7/19/12, and 7/24/12. 
 
Synthesis of compound 5.9 (Diethyl 1-F-2-HEP). The starting material 5.7 (118 mg, 
0.49 mmol) was cooled on ice, and then a solution of 1.0 M BH3-THF (1.5 mL, 3 
equivalents) was added dropwise under N2. The reaction was allowed to warm to room 
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temperature and then stirred for 20 h. The reaction was cooled to 0 ˚C and then EtOH (1 
mL) was slowly added to quench the reaction. The reaction mixture was concentrated 
under reduced pressure and then purified by column chromatography on silica gel 
(gradient of 0% to 6% v/VI MeOH in CH2Cl2) to afford a yellow oil as product. Yield: 88 
mg, 44%. 1H NMR (500 MHz, CDCl3): δ 4.88 (m, 1H, PCHF), 4.24 (m, 4H, POCH2), 
4.05 (m, 2H, CH2OH), 2.77 (br, 1H, CH2OH), 1.38 (dt, JH-H = 7.2 Hz, JP-H = 1.5 Hz, 6H, 
CH2CH3) 13C NMR (126 MHz, CDCl3): δ 89.2 (dd, PCFH, J = 184, 166 Hz)  63.65 (d, 
POCH2, J = 6.7 Hz), 63.11 (d, POCH2, J = 6.7 Hz), 61.42 (dd, CH2OH, J = 21, 4.0 Hz), 
16.4 (d, CH2CH3, J = 5.7 Hz). 19F NMR (470 MHZ, CDCl3): δ -2.35 (m). 31P NMR (202 
MHz, CDCl3): δ 16.60 (d, J = 74.5 Hz, P-CF) ppm. HRMS (ESI+) calculated 
(C6H14O4FNaP)+ 223.0511, found 223.0511. 
 
Synthesis of compound 5.10 (Diethyl 1-Cl-2-HEP). The starting material (508 mg, 2.0 
mmol) was cooled on ice under N2, and then a solution of 1.0 M BH3-THF was added 
dropwise. The reaction was allowed to come to room temperature and stirred for 24 h. 
After concentration under reduced pressure, column chromatography on silica gel 
(gradient of 0% to 4% v/VI MeOH in CH2Cl2) afforded a yellow oil. Yield: 250 mg, 
59%. 1H NMR (400 MHz, CDCl3): δ 4.25 (m, 4H, OCH2CH3), 4.01 (m, 3H, 
PCClHCH2OH), 3.18 (t, 1H, CH2OH, J = 6.3 Hz), 1.38 (t, 6H, OCH2CH3, J = 7.1 Hz) 
ppm. 13C NMR (126 MHz, CDCl3): δ 64.21, (d, POCH2, J = 6.9 Hz), 63.66 (d, CH2OH, 
J = 6.8 Hz)  63.01 (s, POCH2), 52.8 (d, PCH2, J = 154 Hz), 16.41 (d, CH2CH3, J = 5.6 
Hz), 16.39 (d, CH2CH3, J = 5.6 Hz) ppm. 31P NMR (202 MHz, CDCl3): δ 19.2 ppm. 
HRMS (ESI+) calculated (C6H15O435ClP)+: 217.0397, found 217.0392. 
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Synthesis of compound 5.11 (Diethyl 1-F-2-[2-2H2]-HEP).  
Starting material 5.7 (292 mg, 1.2 mmol) was added and then the atmosphere was purged 
with N2. The flask was cooled to 0 ˚C, and then a 1.0 M BD3-THF solution (2.0 mL, 1.6 
equivalents) was added under N2. The mixture was stirred at 0 ˚C for 1 h and then at 
room temperature until it was quenched on ice after 5 days by slow addition of 1 mL 
EtOH and then 1 mL H2O. The solution was then dried under reduced pressure. The 
crude residue was purified by column chromatography on silica gel (loaded in CH2Cl2 
and eluted with a very gradual gradient of 0-5% MeOH in CH2Cl2 (v/v)) to afford . ∆Rf 
of the starting material and product was very low in the elution solvent (~0.03). Yield: 59 
mg, 24%. 1H NMR (500 MHz, CDCl3): δ 4.80 (dd, 1H, PCFH, J = 48, 5.2 Hz), 4.19 (m, 
4H, POCH2), 3.52 (br, 1H, -OH), 1.34 (td, 6H, CH2CH3, J = 7.1, 2.1 Hz) ppm. 13C NMR 
(126 MHz, CDCl3): δ 89.4 (dd, PCF, J = 183, 165 Hz), 63.6 (d, POCH2, J = 6.7 Hz), 63.1 
(d, POCH2, J = 6.6 Hz), 60.7 (m, CD2OH), 16.4 (d, CH2CH3, J = 5.7 Hz) ppm. 19F NMR 
(470 MHz, CDCl3): δ -2.6 (dd, J = 75, 45 Hz) ppm. 31P NMR (242 MHz, CDCl3): δ 16.7 
(d, J = 74 Hz) ppm. HRMS (ESI+) calculated (C61H132H2O4FP)+ 203.0818, found 
203.0820. 
 
Synthesis of compound 5.12 (1-F-2-HEP). Diethyl 1-F-2-HEP (43 mg, 0.2 mmol) was 
dissolved in 6 M HCl (1 mL) and then refluxed for 16 h with stirring. The reaction was 
cooled and then concentrated under reduced pressure. Deionized water (5 mL) was added 
and the solution was again concentrated under reduced pressure to afford a yellow oil. 
Yield: 28 mg, 90%. 1H NMR (500 MHz, D2O): 4.50 (m), 3.73 (m) ppm. 13C NMR (126 
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MHz, D2O): 91.7 (dd, J = 175, 156 Hz), 61.1 (dd, J = 19, 8.2 Hz). 19F NMR (470 MHz, 
DMSO-D6): δ 0.17 (m) ppm. 31P NMR (202 MHz, DMSO-D6): 17.4 (d, J = 73 Hz) ppm. 
HRMS (ESI+): calculated (C2H7FO4P)+ 145.0066, found 145.0064. 
 
Synthesis of 5.13 (1-Cl-2-HEP). Diethyl 1-Cl-2-HEP (108 mg, 0.50 mmol) was 
dissolved in 6 M HCl (3 mL) and refluxed for 24 h with stirring. The solution was 
allowed to cool and then concentrated under reduced pressure. Yield: 71 mg, 88%. 1H 
NMR (400 MHz, D2O): 3.75 (m, 2H, CH2OH), 3.47 (m, 1H, PCClH). 13C NMR (126 
MHz, DMSO-D6): δ 62.9 (s, CH2OH), 57.4 (d, J = 145 Hz, PCHCl). 31P NMR (162 
MHz, D2O): δ 15.3. HRMS (ESI+) calculated (C2H7O435ClP)+ 160.9770, found 160.9771. 
 
Synthesis of compound 5.14 (1-F-2-[2-2H2]-HEP). Compound 5.11 (59 mg, 0.29 mmol) 
was added to 6 M HCl (2 mL), and the mixture was refluxed for 16 h. The mixture was 
cooled and then concentrated under reduced pressure. Deionized water (5 mL) was added 
and the solution was again concentrated under reduced pressure to afford a yellow oil. 
Yield: 39 mg, 92%. 1H NMR (500 MHz, D2O): 4.60 (m). 13C NMR (152 MHz, D2O): 
91.0 (m), 60.2 (m). 19F NMR (470 MHz, D2O): δ 0.4 (m) ppm. 31P NMR (202 MHz, 
D2O): 12.6 (d, J = 173 Hz) ppm. ppm HRMS (ESI+): calculated (C2H52H2FO4P)+: 
147.0192, found 147.0198. 
 
Synthesis of 5.15 (Chloromethylphosphonate) (5/25/12, 6/5/12, 6/8/12). Compound 
5.15 was synthesized by following a previously published literature procedure as 
described in greater detail elsewhere.24,25 
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5.4.10: Assays of HEPD and MPnS with Halogenated Substrate Analogs 
 These assays were performed on 1/20/12, 1/25/12, 2/1/12, 2/10/12, 2/16/12, 
2/18/12, 2/20/12, 2/22/12, 3/4/12, 3/19/12, 8/12/12, and 9/11/12. In a typical experiment, 
WT HEPD and WT MPnS (500 µM) were anaerobically reconstituted with Fe(II) (1 
equivalent) in 25 mM HEPES pH 7.5. The protein (10 µM) was then incubated with 1-F-
2-HEP or 1-Cl-2-HEP (1 mM) in 25 mM HEPES pH 7.5, and the O2 concentration was 
monitored over time. Once O2 consumption ceased, 2-HEP (500 µM) was added to 
confirm that the majority of the protein had been inactivated. A fresh aliquot of Fe(II) 
(100 µM, previously dissolved in anaerobic H2O in a glovebag) or ascorbic acid (1 mM) 
was added and confirmed that partial restoration of activity could occur. For single 
turnover experiments, the protein (200 µM) was incubated with 1-F-2-HEP or 1-Cl-2-
HEP (200 µM) in 25 mM HEPES pH 7.5 and the O2 concentration was monitored as a 
function of time. 2-HEP (500 µM) was added after apparent O2 consumption had ceased 
to check for residual protein activity. Consumption of O2 was fit to the standard equation 
governing biphasic kinetics i.e. C(t) = C0 + A1*e-k1*t + A2*e-k2*t, where C is the 
concentration of O2 as a function of time (t), C0 is the concentration of O2 after a very 
long time, A1 and A2 are the respective amplitudes of the two phases, and k1 and k2 are 
the respective rates of the two phases. By visual inspection, it was apparent that the 
consumption of O2 was not well fit to a single exponential curve. To establish the 
Michaelis-Menten parameters of WT MPnS oxidation of 1-F-2-HEP, WT MPnS (40 µM) 
was anaerobically reconstituted with 1 equivalent of Fe(II) in buffer (25 mM HEPES pH 
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7.5). The protein (2 µM final concentration) was reacted with varying concentrations (10-
300 µM) of compounds 5.12 and 5.14 in air-saturated buffer (25 mM HEPES pH 7.5).  
 Fluoride electrode assays were run in a 15 mL plastic conical tube with the 
electrode inserted in the tube and a small stirbar at the bottom. Calibration with standards 
of known concentrations of fluoride in 25 mM HEPES pH 7.5 allowed the voltage 
reading to be converted to fluoride concentrations. Reactions were run on a 1.5-1.7 mL 
scale, which was sufficient to cover the bottom of the electrode. After reconstituting 
protein as before, Fe(II), WT HEPD, or WT MPnS was removed from the glovebag and 
diluted with oxygenated buffer (25 mM HEPES pH 7.5) to a final concentration of 100 
µM, and the electrode was allowed to equilibrate. After no more than 30 s (prevent loss 
of dissolved O2), 1-F-2-HEP was added (1 mM final concentration) and the voltage was 
manually recorded every 5 seconds. The reactions were then allowed to proceed 
unmonitored for 24 h at room temperature, and the final voltage reading was recorded 
once more. 
 WT HEPD (1.5 mM) was reconstituted with 1 equivalent of Fe(II) in anaerobic 
buffer (25 mM HEPES pH 7.5), and then the protein (750 µM) was incubated with 1-F-2-
HEP (1 mM) in O2-saturated buffer (25 mM HEPES pH 7.5) at room temperature for 20 
min. Dithionite (several grains), EDTA (25 mM) and D2O (20% v/v) were added, and the 
31P NMR spectrum was recorded. The sample was spiked with residual starting material 
and Pi. To analyze the reaction of WT HEPD with 1-Cl-2-HEP, WT HEPD (500 µM) 
was anaerobically reconstituted with 1 equivalent of Fe(II) (500 µM) in 25 mM HEPES 
pH 7.5. The protein (100 µM final concentration) was then incubated with 1-Cl-2-HEP (2 
mM) and ascorbic acid (2 mM) in O2-saturated buffer (25 mM HEPES pH 7.5) at room 
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temperature for 2 h. The solution was filtered by centrifugation (30 kDa MWCO), snap 
frozen, and lyophilized. The lyophilized powder was taken up in D2O and the 31P NMR 
spectrum was recorded. 
 WT MPnS (500 µM final concentration) was exchanged into a volatile buffer 
(100 mM NH4OAc pH 7) by using a centrifuge filter, and anaerobically reconstituted 
with 5 equivalents of Fe(II). 1-F-2-HEP and 1-Cl-2-HEP (1 mM) were added to the 
reconstituted WT MPnS (30 µM for the reaction with 1-F-2-HEP and 250 µM for the 
reaction with 1-Cl-2-HEP) in O2-saturated 100 mM NH4OAc, and then the reactions were 
allowed to proceed at room temperature for 12 h. Chelex was added to the reactions to 
remove the free Fe, and the protein was removed by centrifuging through filters (30 kDa 
MWCO) that had been washed repeatedly (5 x 500 µL ddH2O). The filtrates were 
combined, snap frozen, and lyophilized to dryness. The residue was redissolved in ddH2O 
(2 mL), snap frozen, and lyophilized. The resulting residue was dissolved in H2SO4 (100 
mM, 1 mL). An aliquot (100 µL) was transferred to a separate tube, and the solutions 
were snap frozen and lyophilized. The smaller aliquot was dissolved in 500 µL D2O, 
analyzed by 31P NMR spectroscopy, and spiked with residual starting material and Pi to 
confirm the identities of the peaks. The reaction of WT MPnS with 1-Cl-2-HEP was also 
spiked with chloromethylphosphonate. The larger aliquots were analyzed by 1H, 1H-
coupled 31P, and [1H-31P] gHMBC NMR spectroscopies. 
 
5.4.11: 18O KIE Studies  
 These assays were performed on 3/11/14. WT HEPD and WT MPnS were 
prepared and shipped to the Klinman lab at U.C. Berkeley. 2-HEP and 2-[2-2H2]-HEP 
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were likewise prepared and shipped to the Klinman lab.8 Dr. Florence Bonnot and, later, 
Dr. Hui Zhu, two post-doctoral researchers in the Klinman lab, performed all the 18O KIE 
studies. 
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Chapter 6: Enzymatic Transformations Acting on Phosphonoacetaldehydea 
 
6.1: Introduction 
6.1.1: Background on PhnY 
 Herein, detailed biochemical and crystallographic characterization of the 
phosphonoacetaldehyde (PnAA) dehydrogenase enzyme, PhnY, from the soil-dwelling 
bacterium Sinorhizobium meliloti 1021 are presented. As outlined in Chapter 1, this 
enzyme plays a critical role in enabling certain bacteria to grow on the product of PnAA 
oxidation, phosphonoacetate (PnA), via phosphonoacetate hydrolase (Figure 1.3).1 PhnY 
is the only enzyme known to oxidize to PnAA to PnA, as the enzyme hypothetically 
responsible for this transformation in the fosfazinomycin biosynthetic pathway has not 
yet been identified.2 To better understand the mechanism of PhnY, its structure was 
solved by X-ray crystallography both in the apo state as well as in the presence of various 
phosphorus containing molecules including the native substrate and product. 
Characterization of the site-directed mutants described in this chapter that were generated 
on the basis of the crystal structure demonstrated the importance of the active site 
residues in vitro. Finally, PhnY was assayed for activity with a pair of substrate analogs, 
3-oxopropylphosphonate (3-OPP) and glyceraldehyde-3-phosphate (G3P). Its activity 
towards these substrate analogs leads to the conclusion that PhnY does not discriminate 
between the phosphonate and phosphate moiety, but rather that the physical dimensions 
of the active site modulates substrate preference.  
                                                
a Reprinted in part from Chemistry & Biology, 21, Agarwal, V; Peck, S. C., et al., 
Structure and Function of Phosphonoacetaldehyde Dehydrogenase, 125-135, Copyright 
(2013), with permission from Elsevier. Also adapted in part from reference 13 with 
permission from The Royal Society of Chemistry. 
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6.1.2: Overall Structure of PhnY 
 The structure of PhnY was determined in the apo state to 2.1 Å resolution by Dr. 
Vinayak Agarwal (Nair group, University of Illinois Urbana-Champaign). The 
crystallographic asymmetric unit consists of eight protein chains comprising four sets of 
biologically relevant homodimers (Figure 6.1A). The arrangement of protein chains as 
sets of homodimers is consistent with the behavior of PhnY as a dimer in solution, as 
judged by size exclusion chromatography performed by Dr. Agarwal. In the structure of 
the unliganded PhnY, electron density corresponding to a phosphate ion (presumably 
from the crystallization medium) was observed at the interface of the cofactor binding 
and catalytic domains. The phosphate oxygen atoms were coordinated by hydrogen bonds 
with the side chains of His159, Arg290, Thr292, and Arg447 (Figure 6.1B). The Arg108 
side chain, which is in the vicinity of the phosphate-binding site, showed alternative 
conformations throughout the different molecules in the asymmetric unit. In one 
conformation, Arg108 pointed towards the phosphate binding-pocket with the guanidino 
group within interaction distance of the phosphate. In the alternate conformation, this 
residue pointed away from the active site and was stabilized by interactions with the side 
chain of Asp111. This basic, phosphate-binding pocket is strictly conserved among 
ALDHs that catalyze oxidation of phosphorylated substrates, but is missing in ALDHs 
that function on non-phosphorylated substrates (Figure 6.2). 
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Figure 6.1: Three-dimensional crystal structure of apo PhnY. (A) Structure of the PhnY 
homodimer showing the relative positions of the three domains with one monomer 
colored grey, and the second monomer colored with the cofactor binding and catalytic 
domains in blue, and the oligomerization domain in pink. Cofactor NAD+ is shown in 
ball-and-stick representation. (B) Stereo view showing the active site features of PhnY in 
complex with inorganic phosphate. Superimposed is a difference Fourier electron density 
map (contoured at 2.7σ over background in blue, and 6.0σ in red) calculated with 
coefficients |Fobs| - |Fcalc| and phases from the final refined model with the coordinates of 
the inorganic phosphate deleted prior to one round of refinement. Figure made by Dr. 
Agarwal and reproduced with permission from ref 3.  
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Figure 6.2: Primary sequence alignment, constructed by Dr. Agarwal, between 
characterized ALDHs. Sm_PhnY: S. meliloti 1021 PhnY, Rn_PhnY: R. nubinhibens 
PhnY, Sm_GAPDH: S. mutans GAPDH, Ec_SsALDH: E. coli succinic semialdehyde 
dehydrogenase, Pa_BetALDH: P. aeruginosa betaine ALDH. The absolutely conserved 
catalytic nucleophilic cysteine, catalytic base glutamate and the oxyanion stabilizing 
asparagine residue are highlighted in pink and marked by (^) under the sequences. The 
phosphate/phosphonate binding pocket forming arginine and tyrosine/histidine residues 
are highlighted in blue and boxed. These residues are not conserved in Ec_SsALDH and 
Pa_BetALDH. All residues of interest are highlighted by (*) above the sequences. 
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6.1.3: Cocrystal Structure with the Physiological Substrate PnAA 
 The 2.1 Å resolution cocrystal structure of PhnY in complex with PnAA was 
generated and solved by Dr. Agarwal, and showed unambiguous density for the ligand in 
the active site of all eight copies in the crystallographic asymmetric unit (Figure 6.3A). 
PnAA was bound at the interface of the cofactor-binding and catalytic domains. The side 
chain thiol of Cys291 underwent a 120o rotation relative to the apo structure, which 
positioned the Cys291 side chain suitably for interactions with the substrate. The Cys291-
Sγ atom in this conformation was 3.0 Å and 3.3 Å away from the backbone amide 
nitrogen atoms of Cys291 and Thr292, respectively. Similar interactions have been 
implicated in modulating the nucleophilicity of the Cys side chain for nucleophilic attack 
in related members of the ALDH superfamily.4 
 Strong and continuous electron density was observed between the Cys291-Sγ and 
the PnAA-Cβ atom (at a distance of 1.8 Å) indicative of a covalent bond between these 
two atoms. Unbiased difference Fourier electron density maps were indicative of 
tetrahedral geometry at the PnAA-Cβ atom that was covalently bound to the Cys291 
sulfur atom (Figure 6.3A). This tetrahedral geometry is presumably generated by 
nucleophilic attack of the Cys291-Sγ thiolate at the Re face of planar PnAA to generate a 
tetrahedral thiohemiacetal intermediate with an (R) stereochemical configuration. 
Consequently, the phosphonate in the PhnY-PnAA binary complex was modeled as a 
thiohemiacetal instead of an aldehyde, the first such instance of the observation of the 
thiohemiacetal intermediate in a member of the ALDH superfamily of enzymes. 
 159 
 
Figure 6.3: PhnY active site in complex with substrate PnAA and cofactor NAD+. All 
atoms are shown in ball-and-stick representation with PhnY side chain carbon atoms 
colored yellow, and PnAA and NAD+ carbon atoms colored green. (A) Stereo view 
showing the active site features of PhnY in the binary complex with the substrate PnAA. 
Superimposed is a difference Fourier electron density map (contoured at 2.5σ). 
Stabilizing interactions of PnAA with PhnY are shown as black dashes. (B) Stereo view 
of the PhnY active site in the ternary complex with substrate PnAA and cofactor NAD+. 
Superimposed is the difference electron density map contoured at 2.5σ. Note that the 
nicotinamide and ribose rings for the cofactor have not been modeled. Figure made by 
Dr. Agarwal and reproduced with permission from ref 3. 
 
 The oxygen atom of the thiohemiacetal intermediate was positioned 3.1 Å away 
from the amide side chain of Asn158, and 3.2 Å away from the main chain amide 
nitrogen atom of Cys291 (Figure 6.3A). By analogy to the serine/cysteine protease 
reaction mechanism,5 these two interactions constitute the ‘oxyanion hole’ that stabilizes 
the tetrahedral intermediate. Binding of PnAA ordered the side chain of Arg108 in a 
solitary conformation pointing towards the active site, such that the guanidine moiety 
also interacted with the phosphonate oxygen atoms.  
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6.1.4: Cocrystal Structure of the Ternary Complex with PnAA and NAD+ 
 In the 2.0 Å resolution PhnY-NAD+-PnAA ternary complex (Figure 6.3A), solved 
by Dr. Agarwal, unambiguous electron density could be observed for all atoms of PnAA. 
However, electron density was absent for the nicotinamide ring and the adjoining ribose 
of the cofactor. Only the adenine diphosphate (ADP) moiety of the cofactor was modeled 
in the final structure (Figure 6.3B).  The PnAA substrate in the PhnY-NAD+-PnAA 
ternary complex was positioned analogously to the thiohemiacetal intermediate described 
previously, with all the interactions with the side chains of Asn158, His159, Arg108, 
Arg290, Thr292 and Arg447 conserved. However, the Fo – Fc difference electron density 
map was indicative of planar geometry around the PnAA-Cβ atom, which presumably 
arose due to the transfer of the hydride from the PnAA-Cβ to the cofactor, and the 
concomitant conversion of the tetrahedral thiohemiacetal intermediate to an sp2 
hybridized planar thioester. The bond angles around the PnAA-Cβ were thus refined to a 
planar geometry. Variability was observed in the positioning of the Glu254 side chain in 
the vicinity of the thioester intermediate. Based on sequence homology (Figure 6.2), this 
residue is the catalytic base that primes a water molecule for nucleophilic attack on the 
thioester intermediate generated in the catalytic cycle for PhnY (vide infra). Overall, I 
hoped to confirm the importance of the residues that were observed in the various crystal 
structures by using an in vitro steady-state kinetics assay with site-directed mutants as 
well as assess the scope of substrate tolerance for PhnY. 
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6.1.5: Reduction of PnAA in Phosphonate Biosynthetic Pathways 
 As highlighted in the previous sections, PnAA is a biosynthetic intermediate 
common to catabolic pathways and biosynthetic routes such as the pathways leading to 
fosfomycin, dehydrophos, and phosphinothricin (Chapter 1).6 The biosynthetic gene 
clusters of all three compounds share a gene encoding a group III metal dependent 
alcohol dehydrogenase (AD).7 FomC (fosfomycin), DhpG (dehydrophos), and PhpC 
(phosphinothricin) use NAD(P)H to catalyze the reduction of PnAA to 2-
hydroxyethylphosphonate (2-HEP).7 However, the exact stereochemistry of the 2-HEP 
product had never been determined. Thus, it was postulated that by employing a 
deuterium-labeled cofactor, the face selectivity of substrate reduction of a group III 
metal-dependent AD could be determined for the first time. It was hoped that this result 
would also provide additional insights into the fosfomycin biosynthetic pathway in 
Streptomyces fradiae (Figure 6.4). The overall pathway8 in this organism is still 
incomplete as a consequence of the inability to definitively reconstitute the activity of a 
presumed methyltransferase, Fom3, as well as uncertainty over where in the biosynthetic 
pathway to place the reductase FomC (Figure 6.4).9 At the time of the work presented in 
this chapter, Fom3 had only been hypothesized to catalyze formation of 2-
hydroxypropylphosphonate (HPP) from 2-HEP in vitro.10  
 Previous feeding studies have shown that 2-HEP is converted to fosfomycin by S. 
fradiae.8 Although the mechanism for this conversion is currently unknown, two 
explanations have been offered. In the first hypothesis, FomC acts on 2-HEP to generate 
phosphonoacetaldehyde (PnAA), which is subsequently methylated by Fom3 (Figure 6.4, 
path A).8,11 Alternatively, genetic studies combined with feeding studies suggested FomC 
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reduces PnAA to 2-HEP, which is then methylated by Fom3 (Figure 6.4, path B).9 
Studies by Hammerschmidt and coworkers demonstrated that feeding (R)- or (S)-2-[2-
2H1]-HEP to S. fradiae resulted in 32% incorporation of the deuterium label in 
fosfomycin from the S isomer and no deuterium incorporation from the R isomer.12 This 
observation places a restriction on the stereochemistry of hydride transfer from 2-HEP by 
FomC for path A. Only if FomC were to remove the pro-R hydrogen from C2 of 2-HEP 
could pathway A explain the experimental results. Thus, experimental determination of 
the stereochemistry of hydride transfer could support or refute pathway A. Though PhnY 
and the group III ADs operate on an identical substrate, the former oxidizes it for the 
catabolic reasons while the latter proteins reduce it for secondary metabolism. The results 
in this chapter will therefore be discussed separately, and the investigation into the group 
III ADs will be considered first. 
 
Figure 6.4: Proposed biosynthetic routes of fosfomycin in Streptomyces species. 
 
6.2: Results and Discussion for the Investigation of ADs that Act on PnAA 
6.2.1: Homology of ADs Involved in Phosphonate Biosynthesis 
 Of the three homologous enzymes discussed in section 6.1.5, DhpG was used in 
this study as it proved more stable under the conditions used and expressed better in 
Escherichia coli compared to FomC and PhpC. DhpG has 33% sequence identity with 
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FomC with conservation of the predicted active site residues identified through a multiple 
sequence alignment with other group III alcohol dehydrogenases (Figure 6.5).7,13 The 
cofactor binding motif (Figure 6.5, orange box) and metal binding residues (Figure 6.5, 
blue boxes) are conserved in the three ADs involved in phosphonate biosynthesis. The 
residues responsible for binding of the aldehyde/alcohol substrate are not conserved in 
this class of proteins, but they were identified for the three proteins of interest via 
homology models constructed based on the structures of 1,3-propanediol dehydrogenase 
from Thermotoga maritime (PDB code 1O2D) and lactaldehyde reductase from E. coli 
(PDB code 2BL4).7 Two residues that are conserved only in the 2-HEP dehydrogenases, 
a Ser and a Tyr residue, boxed in red in Figure 6.5, engage in hydrogen bonding to the 
phosphonate moiety in the homology model.7 The conservation of these residues across 
FomC, DhpG, and PhpC along with the overall sequence similarity indicates that hydride 
transfer from NAD(P)H to the aldehyde very likely occurs with the same facial 
selectivity for each protein. 
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Figure 6.5: Sequence alignment of select group III alcohol dehydrogenases. The boxed 
residues are responsible for NAD(P)H binding (orange), metal cofactor binding (blue), 
or, in the case of FomC, DhpG, and PhpC, phosphonate binding (red), and were 
identified through homology modeling.7 
 
6.2.2: An Enzymatic Cascade to Analyze the Stereochemistry of Reduction 
 In vitro assays with DhpG did not produce sufficient quantities of product to 
determine the absolute configuration of 2-[2-2H1]-HEP formed upon reduction of PnAA 
with NADP2H by NMR spectroscopy.14 Instead, I took advantage of the known 
stereochemistry of oxidation of 2-HEP to HMP and formate by 2-HEPD (Figure 6.6). 
Previous studies have shown that oxidation of (R)-2-[2-2H1]-HEP with HEPD produced 
deuterium labeled formate, whereas oxidation of the (S) enantiomer resulted in unlabeled 
formate.14 To eliminate the possibility of spurious formate interfering with analysis of the 
enzymatically produced formate,15 a 13C label was introduced at the C2 position of PnAA 
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such that either 13C,1H- or 13C,2H-formate would be generated, both of which can be 
readily distinguished from spurious formate by mass spectrometry. [2-13C1]-PnAA was 
prepared enzymatically from commercial [2-13C1]-phosphoenolpyruvate (PEP), using a 
recombinant N-terminally His6-tagged PEP mutase (RhiH) and a C-terminally His6-
tagged PnPy decarboxylase (ppd) from Bacteroides fragilis via a modification to a 
previously reported procedure.16 Conversion of [2-13C1]-PEP of [2-13C1]-PnAA was 
confirmed by 31P NMR spectroscopy (Figure 6.7A). 
 
Figure 6.6: Outline of the strategy used to determine the stereochemistry of the DhpG-
catalyzed reduction of PnAA. 
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Figure 6.7: The progress of the enzymatic cascade outlined in Figure 6.6 was followed 
by 31P NMR spectroscopy to confirm the generation of (A) [2-13C1]-PnAA (11 ppm) by 
the successive action of RhiH and PnPy decarboxylase, (B) 2-[2-13C1, 2-2H1]-HEP (21 
ppm) via the reduction of [2-13C1]-PnAA by DhpG in the presence of (4R)-NADP2H, and 
(C) HMP (18 ppm) by the action of HEPD. 31P NMR chemical shifts are very sensitive to 
small changes in pH, and therefore the identity of 2-HEP and HMP was confirmed by 
spiking with an authentic synthetic standard. The additional resonance (10 ppm) in panels 
(B) and (C) is residual [2-13C1]-PnAA. The additional resonance at ~19 ppm in panel (A) 
is an unknown byproduct of PnAA generation. 
 
 Given that FucO, another group III metal-dependent AD, has been reported to 
transfer the pro-R hydride from C4 of the nicotinamide group of NADH to its substrate,17 
(4R)-NADP2H was prepared by incubating deuterated phosphite with an engineered 
phosphite dehydrogenase (PtDH) that can use either NAD+ or NADP+ as substrate 
(Figure 6.6).18,19 After (4R)-NADP2H was generated, phosphite dehydrogenase was 
removed, and the (4R)-NADP2H was incubated with DhpG and excess [2-13C1]-PnAA. 
Once all (4R)-NADP2H was consumed as determined by UV-Vis spectroscopy, DhpG 
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was removed with a centrifuge filter, and the successful formation of 2-HEP was verified 
by 31P NMR spectroscopy (Figure 6.7B). Next, purified HEPD20 was incubated with 2-
[2-2H1]-HEP to convert the substrate into formate and HMP. Total conversion of 2-HEP 
into HMP was confirmed by 31P NMR spectroscopy (Figure 6.7C). To determine the 
absolute stereochemistry of the reduction of PnAA, the formate produced in the previous 
step was activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 
reacted with 2-nitrophenylhydrazine to form the corresponding hydrazide, thus 
converting the formate into a product large enough to be analyzed by LC-MS.14 As 
shown in Figure 6.8, the vast majority of the formate product contained both the 13C and 
2H labels, indicating that reduction catalyzed by DhpG of PnAA with (4R)-NADP2H 
results in (R)-2-[2-2H1]-HEP. This finding establishes that DhpG transfers the pro-R 
hydride of the reduced nicotinamide to its substrate, supporting the recent finding that the 
group III AD FucO transfers the pro-R hydride to its substrate.17 Simultaneously, this 
result establishes that reduction by this family of group III ADs takes place on the Re face 
of phosphonoacetaldehyde, and therefore that the enzymes remove the pro-R hydrogen 
during oxidation of 2-HEP. The experimental determination that DhpG, and by extension 
FomC, removes the pro-R hydrogen from 2-HEP combined with the demonstration by 
Hammerschmidt and coworkers that feeding of (R)-2-[2-2H1]-HEP results in production 
of unlabeled fosfomycin in S. fradiae does not rule out pathway A (Figure 6.4) of 
fosfomycin biosynthesis. Ultimately, definitive demonstration of the activity of the 
methyltransferase, Fom3, was required to determine which pathway is operative during 
fosfomycin biosynthesis, and after completion of this work, the in vitro activity of Fom3 
was reported, demonstrating that pathway B of Figure 6.4 is correct.21 
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Figure 6.8: Extracted ion chromatograms of formyl 2-nitrophenylhydrazide. The major 
product is the 2-nitrophenylhydrazide of [13C, 2H]-formate (182 m/z, blue), whereas 
derivatized spurious formate (180 m/z, red) and formate containing either 13C or 2H  (181 
m/z, black) are minor constituents. 
 
 
6.3: Results and Discussion for the Investigation of PhnY 
6.3.1: Characterization of WT and Site-Directed Mutants of PhnY 
 Using the PhnY crystal structures complexed to various phosphonates as guides 
(Sections 6.1.1-6.1.4), site-specific PhnY mutants were generated. Kinetic 
characterization of the wild-type and variant enzymes were carried out as described 
previously.1 For the wild type enzyme, the kinetic parameters determined in this study, 
kcat = 2.2 ± 0.1 s-1 and KM = 3.2 ± 0.7 µM for PnAA, were in good agreement with the 
previously published values (Table 6.1, Figure 6.9).1 By contrast, no activity was 
observed when Cys291 or Glu254 was replaced by Ala, confirming the vital roles of 
these residues in catalysis. The Glu254Ala mutant likely catalyzed a single oxidation of 
PnAA to PnA with concomitant reduction of NAD+ to NADH followed by very slow 
hydrolysis of the covalent thioester adduct; the first turnover of this conversion could 
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likely be observed using stopped-flow UV-Visible spectroscopy, but this technique was 
not employed. Instead, the PhnY Glu254Ala construct was incubated with NAD+ and 
PnAA and the contents of the reaction were analyzed by electrospray mass spectrometry 
(Figure 6.10). The suppressed deacylation activity enabled the trapping of a PhnY adduct. 
Though the resolution of the mass spectrum did not allow distinction between the 
thiohemiacetal and the thioester, the higher chemical stability of the latter suggested that 
the trapped intermediate corresponded to the thioester.  
 
Table 6.1: ND: not determined; a: this mutant displayed substrate inhibition (see Figure 
6.9), the Ki,PnAA = 420 ± 70 µM. 
 
 170 
 
Figure 6.9: Michaelis-Menten curves for wild-type PhnY and variants. Reaction 
conditions are described in the Materials and Methods section. Data shown are for A) 
wild-type, B) Arg108Ala, C) Asn168Ala, D) Arg290Ala, E) Glu385Ala, and F) 
Arg447Ala PhnY. All lines are fits of the data to the Michaelis-Menten equation except 
for panel E (left), for which the data was fit using the equation for substrate inhibition.3 In 
all cases, one substrate was held at saturating conditions while the other was varied. 
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Figure 6.10: Covalent adduct formation in PhnY-Glu254Ala. PhnY-Glu254Ala was 
treated with thrombin to remove the N-terminal His6 tag; the cleaved protein was then 
reacted with PnAA. The reaction mixture was washed with H2O and analyzed by direct 
infusion into an ESI mass spectrometer. The mass difference between the two peaks 
corresponds to +121 Da, which is in good agreement with the expected mass shift for a 
thioester intermediate of PnAA (+122 Da). 
 
 
 The Asn158Ala mutation resulted in a 200-fold decrease in kcat (Table 6.1, Figure 
6.9). Replacement of Arg108 by Ala led to a 40-fold decrease in kcat and a 3-fold increase 
in KM,PnAA, and the Arg290Ala mutation resulted in a similar 20-fold decrease in kcat with 
a slightly elevated KM,PnAA relative to wild type. The Arg447Ala mutation reduced the kcat 
30-fold and increased the KM,PnAA 50-fold. Glu385 provides the only interaction with the 
nicotinamide ribose 2’ and 3’ hydroxyl groups and mutation of this residue to Ala 
resulted in a 10-fold reduction in kcat, with an approximately 6-fold higher KM,NAD+. The 
origin of the observed substrate inhibition with the PhnY-Glu385Ala mutant is unknown. 
 
6.3.2: Kinetics and Ternary Complex Structures of PhnY-NAD+ with Non-
Physiological Substrates 3-OPP and G3P 
 The active site of PhnY is highly similar to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) from Streptococcus mutans, a well-characterized non-
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phosphorylating ALDH of primary metabolism that catalyzes the conversion of G3P to 3-
phosphoglycerate (Figure 6.11A). A one-to-one mapping of active site side chains was 
observed between GAPDH and PhnY, with the exception that GAPDH-Tyr155 is His159 
in PhnY. In order to explore whether this structural similarity between the two active 
sites translates to substrate promiscuity for PhnY, the activity of PhnY with the 
physiological substrate of GAPDH, G3P, was explored. Additionally, I chemically 
synthesized a one-carbon-atom longer mimic of PnAA (Figure 6.11B). Indeed, Dr. 
Agarwal demonstrated that PhnY could accept both G3P and 3-OPP as substrates. 
Oxidation of 3-OPP by PhnY proceeded with nearly identical kcat, but a 1000-fold 
increase in KM compared to the KM for PnAA (Table 6.1). However, the oxidation of G3P 
proceeded with a 20-fold reduction in kcat for the enzyme and a 30-fold increase in KM for 
G3P compared to KM,PnAA.  No activity was observed for the PhnY Cys291Ala mutant 
enzyme using either 3-OPP or G3P as substrates. 
 
Figure 6.11: Substrate analogs tested with PhnY. (A) The native reaction that GAPDH 
carries out with glyceraldehyde-3-phosphate to make 3-phosphoglycerate. (B) 3-OPP is a 
synthetic substrate analog that is not known to be naturally-occurring. 
 
 In the PhnY-G3P-NAD+ ternary complex, the side chains of Arg108, His159, 
Arg290 and Arg447 bound the phosphoryl oxygen atoms of G3P in a manner analogous 
to PnAA as determined by Dr. Agarwal (Figure 6.12A and 6.12B). In addition, the same 
ternary complex was observed from the interaction of G3P with the GAPDH active site 
residues Arg103, Tyr155, Arg283 and Arg437 (Figure 6.12C). Direct interactions for the 
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bridging phosphoryl ester oxygen atom of G3P, mediated by GAPDH residues Arg437 
and Tyr155 (red dashed lines in Figure 6.12C), were absent in PhnY. However, no 
residues were observed in the PhnY active site that would preclude phosphorylated 
substrates.  
 
Figure 6.12: (A) Stereo view of G3P and NAD+ binding to PhnY. All atoms are colored 
as before. Superimposed is the difference electron density map contoured at 2.5σ in blue. 
(B) Interactions are shown as green dashes for the binding of G3P with PhnY and (C) 
G3P with GAPDH. The interactions for the G3P phosphoryl oxygen atom and CB 
hydroxyl, which are absent in PhnY, are shown in red dashes. Note the different 
conformations of G3P in the PhnY active site and GAPDH active site. Dr. Agarwal 
generated this figure with LigPlot+ using refined coordinates of PhnY-G3P-NAD+ 
complex for panel B, and PDB 2ESD for panel C.22 
 
6.3.3: Relaxed Substrate Specificity of PhnY and Evolution of Enzyme Function in 
the ALDH family 
 The active sites of PhnY and GAPDH are strikingly similar, apart from the 
replacement of GAPDH-Tyr155 by PhnY-His159. In order to determine whether this 
similarity in active sites would lead to substrate promiscuity within the ALDH 
superfamily, I tested whether PhnY could use G3P as a substrate and whether GAPDH 
could accept phosphonate substrates. GAPDH oxidized 3-OPP with a large decrease in 
catalytic efficiency, and multiple turnovers with PnAA as substrate were not detected 
(Table 6.1 and Figure 6.13). However, roughly one equivalent of NADPH was produced 
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upon incubation of GAPDH with PnAA (Figure 6.13A); the observation of burst kinetics 
suggested that GAPDH was competent to oxidize PnAA to PnA but that hydrolysis of the 
non-physiological substrate occurred slowly. In comparison, G3P was a better substrate 
for PhnY than PnAA had been for GAPDH, though a 20-fold reduction in kcat was 
observed for G3P oxidation by PhnY compared to GAPDH oxidation.23 
 
Figure 6.13: Concentration dependence of the activity of GAPDH with various 
substrates. (A) A time course of GAPDH incubation with PnAA. After addition of PnAA 
at ~0.5 min, a "burst" of NADPH formation was observed followed by no significant 
turnover. (B) GAPDH follows normal steady-state Michaelis-Menten kinetics when 
incubated with varying concentrations of 3-OPP and saturating NADP+ or saturating 
concentrations of 3-OPP and varying concentrations of NADP+. (C) The oxidation 
kinetics with GAPDH of the physiological substrate G3P and NADP+ closely match the 
values that were previously reported. 
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 The observed reduction in the catalytic efficiency of G3P oxidation by PhnY as 
compared to GAPDH could have been a result of unfavorable electrostatic interactions. 
In the PhnY-G3P-NAD+ ternary complex (Figure 6.12A and 6.12B), G3P was contorted 
so that the thiohemiacetal oxyanion was positioned only 2.9 Å away from one of the 
phosphoryl oxygen atoms. However, when compared to the GAPDH-G3P-NAD+ ternary 
complex (Figure 6.12C) (PDB: 2ESD),24 G3P was fully extended and the corresponding 
thiohemiacetal oxyanion would not have such destabilizing electrostatic repulsions from 
the phosphoryl oxygen atoms. Thus, the physical dimensions of the PhnY and GAPDH 
active sites seem to dictate substrate specificities. A larger GAPDH active site allowed 
for G3P to be fully extended in the GAPDH active site while a smaller PhnY active site 
distorted G3P so that the thiohemiacetal intermediate was bound in an energetically less 
favorable conformation. In addition, the hydroxyl group of G3P made contact with the 
side chain of Arg437 in GAPDH, whereas this contact was absent in the ternary complex 
of PhnY with G3P and cofactor.  
 A second postulate for the reduction in G3P oxidation activity by PhnY is 
provided by the orientation of the Glu254 side chain for the deacylation half reaction. In 
the PhnY-G3P-NAD+ ternary complex, the reactive sites of the Glu254 side chain were 
pointed away from the thioester in all copies in the asymmetric unit. However, Glu254 
showed variable positioning within the PhnY-PnAA-NAD+ ternary complex. 
Superimposing the two structures revealed that the productive deacylation orientation of 
Glu254 in the PhnY-G3P-NAD+ ternary complex was occluded by the G3P-Cβ hydroxyl 
due to a steric clash. This in turn hindered the deacylation half reaction, which was rate 
limiting for GAPDH.23 
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 In order to test these two postulates, I synthesized 3-OPP, and Dr. Agarwal 
determined the kinetic parameters for its oxidation by PhnY and GAPDH. In 3-OPP, the 
aldehyde is separated from the phosphoryl moiety by one more bond than in PnAA, but 
one bond less than in G3P. PhnY indeed accepted 3-OPP as a substrate. As expected, the 
kcat for 3-OPP oxidation was comparable to that for PnAA as the rate limiting deacylation 
step was not hindered, in contrast to G3P.23 However, the KM for 3-OPP oxidation was 
1000-fold greater than that for PnAA (Table 6.1). This observation provided evidence 
that substrates larger than PnAA would be unfavorably accommodated within the 
constrained PhnY active site. This preference is not dependent on the substrate being a 
phosphate or a phosphonate. The lack of a hydroxyl group and a bridging oxygen on 3-
OPP and the interactions they make with active site residues may explain the greatly 
reduced catalytic activity of GAPDH towards this substrate compared to G3P. These 
results are reflective of the diversity in catalytic activities that can be built upon the 
conserved ALDH superfamily structural core. 
 
6.3.4: A Proposed Catalytic Mechanism for PhnY  
 Prior work has led to the characterization of a novel pathway for phosphonate 
degradation in S. meliloti 1021, which utilizes PhnY to convert PnAA into PnA.1 
Oxidation of PnAA primes the resultant carboxylic acid for subsequent enzymatic 
hydrolysis by PhnA.25-27 PhnY provides the first, and presently the only known, 
biochemical basis for the synthesis of PnA in the microbial metabolome. The structural 
data demonstrate that PhnY belongs to the family of CoA-independent non-
phosphorylating aldehyde dehydrogenases. Structural comparisons of PhnY with other 
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ALDHs revealed how changes to the highly conserved ALDH active site could increase 
the substrate tolerance of the enzymes to include phosphonates and expand upon the role 
of ALDHs in the biodegradation of inert molecules. 
 Three classes of ALDHs have been characterized, and all share a common first 
acylation half reaction, which includes hydride transfer to the cofactor. However, 
variability is observed in the second deacylation half reaction, based on the deacylating 
nucleophile—hydroxyl anion, phosphate, or a coenzyme A (CoA) thiolate. Our 
understanding of the CoA independent non-phosphorylating ALDHs is based primarily 
on the extensive structural and mechanistic characterization of GAPDH.4,23,24,28 Based on 
the PhnY cocrystal structures and kinetic data presented in this study, and the structural 
similarity of the PhnY and GAPDH active sites, a mechanistic proposal for the 
conversion of PnAA to PnA by PhnY is shown in Figure 6.14. 
 
Figure 6.14: A mechanism for PhnY that accounts for the various crystal structures and 
kinetic assays. Figure prepared by Dr. Agarwal. 
 
 In the acylation half reaction catalyzed by PhnY, PnAA is covalently bound to the 
side chain of Cys291 forming a (R)-thiohemiacetal intermediate at the interface of the 
catalytic and cofactor binding domains. Residues Arg108, His159, Arg290, Thr292 and 
Arg447 coordinate phosphoryl oxygen atoms. The side chain of Asn158 and main chain 
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amide nitrogen of Cys291 constitute the ‘oxyanion hole’ to stabilize the intermediate. 
The cofactor is aptly positioned for hydride transfer from the thiohemiacetal to the C4 
carbon atom of the nicotinamide ring from the Re-face, generating a thioester 
intermediate. The conformation of the cofactor that results in hydride transfer occludes 
the side chain of Glu254 from approaching the active site, due to steric clash between the 
Si-face of the nicotinamide ring and the Glu254 side chain. In the succeeding deacylation 
half reaction, the side chain of Glu254 is now positioned close to the thioester 
intermediate allowing the carboxylate to deprotonate a water molecule for nucleophilic 
attack at the thioester. This attack leads to the formation of a thioorthoester intermediate, 
which is resolved by the departure of the Cys291 side chain and generation of the product 
PnA.  
 
6.4: Conclusions 
 Studying the oxidation of PnAA to PnA has helped elucidate the substrate scope 
and mechanism of the dehydrogenase responsible for the transformation. Ultimately, the 
insights gleaned from the study of PhnY may help enable the identification of the 
aldehyde dehydrogenase that is responsible for the oxidation of PnAA to PnA in the 
fosfazinomycin pathway.2 By contrast, studying the reduction of PnAA to 2-HEP helped 
define the facial selectivity of the hydride transfer; unfortunately, the result did not enable 
the exclusion of either hypothetical fosfomycin biosynthetic pathway (Figure 6.4). Taken 
together, these results illustrate that PnAA is a central intermediate in a wide variety of 
pathways including both catabolic processes and secondary metabolism. 
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6.5: Materials and Methods 
6.5.1: Determining the Stereochemistry of Hydride Transfer by DhpG  
 These experiments were performed on 10/9/11 and 10/10/11. NADPH 
stereospecifically labeled with deuterium at C4 of the nicotinamide was synthesized by 
incubating NADP+ (2 mM) in 50 mM HEPES, pH 7.5 with deuterated phosphite (3 mM) 
and phosphite dehydrogenase (PtDH, 7 µM), which were both kindly provided by a then-
graduate student in the van der Donk group, Dr. John Hung.18 The mixture was allowed 
to incubate at 30 ˚C for 90 min, and then PtDH was removed by centrifuge filtration (30 
kDa MWCO). The presence of (4R)-NADP2H was confirmed by the generation of a peak 
at 340 nm in the UV-Vis spectrum. Because of its instability, the cofactor was used 
without further purification.  
 Phosphonoacetaldehyde labeled with 13C at C2 was generated by incubating 
thiamine pyrophosphate (TPP, 1.4 mM) with [2-13C1]-phosphoenolpyruvate (PEP, 10 
mM, Sigma Aldrich) in 50 mM HEPES pH 7.5 with 1 mM Mg2+.16 The reaction was 
initiated by addition of RhiH (80 µM) and the PnPy decarboxylase (40 µM), causing 
turbidity. After incubating at 30 ˚C for 45 min, proteins were removed by centrifuge 
filtration (30 kDa MWCO). An aliquot was taken from the flow through, and the 
presence of [2-13C1]-PnAA was confirmed by 31P NMR spectroscopy. 
 (4R)-NADP2H (1 mM final concentration) was mixed with the prepared [2-13C1]-
PnAA (4 mM final concentration) and DhpG (approximately 75 µM, expressed and 
purified as described previously7) was added in 50 mM HEPES, pH 7.5. The reaction was 
allowed to proceed at room temperature for 60 min, at which point the UV-Visible 
spectrum indicated the consumption of the 340 nm peak associated with the (4R)-
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NADP2H cofactor. Protein was removed via centrifuge filtration (30 kDa MWCO), and 
an aliquot was taken to confirm the presence of 2-[2-13C1, 2-2H1]-HEP via 31P NMR 
spectroscopy. To the isotopically labeled 2-HEP (~0.8 mM) was added HEPD (final 
concentration of 20 µM) in 50 mM HEPES pH 7.5. The solution was incubated at room 
temperature to effect the conversion of 2-HEP to HMP and formate. Protein was removed 
via centrifuge filtration (30 kDa MWCO), and an aliquot of the flowthrough (10 µL) was 
derivatized to afford the 2-nitrophenylhydrazide adduct and analyzed by LC-MS using 
methodology developed previously.15 
 
6.5.2: General Experimental for the PhnY Investigation 
 G3P was obtained from Sigma-Aldrich (G5251-25MG) and used without further 
purification. Media components were purchased from Thermo Fisher Scientific or VWR 
(West Chester, PA). DNA primers were synthesized by Integrated DNA Technologies 
Inc (Coralville, IA). Restriction enzymes were obtained from New England Biolabs 
(Ipswich, MA). DNA sequencing was performed by ACGT Inc (Wheeling, IL). 
Phosphonoacetaldehyde was prepared before use as described elsewhere29 and was stored 
at -20 ˚C when not in use. 
 Cloning, expression, and purification of recombinant PhnY from E. coli has been 
described previously.1 The mutant constructs Arg108Ala, Asn158Ala, His159Ala, 
Glu254Ala, Arg290Ala, Cys291Ala, Thr292Ala, Glu385Ala and Arg447Ala were 
generated by Dr. Agarwal (Nair lab, University of Illinois) using standard site-directed 
mutagenesis protocols and confirmed by plasmid DNA sequencing. Dr. Agarwal also 
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performed all the crystallographic studies reported herein. Wild type and mutant enzymes 
were purified according to procedures described earlier.3 
 
6.5.3: Cloning and Purification of GAPDH  
 These experiments were performed on 9/17/13 and 10/3/13. GAPDH was cloned 
from Streptococcus mutans Clarke ATCC® 25175 using Failsafe Buffer A and expressed 
as an N-terminal His6-fusion protein from a pET15b vector in E. coli Rosetta2. Cells were 
grown to OD600 ~0.6 in LB, expression was induced with 0.3 mM IPTG at 18 ˚C for 16 h, 
and cells were harvested by centrifugation. The cell pellet from 1 L of culture was 
resuspended in lysis buffer B (50 mM HEPES pH 7.5, 200 mM KCl, 10% glycerol, 5 
mM DTT, 20 mM imidazole, 10 U DNAse, 25 mg lysozyme), lysed with a French press 
(15,000 psi), and the lysate was clarified by centrifugation. The clarified lysate was 
loaded onto a pre-equilibrated column with Ni-NTA resin. The column was washed with 
lysis buffer B, lysis buffer B supplemented with 50 mM imidazole, and lysis buffer B 
supplemented with 250 mM imidazole. After concentrating with an Amicon centrifuge 
filter, the protein buffer was exchanged to 50 mM HEPES pH 7.5, 200 mM KCl, 10% 
glycerol, 5 mM DTT using a NAP-25 filter. This process yielded ~60 mg GAPDH/L cell 
culture. 
 
6.5.4: Synthesis of 3-OPP  
 These experiments were performed on 10/3/12 and 12/14/12. Following a 
modified literature procedure,30 2.0 g (7.5 mmol) of diethyl (3,3-
diethoxypropyl)phosphonate was added to a three-necked flask equipped with a 
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condenser under N2. TMSCl (3.8 mL, 30 mmol) was added, and the mixture was refluxed 
for 2 h. Although residual starting material was still present, refluxing for longer periods 
of time led to an increase in byproducts, which were difficult to remove. After 2 h, the 
mixture was cooled to 50 ˚C, and 2 mL of H2O was added to hydrolyze the residual 
TMSCl and deprotect the silyl groups and unmask the aldehyde. The reaction was stirred 
for 30 min. H2O (5 mL) was added, and the solvent was removed using a rotary 
evaporator to afford a yellow oil. 1H, 31P, and [1H-31P] gHMBC NMR analysis and ESI-
MS characterization confirmed the presence of both 3-OPP with diethyl (3-
oxopropyl)phosphonate as the sole byproduct. Spectral data for 3-OPP: NMR: 1H (500 
MHz, D2O): δ 9.52 (s, CHO), 2.72 (dt, J = 14.6, 7.5, PCH2CH2), 2.06 (dt, J = 17.7, 7.5, 
PCH2CH2); 31P (202 MHz, D2O): δ 35.6 ppm. HR-MS (ESI+): found 139.0162, 
calculated 139.0160 (1.4 ppm). 31P NMR analysis of a stock of the 3-OPP mixture with 
an internal standard of Pi allowed the determination of the 3-OPP concentration.  
 
6.5.5: Steady-State Kinetics for PhnY Variants and GAPDH  
 These assays were performed on 6/26/13, 6/27/13, 6/28/13, 6/29/13, 6/30/13, 
7/2/13, 7/7/13, 7/21/13, 7/22/13, 9/30/13, and 10/1/13. The kinetics of substrate oxidation 
by wild type PhnY enzyme and site specific mutants were determined by monitoring the 
reduction of NAD+ by UV-Vis spectroscopy at 340 nm using procedures described 
previously.1 Enzyme (0.1-5 µM depending on the variant) was incubated with NAD+ in 
50 mM HEPES, pH 7.5 supplemented with 10 mM MgSO4 for 5 min at 30 ˚C. The 
reaction was initiated by addition of phosphonate/phosphate substrate. To obtain 
Michaelis-Menten kinetics, one substrate was maintained at saturating levels while the 
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other substrate was varied; rates were obtained in triplicate. Dr. Agarwal determined the 
steady-state kinetics of WT PhnY with 3-OPP; I determined all others. The Cys291Ala 
and Glu254Ala mutant enzymes were assayed at various substrate and enzyme 
concentrations. One mutant, Glu385Ala, displayed substrate inhibition and its kinetic 
parameters were obtained by fitting to the appropriate equation, VI = kcat[E][S]/[KM,s + [S] 
+ ([S]2/Ki,s)], where [E] is the enzyme concentration, [S] is the substrate concentration, 
and Ki,s is the inhibition constant of the substrate. A similar procedure was used for the 
kinetic studies with by GAPDH (0.02-20 µM depending on the substrate) except that the 
buffer used was 50 mM HEPES pH 8.0 supplemented with 5 mM DTT and the cofactor 
used was NADP+. 
 
6.5.6: Detection of a Covalent Adduct with PhnY-Glu254Ala  
 This assay was performed on 9/20/13. To observe the covalent thioester adduct, 
PhnY-Glu254Ala was treated with thrombin to remove the N-terminal His6 tag. The 
protein (2 mg/mL) was then reacted with PnAA (2 mM) in the presence of NAD+ (2 mM) 
in 50 mM HEPES pH 7.5 with 10 mM MgSO4. The reaction mixture was washed 
extensively with H2O with a 0.5 mL 30 kDa MWCO centrifuge filter, mixed with 
unreacted PhnY-Glu254Ala that had been similarly washed (to serve as an internal 
standard), and then analyzed by directly infusing into an ESI mass spectrometer. The 
mass difference between the two peaks corresponds to +121 Da, which is in good 
agreement with the mass shift for a thioester intermediate of PnAA (+122 Da).  
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